Role of angiogenesis in tumor growth and metastasis

Seminars in Oncology 29, 15-18

DOI: 10.1053/sonc.2002.37263

Citation Report

#	Article	IF	CITATIONS
1	Role of hypoxia in tumor angiogenesis?molecular and cellular angiogenic crosstalk. Cell and Tissue Research, 2003, 314, 145-155.	1.5	49
2	Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell, 2003, 4, 19-29.	7.7	363
3	Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell, 2003, 4, 291-299.	7.7	74
4	Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer, 2003, 98, 1377-1385.	2.0	104
5	Optical imaging and tumor angiogenesis. Journal of Cellular Biochemistry, 2003, 90, 484-491.	1.2	31
6	Fibroblast growth factor receptor-1 mediates the inhibition of endothelial cell proliferation and the promotion of skeletal myoblast differentiation by SPARC: A role for protein kinase A. Journal of Cellular Biochemistry, 2003, 90, 408-423.	1.2	63
7	Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Science, 2003, 94, 479-485.	1.7	34
8	Molecular basis of angiogenesis and cancer. Oncogene, 2003, 22, 6549-6556.	2.6	287
9	Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene, 2003, 22, 8441-8447.	2.6	59
10	Cancer genetics and drug discovery in the zebrafish. Nature Reviews Cancer, 2003, 3, 533-539.	12.8	238
11	Translating angiogenesis research into the clinic: the challenges ahead. British Journal of Radiology, 2003, 76, S3-S10.	1.0	36
12	Development of New Agents for the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2003, 3, 154-164.	1.0	5
13	Detection of ultrawide-band ultrasound pulses in optoacoustic tomography. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2003, 50, 1383-1390.	1.7	104
14	Non steroidal antiâ€inflammatory drugs and COXâ€2 inhibitors as antiâ€cancer therapeutics: hypes, hopes and reality. Annals of Medicine, 2003, 35, 476-487.	1.5	67
15	Selective targeting of cancer cells using synthetic peptides. Drug Resistance Updates, 2003, 6, 363-371.	6.5	143
16	Sphingosine 1-phosphate and cell migration: resistance to angiogenesis inhibitors. Biochemical and Biophysical Research Communications, 2003, 310, 884-888.	1.0	4
17	A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochemical and Biophysical Research Communications, 2003, 310, 816-823.	1.0	60
18	Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends in Molecular Medicine, 2003, 9, 244-250.	3.5	101

#	ARTICLE	IF	CITATIONS
19	IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine, 2003, 24, 57-66.	1.4	20
20	The non-classical export routes: FGF1 and IL-1 \hat{l} ± point the way. Journal of Cell Science, 2003, 116, 4871-4881.	1.2	184
21	CCN3 (NOV) Is a Novel Angiogenic Regulator of the CCN Protein Family. Journal of Biological Chemistry, 2003, 278, 24200-24208.	1.6	161
22	Knowledge and Truth: Answers or Questions?. Surgical Infections, 2003, 4, 297-309.	0.7	3
23	An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13507-13512.	3.3	72
24	COX-2 and Angiogenesis in Gastric Cancer. Journal of Clinical Gastroenterology, 2003, 37, 4-6.	1.1	6
25	Radiobiology and vascular targeting in glioma. Current Opinion in Neurology, 2003, 16, 651-655.	1.8	2
26	Angiogenesis in goitrogenesis. Current Opinion in Endocrinology, Diabetes and Obesity, 2003, 10, 341-346.	0.6	2
27	Roxatidine- and Cimetidine-Induced Angiogenesis Inhibition Suppresses Growth of Colon Cancer Implants in Syngeneic Mice. Journal of Pharmacological Sciences, 2003, 93, 321-330.	1.1	50
28	Anti-angiogenic Effects of Dimethyl Sulfoxide on Endothelial Cells. Biological and Pharmaceutical Bulletin, 2003, 26, 1295-1298.	0.6	25
29	Absence of OX-43 antigen expression in invasive capillary sprouts: identification of a capillary sprout-specific endothelial phenotype. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H346-H353.	1.5	14
30	Ultrasonic Analysis of Peptide- and Antibody-Targeted Microbubble Contrast Agents for Molecular Imaging of $\hat{l}\pm\nu$ \hat{l}^2 3 -Expressing Cells. Molecular Imaging, 2004, 3, 153535002004031.	0.7	14
31	Angiogenesis: a potential target for therapy of soft tissue sarcomas., 2004, 120, 169-180.		3
32	Angiogenesis in Multiple Myeloma: Implications in Myeloma Therapy. Cancer Reviews: Asia-Pacific, 2004, 02, 119-129.	0.1	2
33	Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification. Clinical Cancer Research, 2004, 10, 7965-7971.	3.2	215
34	Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study. Journal of Clinical Oncology, 2004, 22, 3316-3322.	0.8	353
35	Exercise delays allogeneic tumor growth and reduces intratumoral inflammation and vascularization. Journal of Applied Physiology, 2004, 96, 2249-2256.	1.2	65
36	Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities. Cancer Research, 2004, 64, 8249-8255.	0.4	429

3

#	Article	IF	CITATIONS
37	Quantitative Assessment of Tumor Vasculature and Response to Therapy in Kaposi's Sarcoma Using Functional Noninvasive Imaging. Technology in Cancer Research and Treatment, 2004, 3, 451-457.	0.8	35
38	Enhanced Protein Profiling Arrays with ELISA-Based Amplification for High-Throughput Molecular Changes of Tumor Patients' Plasma. Clinical Cancer Research, 2004, 10, 598-609.	3.2	43
39	Bevacizumab for Patients with Metastatic Renal Cancer: Fig. 1 Clinical Cancer Research, 2004, 10, 6367S-6370S.	3.2	125
40	Effect of Imatinib Mesylate on Neuroblastoma Tumorigenesis and Vascular Endothelial Growth Factor Expression. Journal of the National Cancer Institute, 2004, 96, 46-55.	3.0	150
41	Differential Activation of the Phosphatidylinositol 3′-Kinase/Akt Survival Pathway by Ionizing Radiation in Tumor and Primary Endothelial Cells. Cancer Research, 2004, 64, 5398-5406.	0.4	55
42	On the emergence of multifocal cancers. Journal of Carcinogenesis, 2004, 3, 13.	2.5	7
43	Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2476-2481.	3.3	658
44	Adeno-Associated Virus 2-Mediated Antiangiogenic Cancer Gene Therapy. Cancer Research, 2004, 64, 1781-1787.	0.4	74
45	Matrix Metalloproteinase-9 Is Required for Adequate Angiogenic Revascularization of Ischemic Tissues. Circulation Research, 2004, 94, 262-268.	2.0	178
46	Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through $\hat{l}\pm2\hat{l}^21$ integrin. Journal of Cell Biology, 2004, 166, 97-109.	2.3	243
47	QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4833-4838.	3.3	186
48	Role of infiltrated leucocytes in tumour growth and spread. British Journal of Cancer, 2004, 90, 2053-2058.	2.9	234
49	Anti-Tumor Efficacy of Human Angiostatin Using Liver-Mediated Adeno-Associated Virus Gene Therapy. Molecular Therapy, 2004, 9, 56-66.	3.7	34
50	Soluble factors from human endometrium promote angiogenesis and regulate the endothelial cell transcriptome. Human Reproduction, 2004, 19, 2356-2366.	0.4	32
51	Human T-Cell Lymphotropic Virus Type I-Infected Cells Extravasate through the Endothelial Barrier by a Local Angiogenesis-Like Mechanism. Cancer Research, 2004, 64, 2039-2046.	0.4	53
52	Vascular Endothelial Growth Factor Activation of Sterol Regulatory Element Binding Protein. Circulation Research, 2004, 95, 471-478.	2.0	66
53	A New Look at an Old Problem: The Survival and Organ-Specific Growth of Metastases. Science Signaling, 2004, 2004, pe3-pe3.	1.6	11
54	Cancer genes and the pathways they control. Nature Medicine, 2004, 10, 789-799.	15.2	3,689

#	Article	IF	CITATIONS
55	The potential of positron-emission tomography to study anticancer-drug resistance. Nature Reviews Cancer, 2004, 4, 457-469.	12.8	35
56	Checkpoint genes, ageing, and the development of cancer. Oncogene, 2004, 23, 7799-7809.	2.6	6
57	Novel endothelial cell markers in hepatocellular carcinoma. Modern Pathology, 2004, 17, 1198-1210.	2.9	78
58	The relationship between hypoxia and angiogenesis. Seminars in Radiation Oncology, 2004, 14, 215-221.	1.0	84
59	Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis. , 2004, 102, 61-85.		157
60	Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell, 2004, 5, 329-339.	7.7	509
61	Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors. Cancer Cell, 2004, 5, 429-441.	7.7	963
62	Lymphangiogenesis is pivotal to the trials of a successful cancer metastasis. Surgery, 2004, 135, 121-124.	1.0	17
63	Dose-dependent effect of dehydroepiandrosterone, but not of its sulphate ester, on angiogenesis. European Journal of Pharmacology, 2004, 502, 21-30.	1.7	11
64	Regulation of angiogenesis by extracellular matrix. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1654, 13-22.	3.3	162
65	Genetic dissection of tumor angiogenesis: are PIGF and VEGFR-1 novel anti-cancer targets?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1654, 79-94.	3.3	40
66	Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1654, 51-67.	3.3	62
67	Tyrosine kinase receptors as attractive targets of cancer therapy. Critical Reviews in Oncology/Hematology, 2004, 50, 23-38.	2.0	164
68	Brain Endothelial Cells as Pharmacological Targets in Brain Tumors. Molecular Neurobiology, 2004, 30, 157-184.	1.9	23
69	Myocardial angiogenesis. Molecular and Cellular Biochemistry, 2004, 264, 35-44.	1.4	37
70	Stabilization of a Progressive Hemangioblastoma under Treatment with Thalidomide. Journal of Neuro-Oncology, 2004, 66, 295-299.	1.4	22
71	Transplanted Bone Marrow Cells Preferentially Home To The Vessels Of In Situ Generated Murine Tumors Rather Than Of Normal Organs. Stem Cells, 2004, 22, 86-92.	1.4	29
72	Establishment of green fluorescent protein-expressing hepatocellular carcinoma cell lines with different metastatic potential: relevant models for in vivo monitoring of metastasis and angiogenesis. Journal of Cancer Research and Clinical Oncology, 2004, 130, 375-82.	1.2	6

#	Article	IF	CITATIONS
73	The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis, 2004, 7, 225-233.	3.7	149
74	Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, 2004, 7, 335-345.	3.7	375
75	Matrix metalloproteinases and matrikines in angiogenesis. Critical Reviews in Oncology/Hematology, 2004, 49, 203-220.	2.0	88
76	Relationship of 99mTc-HYNIC annexin V uptake to microvessel density, FasL and MMP-9 expression, and the number of tumour-infiltrating lymphocytes in head and neck carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1016-1021.	3.3	11
77	MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1081-9.	3.3	139
78	Angiopoietins in tumours: the angiogenic switch. Journal of Pathology, 2004, 204, 1-10.	2.1	206
79	Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer, 2004, 101, 869-877.	2.0	36
80	Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. International Journal of Cancer, 2004, 108, 301-306.	2.3	86
81	Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. International Journal of Cancer, 2004, 112, 329-334.	2.3	29
82	NS398 reduces hypoxia-inducible factor(HIF)- $1\hat{l}\pm$ and HIF-1 activity: Multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. International Journal of Cancer, 2004, 112, 585-595.	2.3	52
83	MAZ51, an indolinone that inhibits endothelial cell and tumor cell growthin vitro, suppresses tumor growthin vivo. International Journal of Cancer, 2004, 112, 986-993.	2.3	59
84	Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplantation, 2004, 10, 1301-1311.	1.3	241
85	A comparison of Ktransmeasurements obtained with conventional and first pass pharmacokinetic models in human gliomas. Journal of Magnetic Resonance Imaging, 2004, 19, 527-536.	1.9	60
86	Design of hypoxia-targeting protein tyrosine kinase inhibitor using an innovative pharmacophore 2-methylene-4-cyclopentene-1,3-dione. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1697, 29-38.	1.1	8
87	The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Critical Reviews in Oncology/Hematology, 2004, 50, 87-100.	2.0	308
88	In Vitro Inhibition of the Activation of Pro-matrix Metalloproteinase 1 (Pro-MMP-1) and Pro-matrix Metalloproteinase 9 (Pro-MMP-9) by Rice and Soybean Bowmanâ´'Birk Inhibitors. Journal of Agricultural and Food Chemistry, 2004, 52, 4730-4736.	2.4	24
89	Recruitment of Bone Marrow-Derived Endothelial Cells to Sites of Pancreatic Â-Cell Injury. Diabetes, 2004, 53, 91-98.	0.3	172
90	Protein Deformation of Lipid Hybrid Bilayer Membranes Studied by Sum Frequency Generation Vibrational Spectroscopy. Langmuir, 2004, 20, 8961-8965.	1.6	51

#	Article	IF	CITATIONS
91	Vascular-targeted cancer gene therapy. Expert Opinion on Biological Therapy, 2004, 4, 1911-1920.	1.4	3
92	ADJUNCTIVE THERAPY FOR MEN WITH HIGH RISK LOCALIZED AND LOCALLY ADVANCED PROSTATE CANCER: TARGETING DISSEMINATED TUMOR CELLS. Journal of Urology, 2004, 172, 2539-2544.	0.2	10
93	Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opinion on Investigational Drugs, 2004, 13, 1-19.	1.9	48
94	Multistep tumorigenesis and the microenvironment. Breast Cancer Research, 2004, 6, 93-101.	2.2	87
95	Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. Hematology/Oncology Clinics of North America, 2004, 18, 1143-1159.	0.9	9
96	Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine and Growth Factor Reviews, 2004, 15, 297-324.	3.2	146
97	Magnesium deficiency inhibits primary tumor growth but favors metastasis in mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1739, 26-32.	1.8	66
98	Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Experimental Cell Research, 2004, 299, 286-293.	1.2	76
99	Nitric oxide complexes in the interaction between primary and secondary tumor of L5178Y lymphoma. Nitric Oxide - Biology and Chemistry, 2004, 11, 279-289.	1.2	5
100	The effects of reduced oxygen tension on swine granulosa cell. Regulatory Peptides, 2004, 120, 69-75.	1.9	68
101	Angiogenesis as an immunopharmacologic target in inflammation and cancer. International Immunopharmacology, 2004, 4, 1537-1547.	1.7	47
102	The role of Osteopontin in tumor metastasis. Journal of Surgical Research, 2004, 121, 228-241.	0.8	330
103	Molecular therapy in pancreatic adenocarcinoma. Lancet Oncology, The, 2004, 5, 541-549.	5.1	69
104	Negative Regulation of Midline Vascular Development by the Notochord. Developmental Cell, 2004, 6, 699-708.	3.1	88
105	Melanoma on the Move: The Progression of Melanoma. American Journal of Dermatopathology, 2004, 26, 504-510.	0.3	10
106	Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. Journal of Clinical Investigation, 2004, 114, 898-907.	3.9	257
107	Cyclooxygenase-2 Expression in Oral Squamous Cell Carcinoma. International Journal of Immunopathology and Pharmacology, 2004, 17, 273-282.	1.0	45
108	Role of monocytes and macrophages in angiogenesis. , 2005, , 127-146.		27

#	Article	IF	CITATIONS
109	Local Delivery of a Synthetic Endostatin Fragment for the Treatment of Experimental Gliomas. Neurosurgery, 2005, 57, 1032-1040.	0.6	23
110	Identification and characterization of novel endogenous proteolytic forms of the human angiogenesis inhibitors restin and endostatin. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1747, 161-170.	1.1	68
111	Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Critical Reviews in Oncology/Hematology, 2005, 53, 35-69.	2.0	237
112	Angiogenesis in Craniopharyngiomas: Microvascular Density and Tissue Expression of the Vascular Endothelial Growth Factor (VEGF) and Endostatin. Endocrine Pathology, 2005, 16, 355-362.	5.2	10
113	Improved correlation of histological data with DCE MRI parameter maps by 3D reconstruction, reslicing and parameterization of the histological images. European Radiology, 2005, 15, 1079-1086.	2.3	20
114	Angiogenesis: update 2005. Journal of Thrombosis and Haemostasis, 2005, 3, 1835-1842.	1.9	272
115	Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma. Neuropathology, 2005, 25, 178-187.	0.7	26
116	Expression of thymidine phosphorylase in human superficial bladder cancer. International Journal of Urology, 2005, 12, 29-34.	0.5	8
117	Cancer risk of patients with ischaemic syndromes. Journal of Internal Medicine, 2005, 258, 124-132.	2.7	21
118	ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. British Journal of Cancer, 2005, 92, S6-S13.	2.9	160
119	Radiation's outer limits. Nature Medicine, 2005, 11, 477-478.	15.2	11
120	Galectins as modulators of tumour progression. Nature Reviews Cancer, 2005, 5, 29-41.	12.8	1,290
121	Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Therapy, 2005, 12, 900-912.	2.2	32
122	Survival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection. Leukemia, 2005, 19, 531-532.	3.3	3
123	Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor ÎB. Oncogene, 2005, 24, 390-398.	2.6	61
124	Vasculostatin, a proteolytic fragment of Brain Angiogenesis Inhibitor 1 , is an antiangiogenic and antitumorigenic factor. Oncogene, 2005, 24, 3632-3642.	2.6	159
125	HIF- $1\hat{i}$ +, STAT3, CBP/p300 and Ref- 1 /APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene, 2005, 24, 3110-3120.	2.6	353
126	Quantification of Angiogenesis in Otosclerosis. Laryngoscope, 2005, 115, 811-816.	1.1	5

#	Article	IF	CITATIONS
127	Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Modern Pathology, 2005, 18, 97-104.	2.9	97
128	VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 2005, 438, 820-827.	13.7	2,841
129	Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell, 2005, 8, 13-23.	7.7	338
130	Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Seminars in Oncology, 2005, 32, 61-68.	0.8	34
132	Trauma-associated growth of suspected dormant micrometastasis. BMC Cancer, 2005, 5, 94.	1.1	29
133	Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. International Journal of Cancer, 2005, 113, 670-677.	2.3	19
134	VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer, 2005, 104, 2517-2521.	2.0	48
135	Decreasing role of lymphatic system surgery in surgical oncology. Journal of Surgical Oncology, 2005, 89, 61-66.	0.8	10
136	Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice?. Critical Reviews in Oncology/Hematology, 2005, 55, 67-81.	2.0	24
137	Progression of head and neck squamous cell cancer. Cancer and Metastasis Reviews, 2005, 24, 107-127.	2.7	51
138	Kinetics of Marked Development of Lung Metastasis of Rat Prostatic Carcinomas Transplanted in Syngeneic Rats. Clinical and Experimental Metastasis, 2005, 22, 309-318.	1.7	2
139	An Orthotopic Model of Human Osteosarcoma Growth and Spontaneous Pulmonary Metastasis. Clinical and Experimental Metastasis, 2005, 22, 319-329.	1.7	200
141	The postnatal rat aorta contains pericyte progenitor cells that form spheroidal colonies in suspension culture. American Journal of Physiology - Cell Physiology, 2005, 289, C1396-C1407.	2.1	121
142	Functional genomic analysis of cancer metastasis: biologic insights and clinical implications. Expert Review of Molecular Diagnostics, 2005, 5, 385-395.	1.5	25
143	Penta- O -galloyl-beta- d -glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. Carcinogenesis, 2005, 26, 1436-1445.	1.3	112
144	Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team. Journal of Clinical Oncology, 2005, 23, 990-998.	0.8	49
145	The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays a Role in Breast Tumor Growth and Is Present in the Urine of Breast Cancer Patients. Clinical Cancer Research, 2005, 11, 5390-5395.	3.2	254
146	Impaired tumor microenvironment in EphA2â€deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB Journal, 2005, 19, 1884-1886.	0.2	123

#	Article	IF	CITATIONS
147	Loss of Caveolin-1 Polarity Impedes Endothelial Cell Polarization and Directional Movement. Journal of Biological Chemistry, 2005, 280, 3541-3547.	1.6	126
148	Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies. Integrative Cancer Therapies, 2005, 4, 315-321.	0.8	75
149	VEGF-integrin interplay controls tumor growth and vascularization. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7589-7594.	3.3	172
150	Functional CT for Quantifying Tumor Perfusion in Antiangiogenic Therapy in a Rat Model. Radiology, 2005, 237, 151-158.	3.6	111
151	Fibroblast Growth Factor Signaling and the Function and Assembly of Basement Membranes. Current Topics in Developmental Biology, 2005, 66, 37-64.	1.0	5
152	Perfusion Imaging of the Liver: Current Challenges and Future Goals. Radiology, 2005, 234, 661-673.	3.6	263
153	p130Rb2 and p27kip1 cooperate to control mobilization of angiogenic progenitors from the bone marrow. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6890-6895.	3.3	19
154	Tumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy: Figure 1 Cancer Research, 2005, 65, 4471-4474.	0.4	94
155	Delivery of Antiangiogenic Agents for Cancer Gene Therapy. Technology in Cancer Research and Treatment, 2005, 4, 331-341.	0.8	5
156	Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell–Depleted Severe Combined Immunodeficient Mice. Clinical Cancer Research, 2005, 11, 8789-8798.	3.2	45
157	Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2. Cancer Research, 2005, 65, 4939-4946.	0.4	91
158	Annexin A2-S100A10 Heterotetramer, a Novel Substrate of Thioredoxin. Journal of Biological Chemistry, 2005, 280, 23584-23592.	1.6	29
159	Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results. Journal of Clinical Oncology, 2005, 23, 5474-5483.	0.8	470
160	The Homeobox Gene Gax Inhibits Angiogenesis through Inhibition of Nuclear Factor-κB–Dependent Endothelial Cell Gene Expression. Cancer Research, 2005, 65, 1414-1424.	0.4	86
161	A New Perspective on Tumor Endothelial Cells: Unexpected Chromosome and Centrosome Abnormalities: Figure 1 Cancer Research, 2005, 65, 2507-2510.	0.4	151
162	Apigenin inhibits VEGF and HIFâ€1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB Journal, 2005, 19, 342-353.	0.2	285
163	Hypoxia Inducible Factor Pathways as Targets for Functional Foods. Journal of Agricultural and Food Chemistry, 2005, 53, 3751-3768.	2.4	28
164	The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Experimental Cell Research, 2005, 310, 205-217.	1.2	197

#	Article	IF	CITATIONS
165	Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Research, 2005, 33, 6070-6080.	6.5	367
166	Robust quantification of in vitro angiogenesis through image analysis. IEEE Transactions on Medical Imaging, 2005, 24, 549-553.	5.4	170
167	Heparan Sulfate:  A Complex Polymer Charged with Biological Activity. Chemical Reviews, 2005, 105, 2745-2764.	23.0	362
168	Angiogenesis: a curse or cure?. Postgraduate Medical Journal, 2005, 81, 236-242.	0.9	83
169	Inhibition of Cell Proliferation and in Vitro Markers of Angiogenesis by Indole-3-carbinol, a Major Indole Metabolite Present in Cruciferous Vegetables. Journal of Agricultural and Food Chemistry, 2005, 53, 5164-5169.	2.4	37
170	Tracer Kinetic Model-Driven Registration for Dynamic Contrast Enhanced MRI Time Series. Lecture Notes in Computer Science, 2005, 8, 91-98.	1.0	11
171	Imaging of tumor angiogenesis in rat brains in vivo by photoacoustic tomography. Applied Optics, 2005, 44, 770.	2.1	189
172	CXC Chemokines in Cancer. Current Topics in Membranes, 2005, 55, 255-288.	0.5	O
173	The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. Clinical Cancer Research, 2005, 11, 7967-7985.	3.2	219
174	Rehabilitation of cancer through oncogene inactivation. Trends in Molecular Medicine, 2005, 11, 316-321.	3.5	27
175	The Effects of ZD6474, an Inhibitor of VEGF Signaling, on Cutaneous Wound Healing in Mice1. Journal of Surgical Research, 2005, 129, 251-259.	0.8	30
176	Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sciences, 2005, 77, 3231-3241.	2.0	91
177	Expression of angiogenesis factors in human umbilical vein endothelial cells and their regulation by PEDF. Biochemical and Biophysical Research Communications, 2005, 326, 387-394.	1.0	43
178	Resistance to epidermal growth factor receptor-targeted therapy. Drug Resistance Updates, 2005, 8, 298-310.	6.5	84
179	From a unique cell to metastasis is a long way to go: clues to stromelysin-3 participation. Biochimie, 2005, 87, 299-306.	1.3	45
180	Recombinant α2(IV)NC1 Domain Inhibits Tumor Cell-Extracellular Matrix Interactions, Induces Cellular Senescence, and Inhibits Tumor Growth in Vivo. American Journal of Pathology, 2005, 166, 901-911.	1.9	47
181	EGFL7 Is a Chemoattractant for Endothelial Cells and Is Up-Regulated in Angiogenesis and Arterial Injury. American Journal of Pathology, 2005, 167, 275-284.	1.9	124
182	Hyaluronan metabolism: a major paradox in cancer biology. Pathologie Et Biologie, 2005, 53, 372-382.	2.2	144

#	Article	IF	CITATIONS
183	Angiogenesis and lipoxins. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 271-275.	1.0	10
184	Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression. Cancer Cell International, 2005, 5, 14.	1.8	25
185	Evolution of Lymphadenectomy in Surgical Oncology. Surgical Oncology Clinics of North America, 2005, 14, 447-459.	0.6	9
186	2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as Covalent-Binding, Irreversible Inhibitors of the Kinase Domain of Vascular Endothelial Growth Factor Receptor-2. Journal of Medicinal Chemistry, 2005, 48, 7560-7581.	2.9	59
187	Comparison of the Performance of Tracer Kinetic Model-Driven Registration for Dynamic Contrast Enhanced MRI Using Different Models of Contrast Enhancement. Academic Radiology, 2006, 13, 1112-1123.	1.3	43
188	ICS-283: a system for targeted intravenous delivery of siRNA. Expert Opinion on Drug Delivery, 2006, 3, 445-454.	2.4	19
189	LOOKING FOR NEW PARADIGMS TOWARDS A BIOLOGICAL-MATHEMATICAL THEORY OF COMPLEX MULTICELLULAR SYSTEMS. Mathematical Models and Methods in Applied Sciences, 2006, 16, 1001-1029.	1.7	58
190	A Multitargeted Receptor Tyrosine Kinase Inhibitor, SU6668, Does Not Affect the Healing of Cutaneous Full-Thickness Incisional Wounds in SKH-1 Mice. Journal of Investigative Surgery, 2006, 19, 245-254.	0.6	7
191	Promising new treatments for neovascular age-related macular degeneration. Expert Opinion on Investigational Drugs, 2006, 15, 779-793.	1.9	68
192	Preferential Attachment of Peritoneal Tumor Metastases to Omental Immune Aggregates and Possible Role of a Unique Vascular Microenvironment in Metastatic Survival and Growth. American Journal of Pathology, 2006, 169, 1739-1752.	1.9	159
193	CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1 \hat{l}_{\pm} /VEGF Signaling. Neoplasia, 2006, 8, 394-401.	2.3	136
195	TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 119-150.	9.6	853
196	Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics, 2006, 7, 67-88.	0.6	60
197	Anti-VEGF Therapies for Diseases of the Retina and Choroid., 2006,, 309-339.		0
198	The tumour microenvironment and implications for cancer immunotherapy. Expert Opinion on Biological Therapy, 2006, 6, 671-684.	1.4	39
199	Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer. Clinical Cancer Research, 2006, 12, 6573-6584.	3.2	144
200	99mTc-Labeled Cyclic RGDfK Dimer:Â Initial Evaluation for SPECT Imaging of Glioma Integrin $\hat{l}\pm\nu\hat{l}^2$ 3Expression. Bioconjugate Chemistry, 2006, 17, 1069-1076.	1.8	65
201	Cellular basis of cancer metastasis: A review of fundamentals and new advances. Acta Histochemica, 2006, 108, 327-334.	0.9	74

#	Article	IF	CITATIONS
202	Vascular endothelial growth factor signalling in endothelial cell survival: A role for NFκB. Biochemical and Biophysical Research Communications, 2006, 340, 984-994.	1.0	70
203	Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells. Biochemical and Biophysical Research Communications, 2006, 343, 183-189.	1.0	49
204	Functions of CXCL12 and CXCR4 in breast cancer. Cancer Letters, 2006, 238, 30-41.	3.2	245
205	The tumor microenvironment in the post-PAGET era. Cancer Letters, 2006, 242, 1-10.	3.2	135
206	Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sciences, 2006, 78, 2558-2563.	2.0	62
207	The finest branches of the biliary tree might induce biliary vascularization necessary for biliary regeneration. Journal of Hepatology, 2006, 44, 947-955.	1.8	14
208	Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. Journal of Hepatology, 2006, 45, 688-695.	1.8	31
209	Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: Implications for targeting to tumor vasculature. Microvascular Research, 2006, 72, 54-61.	1.1	27
210	Dual-Color Imaging of Nascent Blood Vessels Vascularizing Pancreatic Cancer in an Orthotopic Model Demonstrates Antiangiogenesis Efficacy of Gemcitabine. Journal of Surgical Research, 2006, 132, 164-169.	0.8	35
211	Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis. Physiological Genomics, 2006, 27, 20-28.	1.0	81
213	Prognostic Factors and New Methods in Cervical Carcinoma. , 2006, 11, 130-139.		1
214	Targeting angiogenesis for the treatment of sarcoma. Current Opinion in Oncology, 2006, 18, 354-359.	1.1	36
215	Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding. FEBS Journal, 2006, 273, 5320-5332.	2.2	135
216	Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance. British Journal of Cancer, 2006, 94, 1516-1523.	2.9	21
217	Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. British Journal of Pharmacology, 2006, 149, 137-144.	2.7	62
218	Lymphatic microvessel density as prognostic marker in colorectal cancer. Modern Pathology, 2006, 19, 1317-1323.	2.9	103
219	New signals from the invasive front. Nature, 2006, 441, 444-450.	13.7	900
220	TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene, 2006, 25, 650-655.	2.6	48

#	ARTICLE	IF	CITATIONS
221	High Expression of CD105 as a Prognostic Predictor of Early Tongue Cancer. Laryngoscope, 2006, 116, 1175-1179.	1.1	41
222	Cancer: A Systems Biology disease. BioSystems, 2006, 83, 81-90.	0.9	359
223	Combining radiotherapy and angiogenesis inhibitors: Clinical trial design. International Journal of Radiation Oncology Biology Physics, 2006, 64, 15-25.	0.4	40
225	VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 836-841.	0.4	34
226	Therapeutic effects of paclitaxel-containing ultrasound contrast agents. Ultrasound in Medicine and Biology, 2006, 32, 1771-1780.	0.7	148
227	Mechanisms of Angiogenesis in Brain Tumors and their Translation into Therapeutic Anti-tumor Strategies., 2006,, 219-235.		0
228	Radiolabeled Multimeric Cyclic RGD Peptides as Integrin $\hat{l}\pm\nu\hat{l}^2$ 3 Targeted Radiotracers for Tumor Imaging. Molecular Pharmaceutics, 2006, 3, 472-487.	2.3	310
229	The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle. Cancer and Metastasis Reviews, 2006, 25, 459-467.	2.7	18
230	The inhibition of lung colonization of B16-F10 melanoma cells in EFA-deficient animals is related to enhanced apoptosis and reduced angiogenesis. Clinical and Experimental Metastasis, 2006, 23, 159-165.	1.7	4
231	Tissue kallikrein and kinin receptor expression in an angiogenic co-culture neuroblastoma model. Metabolic Brain Disease, 2006, 21, 242-254.	1.4	8
232	S100A13, a new marker of angiogenesis in human astrocytic gliomas. Journal of Neuro-Oncology, 2006, 80, 251-259.	1.4	41
233	Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay. Angiogenesis, 2006, 9, 53-58.	3.7	11
234	Tissue Endostatin Correlates Inversely with Capillary Network in Rat Heart and Skeletal Muscles. Angiogenesis, 2006, 9, 93-99.	3.7	19
235	Angiogenesisâ€"understanding the mathematical challenge. Angiogenesis, 2006, 9, 127-138.	3.7	18
236	$\hat{l}\pm v\hat{l}^2$ 3-integrin imaging: a new approach to characterise angiogenesis?. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 54-63.	3.3	139
237	Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. Journal of Molecular Medicine, 2006, 84, 764-773.	1.7	53
238	Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. Targeted Oncology, 2006, 1 , $123-129$.	1.7	4
239	The effect of twist expression on angiogenesis in hepatocellular carcinoma. Chinese Journal of Clinical Oncology, 2006, 3, 413-418.	0.0	1

#	Article	IF	CITATIONS
240	Melanotransferrin stimulates t-PA-dependent activation of plasminogen in endothelial cells leading to cell detachment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 393-401.	1.9	12
241	Antiangiogenic peptides and proteins: From experimental tools to clinical drugs. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1765, 155-177.	3.3	31
242	The Angiogenic Switch Molecule, Secreted FGF-Binding Protein, an Indicator of Early Stages of Pancreatic and Colorectal Adenocarcinoma. Seminars in Oncology, 2006, 33, 50-56.	0.8	172
243	Heat shock proteins in cancer: chaperones of tumorigenesis. Trends in Biochemical Sciences, 2006, 31, 164-172.	3.7	840
244	mda-7/IL-24: Multifunctional cancer-specific apoptosis-inducing cytokine. , 2006, 111, 596-628.		164
245	Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators. BMC Cancer, 2006, 6, 149.	1.1	6
246	Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression. BMC Cancer, 2006, 6, 280.	1.1	33
247	Development of antibody-based therapeutics for oncology indications. Drug Development Research, 2006, 67, 699-728.	1.4	3
248	Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. Journal of Cellular Biochemistry, 2006, 97, 1370-1378.	1.2	60
249	Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. Journal of Cellular Biochemistry, 2006, 98, 954-965.	1.2	12
250	Adenovirus-mediated intra-tumoral delivery of the humanendostatingene inhibits tumor growth in nasopharyngeal carcinoma. International Journal of Cancer, 2006, 118, 2064-2071.	2.3	31
251	Fibronectin as target for tumor therapy. International Journal of Cancer, 2006, 118, 1331-1339.	2.3	202
252	Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. International Journal of Cancer, 2006, 119, 1194-1207.	2.3	42
253	Outgrowth of human liver metastases after resection of the primary colorectal tumor: A shift in the balance between apoptosis and proliferation. International Journal of Cancer, 2006, 119, 1249-1253.	2.3	118
254	Anti-angiogenic drugs: from bench to clinical trials. Medicinal Research Reviews, 2006, 26, 483-530.	5.0	146
255	Morphological patterns of angiogenesis in ovarian follicle capillary networks. A scanning electron microscopy study of corrosion cast. Microscopy Research and Technique, 2006, 69, 459-468.	1.2	48
256	RE: Correlational of oral tongue cancer inversion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression, by Kim S-H, Cho NH, Kim K, et al Journal of Surgical Oncology, 2006, 93, 253-254.	0.8	15
257	High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis. Journal of Surgical Oncology, 2006, 94, 413-417.	0.8	53

#	Article	IF	CITATIONS
258	Tumor cell dormancy induced by p38SAPK and ER-stress signaling: An adaptive advantage for metastatic cells?. Cancer Biology and Therapy, 2006, 5, 729-735.	1.5	93
259	Opposing Roles of Mitogenic and Stress Signaling Pathways in the Induction of Cancer Dormancy. Cell Cycle, 2006, 5, 1799-1807.	1.3	87
260	The Problem of Cancer Dormancy: Understanding the Basic Mechanisms and Identifying Therapeutic Opportunities. Cell Cycle, 2006, 5, 1740-1743.	1.3	56
261	Systemic Induction of the Angiogenesis Switch by the Tetraspanin D6.1A/CO-029. Cancer Research, 2006, 66, 7083-7094.	0.4	207
263	The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS. Acta Oncol \tilde{A}^3 gica, 2006, 45, 306-316.	0.8	18
264	Potential of fibroblasts to regulate the formation of three-dimensional vessel-like structures from endothelial cells in vitro. American Journal of Physiology - Cell Physiology, 2006, 290, C1385-C1398.	2.1	155
265	HSulf-1 Inhibits Angiogenesis and Tumorigenesis In vivo. Cancer Research, 2006, 66, 6025-6032.	0.4	131
266	Heparanase Induces Vascular Endothelial Growth Factor Expression: Correlation with p38 Phosphorylation Levels and Src Activation. Cancer Research, 2006, 66, 1455-1463.	0.4	234
267	Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate. Toxicologic Pathology, 2006, 34, 131-147.	0.9	63
268	Angiogenesis in Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1948-1957.	1.1	114
269	Functional Coupling of p38-Induced Up-regulation of BiP and Activation of RNA-Dependent Protein Kinase–Like Endoplasmic Reticulum Kinase to Drug Resistance of Dormant Carcinoma Cells. Cancer Research, 2006, 66, 1702-1711.	0.4	291
270	Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species. Journal of Cell Science, 2006, 119, 2727-2738.	1.2	106
271	The Influence of a Human Embryonic Stem Cellâ€"Derived Microenvironment on Targeting of Human Solid Tumor Xenografts. Cancer Research, 2006, 66, 3792-3801.	0.4	43
272	Concurrent Cisplatin-Based Chemoradiation for Cervical Carcinoma: Tumor Response, Toxicity, and Serum Cytokine Profiles. Cancer Investigation, 2006, 24, 390-395.	0.6	19
273	Clinical Implications of EGFR Expression in the Development and Progression of Solid Tumors: Focus on Non‧mall Cell Lung Cancer. Oncologist, 2006, 11, 358-373.	1.9	60
274	Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962. Clinical Cancer Research, 2006, 12, 6978-6984.	3.2	35
275	Mycophenolic Acid Is a Potent Inhibitor of Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2414-2416.	1.1	28
276	Lipopeptide-based liposomes for DNA delivery into cells expressing neuropilin-1. Journal of Drug Targeting, 2006, 14, 694-706.	2.1	22

#	Article	IF	CITATIONS
277	Preparing the "Soilâ€₁ The Primary Tumor Induces Vasculature Reorganization in the Sentinel Lymph Node before the Arrival of Metastatic Cancer Cells. Cancer Research, 2006, 66, 10365-10376.	0.4	262
278	Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma. Clinical Cancer Research, 2006, 12, 2676-2688.	3.2	112
279	Characterization of the Mouse IFN-λ Ligand-Receptor System: IFN-λs Exhibit Antitumor Activity against B16 Melanoma. Cancer Research, 2006, 66, 4468-4477.	0.4	229
280	Hypoxia-Inducible Factor- $1\hat{l}\pm$ Promotes Nonhypoxia-Mediated Proliferation in Colon Cancer Cells and Xenografts. Cancer Research, 2006, 66, 1684-1693.	0.4	108
281	Ephrin-A1 Facilitates Mammary Tumor Metastasis through an Angiogenesis-Dependent Mechanism Mediated by EphA Receptor and Vascular Endothelial Growth Factor in Mice. Cancer Research, 2006, 66, 10315-10324.	0.4	122
282	Endorepellin In Vivo: Targeting the Tumor Vasculature and Retarding Cancer Growth and Metabolism. Journal of the National Cancer Institute, 2006, 98, 1634-1646.	3.0	106
283	Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16266-16271.	3.3	144
284	CCL2 Regulates Angiogenesis via Activation of Ets-1 Transcription Factor. Journal of Immunology, 2006, 177, 2651-2661.	0.4	170
285	Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 2006, 80, 1183-1196.	1.5	287
286	Preliminary Report on Analysis of Bladder-Wall Vasculature Using Conjunctival Microvascular Analysis in Patients with and without Transitional-Cell Carcinoma. Journal of Endourology, 2006, 20, 351-355.	1.1	0
287	Mechanism of Reoxygenation after Antiangiogenic Therapy Using SU5416 and Its Importance for Guiding Combined Antitumor Therapy. Cancer Research, 2006, 66, 9698-9704.	0.4	59
288	Vascular Integrins in Tumor Angiogenesis: Mediators and Therapeutic Targets. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 113-135.	1.7	149
289	Antiangiogenic and Antitumor Activities of IL-27. Journal of Immunology, 2006, 176, 7317-7324.	0.4	161
290	ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells. Cancer Research, 2006, 66, 2028-2037.	0.4	182
291	Antiâ€angiogenesis therapy can overcome endothelial cell anergy and promote leukocyteâ€endothelium interactions and infiltration in tumors. FASEB Journal, 2006, 20, 621-630.	0.2	237
292	Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus–mediated expression of human endostatin. Molecular Cancer Therapeutics, 2006, 5, 1290-1298.	1.9	35
293	A New Mechanism for Prolactin Processing into 16K PRL by Secreted Cathepsin D. Molecular Endocrinology, 2006, 20, 3263-3278.	3.7	44
294	Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy. Journal of the National Cancer Institute, 2007, 99, 1768-1781.	3.0	158

#	Article	IF	CITATIONS
295	Stress Hormones Regulate Interleukin-6 Expression by Human Ovarian Carcinoma Cells through a Src-dependent Mechanism. Journal of Biological Chemistry, 2007, 282, 29919-29926.	1.6	134
296	Tumor Vascular Proteins As Biomarkers in Ovarian Cancer. Journal of Clinical Oncology, 2007, 25, 852-861.	0.8	172
297	Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Molecular Cancer Therapeutics, 2007, 6, 1039-1045.	1.9	67
298	Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology:Theory, Data Acquisition,Analysis, and Examples. Current Medical Imaging, 2007, 3, 91-107.	0.4	325
299	Review: Implications of In Vitro Research on the Effect of Radiotherapy and Chemotherapy Under Hypoxic Conditions. Oncologist, 2007, 12, 690-712.	1.9	124
300	High VEGF with Rapid Growth and Early Metastasis in a Mouse Osteosarcoma Model. Sarcoma, 2007, 2007, 1-7.	0.7	23
301	Mannose 6-Phosphate Receptor Targeting and its Applications in Human Diseases. Current Medicinal Chemistry, 2007, 14, 2945-2953.	1.2	147
302	Adeno-Associated Virus–Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin. Clinical Cancer Research, 2007, 13, 3968-3976.	3.2	39
303	Zidovudine and interferon- \hat{l} ± treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leukemia and Lymphoma, 2007, 48, 330-336.	0.6	36
304	\hat{l}^2 -Carotene Inhibits Tumor-Specific Angiogenesis by Altering the Cytokine Profile and Inhibits the Nuclear Translocation of Transcription Factors in B16F-10 Melanoma Cells. Integrative Cancer Therapies, 2007, 6, 258-270.	0.8	68
305	Nuclear Factor-κB–Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma. Clinical Cancer Research, 2007, 13, 3182-3190.	3.2	110
306	Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Molecular Cancer Therapeutics, 2007, 6, 3297-3306.	1.9	36
308	Functional VEGF and VEGF receptors are expressed in human medulloblastomas. Neuro-Oncology, 2007, 9, 384-392.	0.6	53
309	The Proangiogenic Phenotype of Tumor-Derived Endothelial Cells is Reverted by the Overexpression of Platelet-Activating Factor Acetylhydrolase. Clinical Cancer Research, 2007, 13, 5710-5718.	3.2	10
310	The Homeobox Gene GAX Activates p21WAF1/CIP1 Expression in Vascular Endothelial Cells through Direct Interaction with Upstream AT-rich Sequences. Journal of Biological Chemistry, 2007, 282, 507-517.	1.6	35
312	Imaging Biomarker Applications in Oncology Drug Development. Drug Information Journal, 2007, 41, 561-572.	0.5	1
313	Aqueous Humor sCD44 Concentration and Visual Field Loss in Primary Open-angle Glaucoma. Journal of Glaucoma, 2007, 16, 419-429.	0.8	35
314	Nitric Oxide and Its Gatekeeper Thrombospondin-1 in Tumor Angiogenesis: Fig. 1 Clinical Cancer Research, 2007, 13, 795-798.	3.2	62

#	Article	IF	CITATIONS
315	Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis. Anti-Cancer Drugs, 2007, 18, 349-355.	0.7	17
316	Targeted agents in the treatment of pancreatic cancer: history and lessons learned. Current Opinion in Oncology, 2007, 19, 390-395.	1.1	9
317	The role of adhesion molecules, $\hat{l}\pm v\hat{l}^23$, $\hat{l}\pm v\hat{l}^25$ and their ligands in the tumor cell and endothelial cell adhesion. European Journal of Cancer Prevention, 2007, 16, 517-527.	0.6	28
318	Sulfoglycolipids as candidate antiangiogenic radiosensitizers. Anti-Cancer Drugs, 2007, 18, 1-5.	0.7	6
319	Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anti-Cancer Drugs, 2007, 18, 1189-1200.	0.7	78
320	Bioactivity and stability analysis of endostatin purified from fermentation supernatant of 293 cells transfected with Ad/rhEndo. Protein Expression and Purification, 2007, 56, 205-211.	0.6	8
321	The Elevated Levels of Heat Shock Proteins In Cancer: A Suitable Case For Treatment?., 2007,, 351-366.		2
322	Angiogenic activitiy of syndecan-binding laminin peptide AG73 (RKRLQVQLSIRT). Archives of Biochemistry and Biophysics, 2007, 459, 249-255.	1.4	49
323	An antibody directed against PDGF receptor \hat{l}^2 enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochemical and Biophysical Research Communications, 2007, 357, 1142-1147.	1.0	37
324	Anti-angiogenic peptides identified in thrombospondin type I domains. Biochemical and Biophysical Research Communications, 2007, 359, 63-69.	1.0	24
325	Multipotent Adult Progenitor Cells (MAPC) contribute to hepatocarcinoma neovasculature. Biochemical and Biophysical Research Communications, 2007, 364, 92-99.	1.0	12
326	The effect of anticoagulants on cancer risk and survival: Systematic review. Cancer Treatment Reviews, 2007, 33, 358-368.	3.4	45
327	Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells. International Journal of Biochemistry and Cell Biology, 2007, 39, 2314-2323.	1.2	24
328	Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Letters, 2007, 253, 34-42.	3.2	93
329	Role of chemokines in tumor growth. Cancer Letters, 2007, 256, 137-165.	3.2	516
330	Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Letters, 2007, 257, 97-106.	3.2	32
331	Cancer dissemination: A consequence of limited carrying capacity?. Medical Hypotheses, 2007, 69, 173-177.	0.8	16
332	Targeted gene-delivery strategies for angiostatic cancer treatment. Trends in Molecular Medicine, 2007, 13, 200-209.	3.5	22

#	Article	IF	CITATIONS
333	Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis. Endocrine Reviews, 2007, 28, 297-321.	8.9	319
334	Expression of vascular endothelial-cadherin in human hepatocellular carcinoma tissues. Hepatology Research, 2007, 37, 444-453.	1.8	6
335	Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Therapy, 2007, 14, 503-513.	2.3	38
336	An update on the clinical development of drugs to disable tumor vasculature. Expert Opinion on Drug Discovery, 2007, 2, 1357-1367.	2.5	11
337	PEGylated DX-1000: Pharmacokinetics and Antineoplastic Activity of a Specific Plasmin Inhibitor. Neoplasia, 2007, 9, 927-937.	2.3	36
338	Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy. Topics in Medicinal Chemistry, 2007, , 333-382.	0.4	0
339	The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies. Hematology/Oncology Clinics of North America, 2007, 21, 1007-1034.	0.9	110
340	Novel agents in ovarian cancer. Expert Opinion on Investigational Drugs, 2007, 16, 1227-1239.	1.9	9
341	Alpha-v Integrins as Therapeutic Targets in Oncology. Cancer Investigation, 2007, 25, 632-646.	0.6	94
342	Integrin Inhibitors Reaching the Clinic. Journal of Clinical Oncology, 2007, 25, 1637-1638.	0.8	116
343	Chrysin inhibits expression of hypoxia-inducible factor- $1\hat{l}\pm$ through reducing hypoxia-inducible factor- $1\hat{l}\pm$ stability and inhibiting its protein synthesis. Molecular Cancer Therapeutics, 2007, 6, 220-226.	1.9	155
344	Small Molecule Signal Transduction Inhibitors for the Treatment of Solid Tumors. Cancer Investigation, 2007, 25, 347-365.	0.6	16
345	Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Molecular Oncology, 2007, 1 , 288-302.	2.1	139
346	The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents. Molecular Cancer Research, 2007, 5, 203-220.	1.5	378
347	Matrix Metalloprotease–9 in Cerebrospinal Fluid Correlates with Disease Activity in Lymphomatous Meningitis. Clinical Lymphoma and Myeloma, 2007, 7, 305-308.	1.4	4
348	Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 4351-4373.	2.9	143
349	Measuring Tumor Perfusion in Control and Treated Murine Tumors. Journal of Ultrasound in Medicine, 2007, 26, 749-756.	0.8	54
350	Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized19F MRS pharmacokinetic studies of 5-fluorouracil. NMR in Biomedicine, 2007, 20, 128-140.	1.6	49

#	Article	IF	CITATIONS
351	Angiogenesis in the Caprine Caruncles in Non-Pregnant and Pregnant Normal and Swainsonine-Treated Does. Anatomical Record, 2007, 290, 761-769.	0.8	11
352	Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematological Oncology, 2007, 25, 164-169.	0.8	63
353	The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. International Journal of Cancer, 2007, 120, 753-760.	2.3	44
354	Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. International Journal of Cancer, 2008, 122, 1019-1029.	2.3	63
355	Expression pattern of Vasohibinduring chick development. Developmental Dynamics, 2007, 236, 1358-1362.	0.8	18
356	Ligand-Based Vascular Targeting of Disease. ChemMedChem, 2007, 2, 22-40.	1.6	51
357	Characterization of focal liver lesions: Comparison of pulse-inversion harmonic contrast-enhanced sonography with contrast-enhanced CT. Journal of Clinical Ultrasound, 2007, 35, 109-117.	0.4	45
358	MRI of tumor angiogenesis. Journal of Magnetic Resonance Imaging, 2007, 26, 235-249.	1.9	253
359	Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Critical Reviews in Oncology/Hematology, 2007, 63, 150-159.	2.0	59
360	Calmodulin is essential for angiogenesis in response to hypoxic stress in endothelial cells. Cell Biology International, 2007, 31, 126-134.	1.4	14
361	Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch― Leukemia Research, 2007, 31, 899-906.	0.4	67
362	The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers. Journal of Pathology, 2007, 212, 335-344.	2.1	14
363	Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene, 2007, 26, 1357-1360.	2.6	224
364	Darwinian medicine: a case for cancer. Nature Reviews Cancer, 2007, 7, 213-221.	12.8	145
365	Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 2007, 7, 834-846.	12.8	1,413
366	Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient mice. EMBO Journal, 2007, 26, 3686-3698.	3.5	94
367	An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation. Laboratory Investigation, 2007, 87, 1092-1102.	1.7	33
368	Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 1-14.	0.7	105

#	Article	IF	CITATIONS
369	Natural Antioxidant Pedicularioside G Inhibits Angiogenesis and Tumourigenesis in vitro and in vivo. Basic and Clinical Pharmacology and Toxicology, 2007, 102, 071031053307005-???.	1.2	19
370	PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cellular Signalling, 2007, 19, 2487-2497.	1.7	182
371	Radiation-induced senescence-like phenotype in proliferating and plateau-phase vascular endothelial cells. Experimental Cell Research, 2007, 313, 3326-3336.	1.2	43
372	Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Experimental Cell Research, 2007, 313, 3337-3348.	1.2	72
373	Can loss of apoptosis protect against cancer?. Trends in Genetics, 2007, 23, 232-237.	2.9	39
374	Clinical Significance of Histone Deacetylase Inhibitors in Cancer. , 2007, , 335-361.		0
375	Characterization of the CXCR4 Signaling in Pancreatic Cancer Cells. International Journal of Gastrointestinal Cancer, 2006, 37, 110-9.	0.4	48
376	Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension. American Journal of Obstetrics and Gynecology, 2007, 196, 68.e1-68.e6.	0.7	46
377	In vivo imaging of tumour angiogenesis in mice with the $\hat{l}\pm v\hat{l}^23$ integrin-targeted tracer 99mTc-RAFT-RGD. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 2037-2047.	3.3	62
378	Challenges for patient selection with VEGF inhibitors. Cancer Chemotherapy and Pharmacology, 2007, 60, 151-170.	1.1	77
379	Inhibition of adenovirus-mediated human MAGE-D1 on angiogenesis in vitro and in vivo. Molecular and Cellular Biochemistry, 2007, 300, 89-99.	1.4	11
380	Differential Roles of Angiotensinogen and Angiotensin Receptor type 1 Polymorphisms in Breast Cancer Risk. Breast Cancer Research and Treatment, 2007, 101, 299-304.	1.1	27
381	Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer and Metastasis Reviews, 2007, 26, 241-248.	2.7	364
382	Chemokines: novel targets for breast cancer metastasis. Cancer and Metastasis Reviews, 2007, 26, 401-420.	2.7	155
383	Visualization of nascent tumor angiogenesis in lung and liver metastasis by differential dual-color fluorescence imaging in nestin-linked-GFP mice. Clinical and Experimental Metastasis, 2007, 23, 315-322.	1.7	21
384	Major but not minor hepatectomy accelerates engraftment of extrahepatic tumor cells. Clinical and Experimental Metastasis, 2007, 24, 39-48.	1.7	31
385	Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis, 2007, 10, 23-34.	3.7	21
387	VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. Targeted Oncology, 2007, 2, 153-164.	1.7	10

#	ARTICLE	IF	CITATIONS
388	Assessment of the Early Effects of 5,6-Dimethylxanthenone-4-Acetic Acid Using Macromolecular Contrast Media–Enhanced Magnetic Resonance Imaging: Ectopic Versus Orthotopic Tumors. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1198-1207.	0.4	19
389	Osteopontin: regulation in tumor metastasis. Cancer and Metastasis Reviews, 2008, 27, 103-118.	2.7	287
390	Blood Flow and Glucose Metabolism in Stage IV Breast Cancer: Heterogeneity of Response During Chemotherapy. Molecular Imaging and Biology, 2008, 10, 356-63.	1.3	8
391	Synthesis and characterization of arginine–glycine–aspartic peptides conjugated poly(lactic) Tj ETQq1 1 0.784	1314 rgBT 1.7	/Overlock 21
392	Antiangiogenic and growth inhibitory effects of synthetic novel 1, 5-diphenyl-1,4 pentadiene-3-one-3-yl-ethanone pyridine curcumin analogues on Ehrlich ascites tumor in vivo. Medicinal Chemistry Research, 2008, 17, 515-529.	1.1	8
393	Differentiation of infective from neoplastic brain lesions by dynamic contrast-enhanced MRI. Neuroradiology, 2008, 50, 531-540.	1.1	70
394	Bronchial circulation angiogenesis in the rat quantified with SPECT and micro-CT. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1124-1132.	3.3	18
395	68Ga- and 111In-labelled DOTA-RGD peptides for imaging of $\hat{l}\pm\nu\hat{l}^2$ 3 integrin expression. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1507-1515.	3.3	145
396	What is the impact of biologicals in colorectal cancer?. Targeted Oncology, 2008, 3, 59-69.	1.7	0
397	Functional computed tomography imaging of tumor-induced angiogenesis: preliminary results of new tracer kinetic modeling using a computer discretization approach. Radiation Medicine, 2008, 26, 213-221.	0.8	3
398	Endothelial and Hematopoietic Progenitor Cells (EPCs and HPCs): Hand in Hand Fate Determining Partners for Cancer Cells. Stem Cell Reviews and Reports, 2008, 4, 169-177.	5.6	48
399	Functional analysis of tumor metastasis: modeling colon cancer. Oncology Reviews, 2008, 2, 9-20.	0.8	2
400	High level of endostatin in epididymal epithelium: protection against primary malignancies in this organ?. Histochemistry and Cell Biology, 2008, 130, 527-535.	0.8	8
401	Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. Journal of Molecular Signaling, 2008, 3, 7.	0.5	86
402	Glioblastoma stem cells produce vascular endothelial growth factor by activation of a Gâ€protein coupled formylpeptide receptor FPR. Journal of Pathology, 2008, 215, 369-376.	2.1	68
403	Novel interactions of perlecan: Unraveling perlecan's role in angiogenesis. Microscopy Research and Technique, 2008, 71, 339-348.	1.2	85
404	Adenoâ€associated virusâ€mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. Journal of Gene Medicine, 2008, 10, 508-517.	1.4	31
405	Angiopoietinâ€1 and â€2 expression in recurrent squamous cell carcinoma of the oral cavity. Journal of Surgical Oncology, 2008, 97, 273-277.	0.8	20

#	Article	IF	CITATIONS
406	Rational Design of Highly Active and Selective Ligands for the $\hat{l}\pm5\hat{l}^21$ Integrin Receptor. ChemBioChem, 2008, 9, 1397-1407.	1.3	73
407	Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal <i>in vivo</i> and <i>ex vivo</i> study. NMR in Biomedicine, 2008, 21, 1043-1056.	1.6	98
408	Application of cryobiopsy to morphological and immunohistochemical analyses of xenografted human lung cancer tissues and functional blood vessels. Cancer, 2008, 113, 1068-1079.	2.0	39
409	Integrin α _v β ₃ â€ŧargeted cancer therapy. Drug Development Research, 2008, 69, 329-339.	1.4	267
410	VEGFâ€D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. International Journal of Cancer, 2008, 122, 2471-2481.	2.3	56
411	Novel antiâ€angiogenic peptides derived From ELRâ€containing CXC chemokines. Journal of Cellular Biochemistry, 2008, 104, 1356-1363.	1.2	22
412	Quercetin suppresses hypoxiaâ€induced accumulation of hypoxiaâ€inducible factorâ€1α (HIFâ€1α) through inhibiting protein synthesis. Journal of Cellular Biochemistry, 2008, 105, 546-553.	1.2	66
413	Genetic alterations in juvenile nasopharyngeal angiofibromas. Head and Neck, 2008, 30, 390-400.	0.9	80
414	Quantitative correlation between 1H MRS and dynamic contrast-enhanced MRI of human breast cancer. Magnetic Resonance Imaging, 2008, 26, 523-531.	1.0	34
415	From the mathematical kinetic theory of active particles to multiscale modelling of complex biological systems. Mathematical and Computer Modelling, 2008, 47, 687-698.	2.0	9
416	Recent developments on 3-hydroxy-4-pyridinones with respect to their clinical applications. Coordination Chemistry Reviews, 2008, 252, 1213-1224.	9.5	52
417	Metastatic Dormancy Imposed by the Primary Tumor: Does it Exist in Humans?. Annals of Surgical Oncology, 2008, 15, 3308-3315.	0.7	48
418	The Progression of Inflammation Parallels the Dermal Angiogenesis in a Keratin 14 ILâ€4â€√ransgenic Model of Atopic Dermatitis. Microcirculation, 2008, 15, 49-64.	1.0	41
419	Histone Deacetylase Inhibitors: Mechanisms and Clinical Significance in Cancer: HDAC Inhibitor-Induced Apoptosis. Advances in Experimental Medicine and Biology, 2008, 615, 261-298.	0.8	141
420	The urokinase receptor (uâ€PAR)â€"a link between tumor cell dormancy and minimal residual disease in bone marrow?. Apmis, 2008, 116, 602-614.	0.9	46
421	A New Terrein Glucoside, a Novel Inhibitor of Angiogenin Secretion in Tumor Angiogenesis. Journal of Antibiotics, 2008, 61, 442-448.	1.0	48
422	Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Laboratory Investigation, 2008, 88, 740-749.	1.7	49
423	Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene, 2008, 27, 5373-5384.	2.6	71

#	Article	IF	CITATIONS
424	VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. British Journal of Cancer, 2008, 99, 1204-1209.	2.9	166
425	Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. British Journal of Cancer, 2008, 99, 1579-1585.	2.9	23
426	A microenvironmental model of carcinogenesis. Nature Reviews Cancer, 2008, 8, 56-61.	12.8	651
427	Time-course-dependent microvascular alterations in a model of myeloid leukemia in vivo. Leukemia, 2008, 22, 59-65.	3.3	24
428	Quantification of VEGF expression in canine mammary tumours. Australian Veterinary Journal, 2008, 86, 279-282.	0.5	14
429	New pharmacological strategies against metastatic spread. Fundamental and Clinical Pharmacology, 2008, 22, 465-492.	1.0	19
430	Immunohistochemical evaluation of the microvascular density through the expression of TGF- \hat{l}^2 (CD) Tj ETQq0 0 0 oligodendrogliomas. Neuropathology, 2008, 28, 17-23.	rgBT /Ove 0.7	erlock 10 Tf ! 34
431	Understanding tumor endothelial cell abnormalities to develop ideal antiâ€angiogenic therapies. Cancer Science, 2008, 99, 459-466.	1.7	107
432	Hyaluronidases in cancer biology. Seminars in Cancer Biology, 2008, 18, 275-280.	4.3	220
433	Metastatic tumours to the oral cavity – Pathogenesis and analysis of 673 cases. Oral Oncology, 2008, 44, 743-752.	0.8	403
434	Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. Journal of Controlled Release, 2008, 131, 86-93.	4.8	63
435	The Biology of Vascular Endothelial Cell Growth Factor Isoforms. , 2008, , 1-13.		4
436	Stathmin 1: a novel therapeutic target for anticancer activity. Expert Review of Anticancer Therapy, 2008, 8, 1461-1470.	1.1	130
437	Metastasis: a current perspective. , 2008, , 1-10.		0
438	Myeloid cells functioning in tumor vascularization as a novel therapeutic target. Translational Research, 2008, 151, 59-67.	2.2	22
439	Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Molecular Cancer, 2008, 7, 16 .	7.9	133
440	Chapter 8 An Assay System for In Vitro Detection of Permeability in Human "Endothelium― Methods in Enzymology, 2008, 443, 137-153.	0.4	45
441	VEGF and angiogenesis: implications for breast cancer therapy. European Journal of Cancer, Supplement, 2008, 6, 7-13.	2.2	16

#	Article	IF	CITATIONS
442	Eph receptors in breast cancer: roles in tumor promotion and tumor suppression. Breast Cancer Research, 2008, 10, 217.	2.2	79
443	Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis, 2008, 29, 2330-2334.	1.3	56
444	Coligand effects on the solution stability, biodistribution and metabolism of the 99mTc-labeled cyclic RGDfK tetramer. Nuclear Medicine and Biology, 2008, 35, 111-121.	0.3	38
445	Use of resorbable collagen dural substitutes in the presence of cranial and spinal infectionsâ€"report of 3 cases. World Neurosurgery, 2008, 70, 92-96.	1.3	26
446	The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Neurological Research, 2008, 30, 952-959.	0.6	22
447	Dietary glycine does not affect physiological angiogenesis and reproductive function, but inhibits apoptosis in endometrial and ovarian tissue by down-regulation of nuclear factor-κB. Fertility and Sterility, 2008, 90, 1460-1469.	0.5	7
448	In Vivo and In Vitro Efficacy of Zoledronate for Treating Oral Squamous Cell Carcinoma in Cats. Journal of Veterinary Internal Medicine, 2008, 22, 158-163.	0.6	28
449	Metronomic Therapy with Cyclophosphamide and Piroxicam Effectively Delays Tumor Recurrence in Dogs with Incompletely Resected Soft Tissue Sarcomas. Journal of Veterinary Internal Medicine, 2008, 22, 1373-1379.	0.6	139
450	Tumor–Microenvironment Interactions: Dangerous Liaisons. Advances in Cancer Research, 2008, 100, 203-229.	1.9	113
451	Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America, 2008, 17, 279-301.	0.6	12
452	ASA404: update on drug development. Expert Opinion on Investigational Drugs, 2008, 17, 1547-1551.	1.9	21
453	Has Molecular and Cellular Imaging Enhanced Drug Discovery and Drug Development?. Drugs in R and D, 2008, 9, 351-368.	1.1	26
454	Heat shock proteins: Stress proteins with Janus-like properties in cancer. International Journal of Hyperthermia, 2008, 24, 31-39.	1.1	132
455	Improving Tumor Uptake and Excretion Kinetics of ⁹⁹ ^m Tc-Labeled Cyclic Arginine-Glycine-Aspartic (RGD) Dimers with Triglycine Linkers. Journal of Medicinal Chemistry, 2008, 51, 7980-7990.	2.9	115
456	High resolution mapping of cortical blood flow by mosaicing the laser speckle images. , 2008, 2008, 3743-6.		0
457	An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells. Molecular Cancer Research, 2008, 6, 1630-1638.	1.5	84
458	Phenotypic and Functional Differences between Human Liver Cancer Endothelial Cells and Liver Sinusoidal Endothelial Cells. Journal of Vascular Research, 2008, 45, 78-86.	0.6	32
459	Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis, 2008, 29, 299-306.	1.3	37

#	Article	IF	CITATIONS
460	Suppression of Lung Tumor Growth and Metastasis in Mice by Adeno-Associated Virus-Mediated Expression of Vasostatin. Clinical Cancer Research, 2008, 14, 939-949.	3.2	50
461	Breast Cancer Treatment in the Era of Molecular Imaging. Breast Care, 2008, 3, 409-414.	0.8	2
462	Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood, 2008, 111, 1217-1226.	0.6	437
463	Anti-VEGF therapy: the search for clinical biomarkers. Expert Review of Molecular Diagnostics, 2008, 8, 301-314.	1.5	27
464	ON THE FOUNDATIONS OF CANCER MODELLING: SELECTED TOPICS, SPECULATIONS, AND PERSPECTIVES. Mathematical Models and Methods in Applied Sciences, 2008, 18, 593-646.	1.7	341
465	IFN-Î ² -Dependent Inhibition of Tumor Growth by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA). Journal of Interferon and Cytokine Research, 2008, 28, 133-139.	0.5	27
466	T-CAM, a fastatin-FIII 9-10 fusion protein, potently enhances anti-angiogenic and anti-tumor activity $\hat{l}\pm\hat{v}^2$ 3 and $\hat{l}\pm\hat{l}^2$ 1 integrins. Experimental and Molecular Medicine, 2008, 40, 196.	3.2	2
467	Synergistic Damage of Tumor Vessels with Ultra Low-Dose Endothelial-Monocyte Activating Polypeptide-II and Neovasculature-Targeted Tumor Necrosis Factor-α. Cancer Research, 2008, 68, 1154-1161.	0.4	45
468	Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012. Journal of Clinical Oncology, 2008, 26, 919-924.	0.8	143
469	Use of H215O-PET and DCE-MRI to Measure Tumor Blood Flow. Oncologist, 2008, 13, 631-644.	1.9	63
470	In Vivo Bioluminescence Imaging Monitoring of Hypoxia-Inducible Factor $1\hat{l}_{\pm}$, a Promoter That Protects Cells, in Response to Chemotherapy. American Journal of Roentgenology, 2008, 191, 1779-1784.	1.0	32
471	Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis. Clinical Cancer Research, 2008, 14, 6855-6866.	3.2	124
472	Isoaspartate-Glycine-Arginine: A New Tumor Vasculature–Targeting Motif. Cancer Research, 2008, 68, 7073-7082.	0.4	71
473	Kaposi's Sarcoma–Associated Herpesvirus Confers a Survival Advantage to Endothelial Cells. Cancer Research, 2008, 68, 4640-4648.	0.4	111
474	The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex–interactive agents. Molecular Cancer Therapeutics, 2008, 7, 880-889.	1.9	159
475	Chemical and Biological Evaluations of an $\langle \sup 111 \langle \sup $ In-Labeled RGD-Peptide Targeting Integrin Alpha(V) Beta(3) in a Preclinical Tumor Model. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 691-700.	0.7	18
476	Minute dosages of α <i>_ν</i> νi>β ₃ â€ŧargeted fumagillin nanoparticles impair Vxâ€2 tumor angiogenesis and development in rabbits. FASEB Journal, 2008, 22, 2758-2767.	0.2	102
477	Suppression of Renal Cell Carcinoma Growth and Metastasis with Sustained Antiangiogenic Gene Therapy. Human Gene Therapy, 2008, 19, 487-495.	1.4	5

#	Article	IF	Citations
478	Shikonin, Acetylshikonin, and Isobutyroylshikonin Inhibit VEGF-induced Angiogenesis and Suppress Tumor Growth in Lewis Lung Carcinoma-bearing Mice. Yakugaku Zasshi, 2008, 128, 1681-1688.	0.0	63
479	Vascular and Lymphatic Properties of the Superficial and Deep Lamina Propria in Barrett Esophagus. American Journal of Surgical Pathology, 2008, 32, 1454-1461.	2.1	22
480	Antiangiogenic therapy in nonsmall cell lung cancer. Current Opinion in Oncology, 2008, 20, 176-182.	1.1	22
481	Dynamic Contrast-Enhanced Derived Cerebral Blood Volume Correlates Better With Leak Correction Than With No Correction for Vascular Endothelial Growth Factor, Microvascular Density, and Grading of Astrocytoma. Journal of Computer Assisted Tomography, 2008, 32, 955-965.	0.5	34
482	Cancer Stem Cells and New Therapeutic Approaches. , 0, , 217-232.		O
483	Hyaluronidases in Cancer Biology. , 2008, , 207-220.		15
485	The Controversial Clinicobiological Role of Breast Cancer Stem Cells. Journal of Oncology, 2008, 2008, 1-12.	0.6	5
486	The Role of PPARs in the Endothelium: Implications for Cancer Therapy. PPAR Research, 2008, 2008, 1-12.	1.1	22
487	Role of Imaging Biomarkers in Drug Development. , 2008, , 139-159.		1
488	Increased Antiangiogenic Protein Expression in the Skeletal Muscle of Diabetic Swine and Patients. Archives of Surgery, 2008, 143, 463.	2.3	20
489	Role of Hyaluronan Metabolism in the Initiation, Invasion, and Metastasis of Breast Cancer. , 2009, , 341-360.		0
490	Age-related macular degeneration: experimental and emerging treatments. Clinical Ophthalmology, 2009, 3, 167.	0.9	13
491	Computational modeling in quantitative cancer imaging. , 2009, , .		0
492	Suppression of Tumor Angiogenesis by $\widehat{Gl}\pm 13$ Haploinsufficiency. Journal of Biological Chemistry, 2009, 284, 27409-27415.	1.6	10
493	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17769-17774.	3.3	33
494	Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg). International Immunology, 2009, 21, 1057-1063.	1.8	9
495	Conjunctival Melanomas: Can the Cancer Stem Cell Hypothesis be Applied?. Seminars in Ophthalmology, 2009, 24, 161-165.	0.8	2
496	A Novel Antiangiogenic Effect for Telomerase-Specific Virotherapy through Host Immune System. Journal of Immunology, 2009, 182, 1763-1769.	0.4	20

#	Article	IF	CITATIONS
497	S100A2 Induces Metastasis in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 22-29.	3.2	99
498	Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clinical Chemistry and Laboratory Medicine, 2009, 47, 874-9.	1.4	38
499	Signal Transducers and Activators of Transcription Mediate Fibroblast Growth Factor–Induced Vascular Endothelial Morphogenesis. Cancer Research, 2009, 69, 1668-1677.	0.4	65
500	VEGF-A Induces Angiogenesis by Perturbing the Cathepsin-Cysteine Protease Inhibitor Balance in Venules, Causing Basement Membrane Degradation and Mother Vessel Formation. Cancer Research, 2009, 69, 4537-4544.	0.4	110
501	EPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation. Clinical Cancer Research, 2009, 15, 4904-4914.	3.2	22
502	Decrease in Tumor Cell Oxygen Consumption after Treatment with Vandetanib (ZACTIMAâ,,¢; ZD6474) and its Effect on Response to Radiotherapy. Radiation Research, 2009, 172, 584-591.	0.7	39
503	Novel technologies for antiangiogenic drug delivery in the brain. Cell Adhesion and Migration, 2009, 3, 224-229.	1.1	10
504	Matrix Metalloproteinases in the Urine and Tissue of Patients With Juvenile Polyps: Potential Biomarkers for the Presence of Polyps. Journal of Pediatric Gastroenterology and Nutrition, 2009, 48, 405-411.	0.9	2
505	Mode of action and clinical impact of VEGF signaling inhibitors. Expert Review of Anticancer Therapy, 2009, 9, 649-662.	1.1	25
506	Structural Adaptation and Heterogeneity of Normal and Tumor Microvascular Networks. PLoS Computational Biology, 2009, 5, e1000394.	1.5	156
507	Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H428-H434.	1.5	81
508	EXPOSURE TO ENVIRONMENTAL TOBACCO SMOKE INDUCES ANGIOGENESIS AND LEUKOCYTE TRAFFICKING IN LUNG MICROVESSELS. Experimental Lung Research, 2009, 35, 119-135.	0.5	20
509	Phenobarbital Elicits Unique, Early Changes in the Expression of Hepatic Genes that Affect Critical Pathways in Tumor-Prone B6C3F1 Mice. Toxicological Sciences, 2009, 109, 193-205.	1.4	31
510	Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium/calmodulin-dependent protein kinase II. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L706-L714.	1.3	20
511	Niche-Dependent Tumorigenic Capacity of Malignant Ovarian Ascites-Derived Cancer Cell Subpopulations. Clinical Cancer Research, 2009, 15, 70-80.	3.2	32
512	Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness. Clinical Cancer Research, 2009, 15, 5511-5517.	3.2	150
513	Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Molecular Cancer Therapeutics, 2009, 8, 1596-1605.	1.9	58
514	The regulatory mechanism of $Hsp90\hat{l}_{\pm}$ secretion and its function in tumor malignancy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21288-21293.	3.3	226

#	Article	IF	CITATIONS
515	The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis. Seminars in Cancer Biology, 2009, 19, 111-115.	4.3	65
516	Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial. Gynecologic Oncology, 2009, 115, 90-96.	0.6	88
518	Plateletâ€derived microparticles promote invasiveness of prostate cancer cells <i>via</i> upregulation of MMPâ€2 production. International Journal of Cancer, 2009, 124, 1773-1777.	2.3	120
519	Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. International Journal of Cancer, 2009, 125, 1143-1146.	2.3	9
520	Cyclic RGD ontaining Functionalized Azabicycloalkane Peptides as Potent Integrin Antagonists for Tumor Targeting. ChemMedChem, 2009, 4, 615-632.	1.6	44
521	Targeted therapies in squamous cell carcinoma of the head and neck. Cancer, 2009, 115, 922-935.	2.0	122
522	In Vivo Electrochemical Detection of Nitroglycerinâ€Derived Nitric Oxide in Tumorâ€Bearing Mice. Electroanalysis, 2009, 21, 631-634.	1.5	10
523	Breaking the Dogma of the Metalâ€Coordinating Carboxylate Group in Integrin Ligands: Introducing Hydroxamic Acids to the MIDAS To Tune Potency and Selectivity. Angewandte Chemie - International Edition, 2009, 48, 4436-4440.	7.2	35
524	High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1359-1367.	1,2	16
525	Vascular targeted therapies in oncology. Cell and Tissue Research, 2009, 335, 241-248.	1.5	83
526	Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis, 2009, 12, 325-338.	3.7	83
527	Plasminogen fragment K1–3 inhibits expression of adhesion molecules and experimental HCC recurrence in the liver. International Journal of Colorectal Disease, 2009, 24, 837-844.	1.0	4
528	Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. Journal of Nutritional Biochemistry, 2009, 20, 663-676.	1.9	121
529	Imaging and quantifying the dynamics of tumor-associated proteolysis. Clinical and Experimental Metastasis, 2009, 26, 299-309.	1.7	44
530	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncology Reviews, 2009, 3, 79-87.	0.8	3
531	Effect of Small Interference RNA Targeting HIF- $1\hat{l}\pm$ Mediated by rAAV Combined l-Ascorbate on Pancreatic Tumors in Athymic Mice. Pathology and Oncology Research, 2009, 15, 109-114.	0.9	14
532	The foundations of a unified approach to mathematical modelling of angiogenesis. International Journal of Advances in Engineering Sciences and Applied Mathematics, 2009, 1, 43-52.	0.7	7
534	The effect of photodynamic therapy on tumor angiogenesis. Cellular and Molecular Life Sciences, 2009, 66, 2275-2283.	2.4	85

#	Article	IF	CITATIONS
535	68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin $\hat{l}\pm\nu\hat{l}^2$ 3 PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 947-957.	3.3	132
536	Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1296-1307.	3.3	115
537	Cadmium induces lung inflammation independent of lung cell proliferation: a molecular approach. Journal of Inflammation, 2009, 6, 19.	1.5	78
538	Neutrophils: key mediators of tumour angiogenesis. International Journal of Experimental Pathology, 2009, 90, 222-231.	0.6	257
539	Dkkâ€3 expression in the tumor endothelium: A novel prognostic marker of pancreatic adenocarcinomas. Cancer Science, 2009, 100, 1414-1420.	1.7	47
540	PEDF inhibits growth of retinoblastoma by antiâ€angiogenic activity. Cancer Science, 2009, 100, 2419-2425.	1.7	45
541	The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia. Leukemia, 2009, 23, 251-261.	3.3	29
542	Exploiting the tumor microenvironment in the development of targeted cancer gene therapy. Cancer Gene Therapy, 2009, 16, 279-290.	2.2	11
543	Orthotopic mouse lung transplantation as experimental methodology to study transplant and tumor biology. Nature Protocols, 2009, 4, 86-93.	5.5	68
544	Microenvironmental regulation of metastasis. Nature Reviews Cancer, 2009, 9, 239-252.	12.8	3,157
545	The metastatic niche: adapting the foreign soil. Nature Reviews Cancer, 2009, 9, 285-293.	12.8	1,081
546	Trophic macrophages in development and disease. Nature Reviews Immunology, 2009, 9, 259-270.	10.6	1,028
547	A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy. Journal of Theoretical Biology, 2009, 260, 545-562.	0.8	80
548	The Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor Cediranib (Recentin;) Tj ETQq1 1 0.7 International Journal of Radiation Oncology Biology Physics, 2009, 73, 897-903.	784314 rg 0.4	BT /Overlock 14
549	A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy. Immunology Letters, 2009, 126, 60-66.	1.1	12
550	Synthesis, discovery and preliminary SAR study of benzofuran derivatives as angiogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1851-1854.	1.0	33
551	Molecular Diversity of VEGF-A as a Regulator of Its Biological Activity. Microcirculation, 2009, 16, 572-592.	1.0	119
552	The Role of Lymph Node Metastasis in the Systemic Dissemination of Breast Cancer. Annals of Surgical Oncology, 2009, 16, 3396-3405.	0.7	44

#	Article	IF	CITATIONS
553	Tumor Stem Cells and Metastasis. , 2009, , 47-63.		0
554	Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence. Cancer Research, 2009, 69, 2685-2693.	0.4	262
556	Drugs targeting integrins for cancer therapy. Expert Opinion on Drug Discovery, 2009, 4, 229-241.	2.5	6
557	Improving Tumor Uptake and Pharmacokinetics of 64Cu-Labeled Cyclic RGD Peptide Dimers with Gly3and PEG4Linkers. Bioconjugate Chemistry, 2009, 20, 750-759.	1.8	123
558	Radiolabeled Cyclic RGD Peptides as Integrin $\hat{l}\pm \langle sub \rangle v \langle sub \rangle \hat{l}^2 \langle sub \rangle 3 \langle sub \rangle$ -Targeted Radiotracers: Maximizing Binding Affinity via Bivalency. Bioconjugate Chemistry, 2009, 20, 2199-2213.	1.8	315
559	Tumour vascularisation: a druggable target. Current Opinion in Pharmacology, 2009, 9, 96-101.	1.7	15
560	Targeted therapies in the treatment of advanced/metastatic NSCLC. European Journal of Cancer, 2009, 45, 2473-2487.	1.3	68
561	Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo. Cancer Letters, 2009, 281, 108-116.	3.2	51
562	Targeting critical steps of cancer metastasis and recurrence using telomerase template antagonists. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 240-247.	1.8	20
563	64Cu-Labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nuclear Medicine and Biology, 2009, 36, 277-285.	0.3	87
564	Angiogenesis and Tumor Progression in Neuroendocrine Digestive Tumors. Journal of Surgical Research, 2009, 154, 68-77.	0.8	28
565	The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Archives of Biochemistry and Biophysics, 2009, 489, 82-91.	1.4	58
566	PRO: Patients with Recurrent Ovarian Cancer Should Be Treated with Antiangiogenic Agents in Combination with Chemotherapy. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2009, 2, 12-15.	0.2	1
567	Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Molecular Cancer, 2009, 8, 94.	7.9	48
568	Applications of nanotechnology in molecular imaging of the brain. Progress in Brain Research, 2009, 180, 72-96.	0.9	16
569	Development of a Fully Human Anti-PDGFRβ Antibody That Suppresses Growth of Human Tumor Xenografts and Enhances Antitumor Activity of an Anti-VEGFR2 Antibody. Neoplasia, 2009, 11, 594-604.	2.3	55
570	¿Metastasis tardia, tumor latente o ambas cosas?. Gaceta Medica De Bilbao, 2009, 106, 97-100.	0.0	0
571	Stochastic Population Dynamic Effects for Lung Cancer Progression. Radiation Research, 2009, 172, 383-393.	0.7	17

#	Article	IF	CITATIONS
572	Fibroblastic reaction and vascular maturation in human colon cancers. International Journal of Radiation Biology, 2009, 85, 1013-1025.	1.0	11
573	Protective Effects of Mastic Oil From <i>Pistacia Lentiscus</i> Variation <i>Chia</i> Against Experimental Growth of Lewis Lung Carcinoma. Nutrition and Cancer, 2009, 61, 640-648.	0.9	51
574	Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma. Laboratory Investigation, 2009, 89, 575-586.	1.7	44
575	Autocrine Loop between Vascular Endothelial Growth Factor (VEGF)-C and VEGF Receptor-3 Positively Regulates Tumor-Associated Lymphangiogenesis in Oral Squamoid Cancer Cells. American Journal of Pathology, 2009, 175, 1709-1721.	1.9	43
576	A Key Role for the Integrin $\hat{i}\pm2\hat{i}^21$ in Experimental and Developmental Angiogenesis. American Journal of Pathology, 2009, 175, 1338-1347.	1.9	69
577	Biophysical models of tumour growth. Reports on Progress in Physics, 2009, 72, 056701.	8.1	145
578	Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncology, The, 2009, 10, 559-568.	5.1	398
579	Expression and release of angiopoietin-1 from human neutrophils: Intracellular mechanisms. Growth Factors, 2009, 27, 335-344.	0.5	48
580	Regulation of Membrane-Type 4 Matrix Metalloproteinase by SLUG Contributes to Hypoxia-Mediated Metastasis. Neoplasia, 2009, 11, 1371-IN14.	2.3	95
581	Cross talk Initiated by Endothelial Cells Enhances Migration and Inhibits Anoikis of Squamous Cell Carcinoma Cells through STAT3/Akt/ERK Signaling. Neoplasia, 2009, 11, 583-IN14.	2.3	122
582	Sonographic Assessment of Tumor Response. Ultrasound Quarterly, 2009, 25, 175-183.	0.3	20
583	High Sensitivity. Investigative Radiology, 2009, 44, 15-22.	3.5	75
584	A Somatostatin Analogue, Octreotide, Inhibits the Occurrence of Second Primary Tumors and Lung Metastasis after Resection of Hepatocellular Carcinoma in Mice. Tohoku Journal of Experimental Medicine, 2009, 218, 155-160.	0.5	15
585	Humanized large-scale expanded endothelial colony–forming cells function in vitro and in vivo. Blood, 2009, 113, 6716-6725.	0.6	201
586	Nutrigenomics and Nutrigenetics., 2009,, 457-475.		1
587	Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. Anti-Cancer Drugs, 2010, 21, 151-168.	0.7	9
588	Assessment of Bone Marrow Microvessel Density in Chronic Lymphocytic Leukemia. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 353-356.	0.6	8
589	Hexane–ethanol extract of <i>Glycyrrhiza uralensis</i> capacity of DU145 human prostate cancer cells. British Journal of Nutrition, 2010, 104, 1272-1282.	1.2	43

#	Article	IF	Citations
590	In Vivo Biological Purging for Lymph Node Metastasis of Human Colorectal Cancer by Telomerase-Specific Oncolytic Virotherapy. Annals of Surgery, 2010, 251, 1079-1086.	2.1	25
591	Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica, 2010, 95, 2157-2160.	1.7	44
592	Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells. Journal of Pharmacy and Pharmacology, 2010, 61, 1057-1066.	1.2	7
593	Shape Effect of Carbon Nanovectors on Angiogenesis. ACS Nano, 2010, 4, 574-582.	7.3	121
594	Positron emission tomography tracers for imaging angiogenesis. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 86-103.	3.3	102
595	Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti- $\hat{l}\pm 5\hat{l}^21$ integrin monoclonal antibody (volociximab) in cancer patients. Cancer Chemotherapy and Pharmacology, 2010, 65, 207-217.	1.1	31
596	Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 66, 935-943.	1.1	17
597	Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. European Journal of Clinical Pharmacology, 2010, 66, 813-821.	0.8	72
598	Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. Journal of Cancer Research and Clinical Oncology, 2010, 136, 667-675.	1.2	36
599	The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro. Journal of Cancer Research and Clinical Oncology, 2010, 136, 873-881.	1.2	13
600	PARP and PARG Inhibitorsâ€"New Therapeutic Targets in Cancer Treatment. Pathology and Oncology Research, 2010, 16, 469-478.	0.9	41
601	The Role of Lymph Node Metastasis in the Systemic Dissemination of Breast Cancer. Indian Journal of Surgical Oncology, 2010, 1, 313-322.	0.3	4
602	FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Molecular and Cellular Biochemistry, 2010, 337, 201-212.	1.4	68
603	A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier. Journal of Controlled Release, 2010, 145, 91-101.	4.8	52
604	The role of HER2 in cancer therapy and targeted drug delivery. Journal of Controlled Release, 2010, 146, 264-275.	4.8	442
605	Zebrafish Model: Worth Considering in Defining Tumor Angiogenesis. Trends in Cardiovascular Medicine, 2010, 20, 114-119.	2.3	28
606	Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid. BMC Cancer, 2010, 10, 175.	1.1	47
607	GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer, 2010, 10, 397.	1.1	36

#	Article	IF	Citations
608	Mechanism of endothelial progenitor cell recruitment into neo-vessels in adjacent non-tumor tissues in hepatocellular carcinoma. BMC Cancer, 2010, 10, 435.	1.1	32
609	Interleukins, laminin and epstein - barr virus latent membrane protein 1 (EBV LMP1) Promote metastatic phenotype in nasopharyngeal carcinoma. BMC Cancer, 2010, 10, 574.	1.1	32
610	Propranolol suppresses angiogenesis in vitro: Inhibition of proliferation, migration, and differentiation of endothelial cells. Vascular Pharmacology, 2010, 53, 200-208.	1.0	142
611	The interaction of angiocidin with tissue transglutaminase. Experimental and Molecular Pathology, 2010, 88, 15-25.	0.9	7
612	High efficacy and minimal peptide required for the antiâ€angiogenic and antiâ€hepatocarcinoma activities of plasminogen K5. Journal of Cellular and Molecular Medicine, 2010, 14, 2519-2530.	1.6	12
613	Combined DCEâ€MRI and singleâ€voxel 2D MRS for differentiation between benign and malignant breast lesions. NMR in Biomedicine, 2010, 23, 922-930.	1.6	30
614	Dynamics of microvascular remodelling during tumor growth in bone. Journal of Orthopaedic Research, 2010, 28, 27-31.	1.2	12
615	Cigarette smoke condensate induces nuclear factor kappaâ€b activity and proangiogenic growth factors in aerodigestive cells. Laryngoscope, 2010, 120, 1609-1613.	1.1	15
616	Significance of anti-angiogenic therapy in head and neck cancer—Heterogeneity of tumor endothelium. Japanese Dental Science Review, 2010, 46, 26-32.	2.0	4
617	Studies on glyphosate-induced carcinogenicity in mouse skin: A proteomic approach. Journal of Proteomics, 2010, 73, 951-964.	1.2	98
618	Methods for the identification of vascular markers in health and disease: From the bench to the clinic. Journal of Proteomics, 2010, 73, 2219-2229.	1.2	10
619	Detection of T2 changes in an early mouse brain tumor. Magnetic Resonance Imaging, 2010, 28, 784-789.	1.0	12
620	Synthesis and in vivo evaluation of Tc-99m-labeled cyclic CisoDGRC peptide conjugates for targeting $\hat{l}\pm v\hat{l}^23$ integrin expression. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5969-5972.	1.0	13
621	Gallium labeled NOTA-based conjugates for peptide receptor-mediated medical imaging. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7345-7348.	1.0	28
622	Antiangiogenic properties of substituted (Z)- $(\hat{A}\pm)$ -2- $(N$ -benzylindol-3-ylmethylene)quinuclidin-3-ol/one analogs and their derivatives. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7323-7326.	1.0	7
623	Hyaluronidases, a group of glycosidases: Current and future perspectives. Carbohydrate Polymers, 2010, 81, 165-181.	5.1	91
624	ELL is an HIFâ€1α partner that regulates and responds to hypoxia response in PC3 cells. Prostate, 2010, 70, 797-805.	1.2	15
625	Dynamic Visualization of RGDâ€Quantum Dot Binding to Tumor Neovasculature and Extravasation in Multiple Living Mouse Models Using Intravital Microscopy. Small, 2010, 6, 2222-2229.	5.2	49

#	Article	IF	CITATIONS
626	Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma. Pediatric Blood and Cancer, 2010, 55, 1272-1277.	0.8	9
627	Combretastatin Aâ€4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. British Journal of Pharmacology, 2010, 160, 2008-2027.	2.7	53
628	Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth. Cancer Science, 2010, 101, 448-452.	1.7	25
629	Coupled mathematical model of tumorigenesis and angiogenesis in vascular tumours. Cell Proliferation, 2010, 43, 542-552.	2.4	5
630	Inhibitor of DNA binding-4 promotes angiogenesis and growth of glioblastoma multiforme by elevating matrix GLA levels. Oncogene, 2010, 29, 3793-3802.	2.6	48
631	Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma. British Journal of Cancer, 2010, 103, 43-51.	2.9	36
632	Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British Journal of Cancer, 2010, 103, 597-606.	2.9	25
633	Dissecting cancer through mathematics: from the cell to the animal model. Nature Reviews Cancer, 2010, 10, 221-230.	12.8	380
635	An Implantable Vascularized Protein Gel Construct That Supports Human Fetal Hepatoblast Survival and Infection by Hepatitis C Virus in Mice. PLoS ONE, 2010, 5, e9987.	1,1	9
636	Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anti-Cancer Drugs, 2010, 21, 65-76.	0.7	65
637	Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?. Oncologist, 2010, 15, 130-141.	1.9	110
638	Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors. Clinical Cancer Research, 2010, 16, 3044-3056.	3.2	123
639	Evaluation of hypericin-mediated photodynamic therapy in combination with angiogenesis inhibitor bevacizumab using in vivo fluorescence confocal endomicroscopy. Journal of Biomedical Optics, 2010, 15, 011114.	1.4	25
640	IFN- \hat{l}^2 Restricts Tumor Growth and Sensitizes Alveolar Rhabdomyosarcoma to Ionizing Radiation. Molecular Cancer Therapeutics, 2010, 9, 761-771.	1.9	11
641	Cell Cycle Regulator ING4 Is a Suppressor of Melanoma Angiogenesis That Is Regulated by the Metastasis Suppressor BRMS1. Cancer Research, 2010, 70, 10445-10453.	0.4	49
642	Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients. Journal of the American Society of Nephrology: JASN, 2010, 21, 1381-1389.	3.0	199
643	Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncológica, 2010, 49, 287-297.	0.8	259
644	Using the Transcription Factor Inhibitor of DNA Binding 1 to Selectively Target Endothelial Progenitor Cells Offers Novel Strategies to Inhibit Tumor Angiogenesis and Growth. Cancer Research, 2010, 70, 7273-7282.	0.4	63

#	Article	IF	CITATIONS
645	Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients. Clinical Cancer Research, 2010, 16, 2881-2889.	3.2	92
646	BIBF 1120 for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2010, 19, 789-794.	1.9	13
647	Efficient Inhibition of Non-Small-Cell Lung Cancer Xenograft by Systemic Delivery of Plasmid-Encoding Short-Hairpin RNA Targeting VEGF. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 65-73.	0.7	18
648	Regulation of the Expression and Activity of the Antiangiogenic Homeobox Gene <i>GAX</i> /i>/Ki>MEOX2 by ZEB2 and MicroRNA-221. Molecular and Cellular Biology, 2010, 30, 3902-3913.	1.1	77
649	Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis. American Journal of Hypertension, 2010, 23, 460-468.	1.0	210
650	MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo. Molecular Cancer Therapeutics, 2010, 9, 3254-3266.	1.9	119
651	Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review. Oncologist, 2010, 15, 216-235.	1.9	47
652	MULTISCALE BIOLOGICAL TISSUE MODELS AND FLUX-LIMITED CHEMOTAXIS FOR MULTICELLULAR GROWING SYSTEMS. Mathematical Models and Methods in Applied Sciences, 2010, 20, 1179-1207.	1.7	143
653	Stress Effects on FosB- and Interleukin-8 (IL8)-driven Ovarian Cancer Growth and Metastasis. Journal of Biological Chemistry, 2010, 285, 35462-35470.	1.6	157
654	Roles of Arrest-Defective Protein 1225 and Hypoxia-Inducible Factor $1\hat{l}_{\pm}$ in Tumor Growth and Metastasis. Journal of the National Cancer Institute, 2010, 102, 426-442.	3.0	20
655	MR angiogenesis imaging with Robo4― <i>vs</i> . α _V β ₃ â€ŧargeted nanoparticles in a B16/F10 mouse melanoma model. FASEB Journal, 2010, 24, 4262-4270.	0.2	36
656	Fractalkine-Induced Endothelial Cell Migration Requires MAP Kinase Signaling. Pathobiology, 2010, 77, 7-16.	1.9	27
657	Assessment of Non–Small Cell Lung Cancer Perfusion: Pathologic-CT Correlation in 15 Patients. Radiology, 2010, 257, 863-871.	3.6	64
658	Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features. Hematology, 2010, 15, 210-214.	0.7	8
659	Feasibility of high temporal resolution breast DCEâ€MRI using compressed sensing theory. Medical Physics, 2010, 37, 4971-4981.	1.6	55
660	Crosstalk between Blood Vessels and Tumor Microenvironment. Oral Science International, 2010, 7, 1-10.	0.3	7
661	Differentiation of tubercular infection and metastasis presenting as ring enhancing lesion by diffusion and perfusion magnetic resonance imaging. Journal of Neuroradiology, 2010, 37, 167-171.	0.6	27
662	Engineering Tumors: A Tissue Engineering Perspective in Cancer Biology. Tissue Engineering - Part B: Reviews, 2010, 16, 351-359.	2.5	163

#	Article	IF	CITATIONS
663	Application of intravital microscopy in studies of tumor microcirculation. Journal of Biomedical Optics, 2010, 15, 011113.	1.4	25
664	Fluorescent Nanoprobes as a Biomarker for Increased Vascular Permeability: Implications in Diagnosis and Treatment of Cancer and Inflammation. Bioconjugate Chemistry, 2010, 21, 93-101.	1.8	63
665	Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends in Molecular Medicine, 2010, 16, 133-144.	3.5	603
666	lon channels and the hallmarks of cancer. Trends in Molecular Medicine, 2010, 16, 107-121.	3.5	355
667	Targeting multiple angiogenic pathways for the treatment of neuroblastoma. Journal of Pediatric Surgery, 2010, 45, 1103-1109.	0.8	6
668	The Role of VEGF Pathways in Human Physiologic and Pathologic Angiogenesis. Journal of Surgical Research, 2010, 159, 517-527.	0.8	19
669	Bee venom inhibits tumor angiogenesis and metastasis by inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing mice. Cancer Letters, 2010, 292, 98-110.	3.2	68
670	Isolated tumor endothelial cells maintain specific character during long-term culture. Biochemical and Biophysical Research Communications, 2010, 394, 947-954.	1.0	116
671	In vitro antiproliferative and antiangiogenic effects of synthetic chalcone analogues. Toxicology in Vitro, 2010, 24, 1347-1355.	1.1	65
672	Nucleic acid therapeutics: concepts for targeted delivery to solid tumors. Therapeutic Delivery, 2010, 1, 91-107.	1.2	8
673	Rational combinations in metastatic breast cancer: bevacizumab with chemotherapy. Community Oncology, 2010, 7, 253-262.	0.2	0
674	Possible Benefits of Curcumin Regimen in Combination With Taxane Chemotherapy for Hormone-Refractory Prostate Cancer Treatment. Nutrition and Cancer, 2010, 62, 148-153.	0.9	19
675	Platelet-Derived Growth Factor-B Normalizes Micromorphology and Vessel Function in Vascular Endothelial Growth Factor-A-Induced Squamous Cell Carcinomas. American Journal of Pathology, 2010, 176, 981-994.	1.9	33
676	COX-2 and Prostaglandin EP3/EP4 Signaling Regulate the Tumor Stromal Proangiogenic Microenvironment via CXCL12-CXCR4 Chemokine Systems. American Journal of Pathology, 2010, 176, 1469-1483.	1.9	97
677	Angiopoietin/Tie2 Signaling Transforms Capillaries into Venules Primed for Leukocyte Trafficking in Airway Inflammation. American Journal of Pathology, 2010, 176, 2009-2018.	1.9	29
678	DMBA-induced hamster buccal pouch carcinoma and VX2-induced rabbit cancer as a model for human oral carcinogenesis. Expert Review of Anticancer Therapy, 2010, 10, 1485-1496.	1.1	36
679	The Role of Angiogenesis in Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America, 2010, 39, 839-852.	1.2	8
680	Imaging angiogenesis of genitourinary tumors. Nature Reviews Urology, 2010, 7, 69-82.	1.9	27

#	Article	IF	CITATIONS
681	Modeling tumor growth and treatment response based on quantitative imaging data. Integrative Biology (United Kingdom), 2010, 2, 338.	0.6	12
682	Imaging tumour physiology and vasculature to predict and assess response to heat. International Journal of Hyperthermia, 2010, 26, 264-272.	1.1	5
683	A passage through systems biology to systems medicine: adoption of middle-out rational approaches towards the understanding of therapeutic outcomes in cancer. Analyst, The, 2011, 136, 663-678.	1.7	23
684	Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 135-139.	0.7	16
685	Wound Healing after Trauma May Predispose to Lung Cancer Metastasis. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 591-596.	1.4	61
686	Preclinical Orthotopic and Intracardiac Injection Models of Human Breast Cancer Metastasis to Bone and Their Use in Drug Discovery. Current Protocols in Pharmacology, 2011, 52, Unit 14.18.	4.0	4
687	Mastic Oil Inhibits the Metastatic Phenotype of Mouse Lung Adenocarcinoma Cells. Cancers, 2011, 3, 789-801.	1.7	12
688	PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2011, 4, 70-73.	0.2	0
689	VEGF and IL-18 in induced sputum of lung cancer patients. Cytokine, 2011, 54, 277-281.	1.4	20
690	Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients. Cancer Letters, 2011, 304, 144-153.	3.2	13
691	Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells. Cancer Letters, 2011, 310, 198-206.	3.2	63
692	Overexpression of human papillomavirus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF- $\hat{\Pi}_{\pm}$ and VEGF expression in non-small cell lung cancer cells. Cancer Letters, 2011, 311, 160-170.	3.2	67
693	A study of anti-cancer effects of Funalia trogii in vitro and in vivo. Food and Chemical Toxicology, 2011, 49, 1477-1483.	1.8	35
694	Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. European Journal of Cancer, 2011, 47, 277-286.	1.3	43
695	A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. European Journal of Cancer, 2011, 47, 479-490.	1.3	52
696	Haematologic toxicities associated with the addition of bevacizumab in cancer patients. European Journal of Cancer, 2011, 47, 1161-1174.	1.3	39
697	Current status and future perspectives of in vivo small animal imaging using radiolabeled nanoparticles. European Journal of Radiology, 2011, 78, 287-295.	1.2	48
698	Effects of Interferons $\hat{l}\pm/\hat{l}^2$ on the Proliferation of Human Micro- and Macrovascular Endothelial Cells. Journal of Interferon and Cytokine Research, 2011, 31, 451-458.	0.5	19

#	Article	IF	Citations
699	The role of Twist1 in hepatocellular carcinoma angiogenesis: a clinical study. Human Pathology, 2011, 42, 840-847.	1.1	27
700	Toona sinensis (leaf extracts) inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis in vascular endothelial cells. Journal of Ethnopharmacology, 2011, 134, 111-121.	2.0	60
701	Inhibitory effects of Physalis angulata on tumor metastasis and angiogenesis. Journal of Ethnopharmacology, 2011, 135, 762-771.	2.0	44
702	Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study. Journal of Clinical Oncology, 2011, 29, 4436-4441.	0.8	80
703	Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Medicine, 2011, 17, 1359-1370.	15.2	1,518
704	Recent Advances in Anti-Angiogenic Therapy of Cancer. Oncotarget, 2011, 2, 122-134.	0.8	114
705	PET Imaging of Integrin Positive Tumors Using ¹⁸ F Labeled Knottin Peptides. Theranostics, 2011, 1, 403-412.	4.6	30
706	Angiogenesis and Lung Cancer. Medical Radiology, 2011, , 17-41.	0.0	1
707	Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective. Pathology Research International, 2011, 2011, 1-13.	1.4	18
708	Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer. Journal of Oncology, 2011, 2011, 1-11.	0.6	6
709	Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics, 2011, 1, 58-82.	4.6	124
710	Down-Regulation of miR-101 in Endothelial Cells Promotes Blood Vessel Formation through Reduced Repression of EZH2. PLoS ONE, 2011, 6, e16282.	1.1	96
711	Oleanolic Acid Initiates Apoptosis in Non-Small Cell Lung Cancer Cell Lines and Reduces Metastasis of a B16F10 Melanoma Model In Vivo. PLoS ONE, 2011, 6, e28596.	1.1	80
712	PI3K/AKT/mTOR Pathway in Angiogenesis. Frontiers in Molecular Neuroscience, 2011, 4, 51.	1.4	1,002
713	Localization and characterization of lymphatic vessels in oral and cervical squamous cell carcinoma. Experimental and Therapeutic Medicine, 2011, 2, 793-797.	0.8	8
714	Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with ⁶⁴ Cu″abeled bevacizumab in colorectal cancer xenografts. Cancer Science, 2011, 102, 117-121.	1.7	52
715	<i>In vitro</i> and <i>in vivo</i> evaluation of the antiâ€angiogenic actions of 4â€hydroxybenzyl alcohol. British Journal of Pharmacology, 2011, 163, 835-844.	2.7	43
716	New potential antiscarring approaches. Wound Repair and Regeneration, 2011, 19, s22-31.	1.5	10

#	Article	IF	CITATIONS
717	Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Medicine, 2011, 17, 320-329.	15.2	1,296
718	The molecular biology of head and neck cancer. Nature Reviews Cancer, 2011, 11, 9-22.	12.8	2,151
719	Chemotaxis in cancer. Nature Reviews Cancer, 2011, 11, 573-587.	12.8	785
720	Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. Oncogene, 2011, 30, 54-64.	2.6	83
721	Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene, 2011, 30, 896-906.	2.6	49
722	Expression of human papillomavirus type 16 E7 is sufficient to significantly increase expression of angiogenic factors but is not sufficient to induce endothelial cell migration. Virology, 2011, 410, 283-290.	1.1	16
723	MicroRNA regulation in angiogenesis. Vascular Pharmacology, 2011, 55, 79-86.	1.0	155
724	CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo. Experimental Cell Research, 2011, 317, 1677-1688.	1.2	20
725	Altered angiogenesis in the tumor microenvironment. Pathology International, 2011, 61, 630-637.	0.6	27
726	The further study on radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging. Journal of Radioanalytical and Nuclear Chemistry, 2011, 290, 623-630.	0.7	5
727	Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. Journal of Neuro-Oncology, 2011, 104, 103-112.	1.4	27
728	Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case–control studies. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1027-1036.	1.2	29
729	Molecular mechanisms of liver metastasis. International Journal of Clinical Oncology, 2011, 16, 464-472.	1.0	27
730	Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2011, 67, 613-623.	0.8	87
731	Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. BMC Cancer, 2011, 11, 365.	1.1	40
732	Antiangiogenic properties of Koetjapic acid, a natural triterpene isolated from Sandoricum koetjaoe Merr. Cancer Cell International, 2011, 11, 12.	1.8	25
733	Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model. Lasers in Surgery and Medicine, 2011, 43, 651-662.	1.1	24
734	Evaluation of a ¹⁸⁸ Reâ€radiolabeled Argâ€Glyâ€Asp peptide for tumor overexpressed α _v β ₃ receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 602-606.	0.5	1

#	Article	IF	CITATIONS
735	Growth inhibitory efficacy of lycopene and βâ€carotene against androgenâ€independent prostate tumor cells xenografted in nude mice. Molecular Nutrition and Food Research, 2011, 55, 606-612.	1.5	72
736	Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and antiâ€angiogenic drug effects. NMR in Biomedicine, 2011, 24, 473-482.	1.6	35
737	Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology, 2011, 53, 483-492.	3.6	97
738	PET imaging of tumor angiogenesis in mice with VEGFâ€A–targeted ⁸⁶ Yâ€CHXâ€A″â€DTPAâ€bevacizumab. International Journal of Cancer, 2011, 128, 920-926.	2.3	64
739	Sunitinib facilitates the activation and recruitment of therapeutic antiâ€tumor immunity in concert with specific vaccination. International Journal of Cancer, 2011, 129, 2158-2170.	2.3	127
740	Gene modification with integrinâ€linked kinase improves function of endothelial progenitor cells in preâ€eclampsia in vitro. Journal of Cellular Biochemistry, 2011, 112, 3103-3111.	1.2	8
741	Phosphatidylinositol $3\hat{a}\in^2$ -kinase signaling pathway is essential for Rac1-induced hypoxia-inducible factor- $1\hat{1}\pm$ and vascular endothelial growth factor expression. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H2169-H2176.	1.5	18
742	Ion channels and transporters in cancer. 3. Ion channels in the tumor cell-microenvironment cross talk. American Journal of Physiology - Cell Physiology, 2011, 301, C762-C771.	2.1	57
743	The effects of recombinant human GH on promoting tumor growth depend on the expression of GH receptor in vivo. Journal of Endocrinology, 2011, 211, 249-256.	1.2	11
744	The requirement for fibroblasts in angiogenesis: fibroblast-derived matrix proteins are essential for endothelial cell lumen formation. Molecular Biology of the Cell, 2011, 22, 3791-3800.	0.9	391
745	Inhibition of aldose reductase prevents colon cancer metastasis. Carcinogenesis, 2011, 32, 1259-1267.	1.3	53
746	Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells. Clinical Cancer Research, 2011, 17, 6192-6205.	3.2	148
747	Combined inhibitors of angiogenesis and histone deacetylase: Efficacy in rat hepatoma. World Journal of Gastroenterology, 2011, 17, 3623.	1.4	3
748	Pilot Pharmacokinetic and Dosimetric Studies of $<$ sup $>$ 18 $<$ sup $>$ F-FPPRGD2: A PET Radiopharmaceutical Agent for Imaging $\hat{1}$ $\pm <$ sub $>$ $v <$ sub $>$ 1 $2 <$ sub $>$ Integrin Levels. Radiology, 2011, 260, 182-191.	3.6	131
749	IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer. Cancer Research, 2011, 71, 424-434.	0.4	184
750	Prognostic Significance of Angiogenesis in Relation to Ki-67, p-53, p-27, and bcl-2 Expression in Embryonal Tumors. Pediatric Neurosurgery, 2011, 47, 241-247.	0.4	11
751	Evidence of the formation of G-quadruplex structures in the promoter region of the human vascular endothelial growth factor gene. Nucleic Acids Research, 2011, 39, 1256-1265.	6.5	100
752	SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> . Clinical Cancer Research, 2011, 17, 4439-4450.	3.2	92

#	ARTICLE	IF	CITATIONS
753	$<$ sup>99m Tc-Labeled Cyclic RGD Peptides for Noninvasive Monitoring of Tumor Integrin $\hat{l}\pm <$ sub>v \hat{l}^2 $<$ sub>3 Expression. Molecular Imaging, 2011, 10, 7290.2011.00006.	0.7	58
7 54	Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biology and Therapy, 2011, 12, 169-180.	1.5	33
755	Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation <i>In Vivo</i> and <i>In Vitro</i> Clinical Cancer Research, 2011, 17, 1815-1827.	3.2	76
756	Tumor exploits alternative strategies to achieve vascularization. FASEB Journal, 2011, 25, 2874-2882.	0.2	89
757	Apoptosis regulator through modulating IAP expression (ARIA) controls the PI3K/Akt pathway in endothelial and endothelial progenitor cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9472-9477.	3.3	40
758	Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncology, 2011, 7, 1415-1428.	1.1	27
759	SV40 T/t-common polypeptide inhibits angiogenesis and growth of HER2-overexpressing human ovarian cancer. Cancer Gene Therapy, 2011, 18, 859-870.	2.2	2
760	Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer. Expert Review of Anticancer Therapy, 2011, 11, 525-532.	1.1	14
761	Beclin1/P13K-Mediated Autophagy Prevents Hypoxia-Induced Apoptosis in EAhy926 Cell Line. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 335-343.	0.7	17
762	Role of tyrosine kinase inhibitors in the management of high-grade gliomas. Expert Review of Anticancer Therapy, 2011, 11, 1739-1748.	1.1	4
764	Decoding Melanoma Metastasis. Cancers, 2011, 3, 126-163.	1.7	142
765	Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) Inhibition of Human Osteosarcoma Angiogenesis via VEGF/PI3K/AKT Signaling. International Journal of Molecular Sciences, 2012, 13, 12573-12583.	1.8	33
766	MetastamiRs: Non-Coding MicroRNAs Driving Cancer Invasion and Metastasis. International Journal of Molecular Sciences, 2012, 13, 1347-1379.	1.8	53
767	The Role of Traditional Chinese Medicine in Clinical Oncology. , 2012, , 405-429.		0
768	Fisetin inhibits various attributes of angiogenesis in vitro and in vivo-implications for angioprevention. Carcinogenesis, 2012, 33, 385-393.	1.3	80
769	High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Modern Pathology, 2012, 25, 1079-1085.	2.9	69
770	ON THE ASYMPTOTIC THEORY FROM MICROSCOPIC TO MACROSCOPIC GROWING TISSUE MODELS: AN OVERVIEW WITH PERSPECTIVES. Mathematical Models and Methods in Applied Sciences, 2012, 22, .	1.7	80
771	Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. British Journal of Cancer, 2012, 106, 1214-1223.	2.9	90

#	Article	IF	CITATIONS
772	E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma. Cancer Gene Therapy, 2012, 19, 144-152.	2.2	12
773	MEG3 noncoding RNA: a tumor suppressor. Journal of Molecular Endocrinology, 2012, 48, R45-R53.	1.1	643
774	Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 301-319.	1.4	26
775	Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization. Ophthalmic Research, 2012, 47, 13-18.	1.0	19
776	Micronutrient Synergy in the Fight against Hepatocellular Carcinoma. Cancers, 2012, 4, 323-339.	1.7	8
777	Stroma Targeting Nuclear Imaging and Radiopharmaceuticals. International Journal of Molecular Imaging, 2012, 2012, 1-23.	1.3	3
778	Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients – an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. International Journal of Biological Markers, 2012, 27, 295-304.	0.7	33
779	Grape seed proanthocyanidins inhibit colon cancer-induced angiogenesis through suppressing the expression of VEGF and Angl. International Journal of Molecular Medicine, 2012, 30, 1410-1416.	1.8	50
780	Electrochemical Detection of Vascular Endothelial Growth Factor by an Aptamer-Based Bound/Free Separation System. Electrochemistry, 2012, 80, 348-352.	0.6	14
781	Stochastic region competition algorithm for Doppler sonography segmentation. Medical Physics, 2012, 39, 2867-2876.	1.6	1
782	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines. Oncology Reports, 2012, 28, 768-776.	1.2	22
783	Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models. Oncology Letters, 2012, 4, 976-980.	0.8	21
784	Overcoming Resistance to Antiangiogenic Therapies. Oncologist, 2012, 17, 1039-1050.	1.9	53
785	miR-27b controls venous specification and tip cell fate. Blood, 2012, 119, 2679-2687.	0.6	107
786	Role of angiogenesis in the pathogenesis of cancer. Cancer Treatment Reviews, 2012, 38, 825-833.	3. 4	76
787	Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma. International Journal of Clinical Oncology, 2012, 17, 412-416.	1.0	10
788	Structure-activity relationship study of WSS25 derivatives with anti-angiogenesis effects. Glycoconjugate Journal, 2012, 29, 389-398.	1.4	16
789	Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes. Pharmaceutical Research, 2012, 29, 2902-2911.	1.7	47

#	Article	IF	CITATIONS
790	Monocyte chemotactic protein-induced protein (MCPIP) promotes inflammatory angiogenesis via sequential induction of oxidative stress, endoplasmic reticulum stress and autophagy. Cellular Signalling, 2012, 24, 2123-2131.	1.7	62
791	Reappraisal of the Role of Bevacizumab in the Therapeutic Strategy in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2012, 10, 147-152.	0.9	3
792	Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours. Tumor Biology, 2012, 33, 1709-1717.	0.8	29
793	ADAMTS5 Functions as an Anti-Angiogenic and Anti-Tumorigenic Protein Independent of Its Proteoglycanase Activity. American Journal of Pathology, 2012, 181, 1056-1068.	1.9	65
794	Battling Cancer: In the End What Matters the Most?. Disruptive Science and Technology, 2012, 1, 108-109.	1.0	4
795	Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma – an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. Expert Opinion on Therapeutic Targets, 2012, 16. S69-S78.	1.5	11
796	Cadmium Increases HIF-1 and VEGF Expression through ROS, ERK, and AKT Signaling Pathways and Induces Malignant Transformation of Human Bronchial Epithelial Cells. Toxicological Sciences, 2012, 125, 10-19.	1.4	182
797	Tanshinones: Sources, Pharmacokinetics and Anti-Cancer Activities. International Journal of Molecular Sciences, 2012, 13, 13621-13666.	1.8	200
798	Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4. Angiogenesis, 2012, 15, 569-580.	3.7	27
799	Coronary collateral growthâ€"Back to the future. Journal of Molecular and Cellular Cardiology, 2012, 52, 905-911.	0.9	51
800	Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients. British Journal of Cancer, 2012, 106, 2004-2009.	2.9	21
801	Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment. American Journal of Pathology, 2012, 180, 1283-1293.	1.9	137
802	Heterogeneity of Tumor Endothelial Cells. American Journal of Pathology, 2012, 180, 1294-1307.	1.9	138
803	Intussusceptive microvascular growth in tumors. Cancer Letters, 2012, 316, 126-131.	3.2	100
804	Progesterone receptor is involved in 2,3,7,8-tetrachlorodibenzo- p -dioxin-stimulated breast cancer cells proliferation. Cancer Letters, 2012, 319, 223-231.	3.2	20
805	Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2012, 38, 173-184.	3.4	31
806	A comparison of 3D-CTA and 4D-CE-MRA for the dynamic monitoring of angiogenesis in a rabbit VX2 tumor. European Journal of Radiology, 2012, 81, 104-110.	1.2	12
807	Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Journal of Ovarian Research, 2012, 5, 23.	1.3	29

#	ARTICLE	IF	CITATIONS
808	A novel regulation of VEGF expression by HIFâ€lα and STAT3 in HDM2 transfected prostate cancer cells. Journal of Cellular and Molecular Medicine, 2012, 16, 1750-1757.	1.6	24
809	A novel treatment for glioblastoma: integrin inhibition. Expert Review of Neurotherapeutics, 2012, 12, 421-435.	1.4	34
810	Anti-angiogenic activity of thymoquinone by the down-regulation of VEGF using zebrafish (Danio) Tj ETQq0 0 0	rgBT_lOve	rlock 10 Tf 50
811	Development of a bifunctional chelating agent containing isothiocyanate residue for one step F-18 labeling of peptides and application for RGD labeling. Bioorganic and Medicinal Chemistry, 2012, 20, 5941-5947.	1.4	21
812	Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: Molecular basis for therapeutic implications. Cytokine and Growth Factor Reviews, 2012, 23, 343-356.	3.2	37
813	Bacterial survival strategies suggest rethinking cancer cooperativity. Trends in Microbiology, 2012, 20, 403-410.	3.5	103
814	Growth factor signaling in metastasis: current understanding and future opportunities. Cancer and Metastasis Reviews, 2012, 31, 479-491.	2.7	27
815	Tumor endothelial markers as a target in cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 1215-1225.	1.5	28
816	Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma. Medical Oncology, 2012, 29, 3325-3334.	1.2	23
817	Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma. International Orthopaedics, 2012, 36, 2307-2313.	0.9	39
818	Semaphorin 3A Suppresses Tumor Growth and Metastasis in Mice Melanoma Model. PLoS ONE, 2012, 7, e33633.	1.1	73
819	The Invasion and Metastasis Promotion Role of CD97 Small Isoform in Gastric Carcinoma. PLoS ONE, 2012, 7, e39989.	1.1	36
820	Dehydrocostuslactone Suppresses Angiogenesis In Vitro and In Vivo through Inhibition of Akt/GSK-3 \hat{l}^2 and mTOR Signaling Pathways. PLoS ONE, 2012, 7, e31195.	1.1	41
821	Plasma Vascular Endothelial Growth Factor Dysregulation in Defining Aggressiveness of Head and Neck Squamous Cell Carcinoma. Journal of Oncology, 2012, 2012, 1-7.	0.6	11
822	Magnetic Nanoparticles in the Imaging of Tumor Angiogenesis. Applied Sciences (Switzerland), 2012, 2, 525-534.	1.3	7
823	Liquiritigenin Inhibits Tumor Growth and Vascularization in a Mouse Model of Hela Cells. Molecules, 2012, 17, 7206-7216.	1.7	42
824	Recent Advances in Nasopharyngeal Carcinoma Research and Its Pathogenesis., 2012,, 453-492.		1
825	Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. OncoTargets and Therapy, 2012, 5, 133.	1.0	12

#	Article	IF	CITATIONS
826	Liquiritigenin Inhibits Serumâ€induced HIFâ€1α and VEGF Expression via the AKT/mTORâ€p70S6K Signalling Pathway in HeLa Cells. Phytotherapy Research, 2012, 26, 1133-1141.	2.8	28
827	Systemic Delivery of siRNA via LCP Nanoparticle Efficiently Inhibits Lung Metastasis. Molecular Therapy, 2012, 20, 609-615.	3.7	116
828	Evolving models of tumor origin and progression. Tumor Biology, 2012, 33, 911-917.	0.8	16
829	Strategies for the discovery and development of therapies for metastatic breast cancer. Nature Reviews Drug Discovery, 2012, 11, 479-497.	21.5	310
830	A highâ€fat diet increases angiogenesis, solid tumor growth, and lung metastasis of CT26 colon cancer cells in obesityâ€resistant BALB/c mice. Molecular Carcinogenesis, 2012, 51, 869-880.	1.3	75
831	[¹⁸ F]Siâ€RiboRGD: From Design and Synthesis to the Imaging of α _v β ₃ â€Integrins in Melanoma Tumors. ChemPlusChem, 2012, 77, 345-349.	1.3	11
832	Inhibition of transforming growth factor- \hat{l}^2 -activated kinase-1 blocks cancer cell adhesion, invasion, and metastasis. British Journal of Cancer, 2012, 107, 129-136.	2.9	26
833	Transforming growth factor-beta1 induces microvascular abnormalities through a down-modulation of neural cell adhesion molecule in human hepatocellular carcinoma. Laboratory Investigation, 2012, 92, 1297-1309.	1.7	22
834	Use of radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 52-59.	0.7	7
835	A Study of Pipeline Drugs in Neuroendocrine Tumors. Journal of Gastrointestinal Cancer, 2012, 43, 296-304.	0.6	1
836	Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer. Clinical and Translational Oncology, 2012, 14, 437-443.	1.2	15
837	Recombinant Human Endostatin Endostar Inhibits Tumor Growth and Metastasis in a Mouse Xenograft Model of Colon Cancer. Pathology and Oncology Research, 2012, 18, 315-323.	0.9	34
838	Imaging proliferation of 18F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1289-1296.	3.3	30
839	Targeting the vasculature of visceral tumors: novel insights and treatment perspectives. Langenbeck's Archives of Surgery, 2012, 397, 569-578.	0.8	5
841	Microfluidics for Mammalian Cell Chemotaxis. Annals of Biomedical Engineering, 2012, 40, 1316-1327.	1.3	80
842	Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions. European Journal of Pharmacology, 2012, 685, 1-7.	1.7	27
843	Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials, 2012, 33, 3071-3082.	5 . 7	224
844	Angiogenesis inhibitors identified by cell-based high-throughput screening: Synthesis, structure–activity relationships and biological evaluation of 3-[(E)-styryl]benzamides that specifically inhibit endothelial cell proliferation. Bioorganic and Medicinal Chemistry, 2012, 20, 1442-1460.	1.4	12

#	Article	IF	CITATIONS
845	Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 110-114.	1.0	21
846	Megakaryocytes, malignancy and bone marrow vascular niches. Journal of Thrombosis and Haemostasis, 2012, 10, 177-188.	1.9	55
847	Structure–Activity Relationship Study of Collagenâ€Derived Antiâ€Angiogenic Biomimetic Peptides. Chemical Biology and Drug Design, 2012, 80, 27-37.	1.5	14
848	Hypoxia control to normalize pathologic angiogenesis: Potential role for endothelial precursor cells and miRNAs regulation. Vascular Pharmacology, 2012, 56, 252-261.	1.0	40
849	HOXB9 Expression Promoting Tumor Cell Proliferation and Angiogenesis Is Associated with Clinical Outcomes in Breast Cancer Patients. Annals of Surgical Oncology, 2012, 19, 1831-1840.	0.7	44
850	Proâ€opiomelanocortin gene delivery suppresses the growth of established Lewis lung carcinoma through a melanocortinâ€1 receptorâ€independent pathway. Journal of Gene Medicine, 2012, 14, 44-53.	1.4	31
851	Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus mâ€₹OR inhibitors monotherapy?. Journal of Surgical Oncology, 2012, 105, 111-112.	0.8	9
852	Different combination schedules of gemcitabine with endostar affect antitumor efficacy. Cancer Chemotherapy and Pharmacology, 2012, 69, 239-246.	1.1	11
853	The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer. Breast Cancer Research and Treatment, 2012, 131, 837-848.	1.1	72
854	Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a src-dependent fashion. Angiogenesis, 2012, 15, 33-45.	3.7	234
855	In vivo imaging of vessel diameter, size, and density: A comparative study between MRI and histology. Magnetic Resonance in Medicine, 2013, 69, 18-26.	1.9	59
856	Feasibility of measuring prostate perfusion with arterial spin labeling. NMR in Biomedicine, 2013, 26, 51-57.	1.6	17
857	Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy. Journal of Hematology and Oncology, 2013, 6, 49.	6.9	38
858	Mitochondrial UQCRB regulates VEGFR2 signaling in endothelial cells. Journal of Molecular Medicine, 2013, 91, 1117-1128.	1.7	25
859	The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis. Journal of Neuro-Oncology, 2013, 112, 329-338.	1.4	17
860	lmaging Tumor Angiogenesis: The Road to Clinical Utility. American Journal of Roentgenology, 2013, 201, W183-W191.	1.0	55
861	Modeling the connection between primary and metastatic tumors. Journal of Mathematical Biology, 2013, 67, 657-692.	0.8	8
862	Breast cancer as a systemic disease: a view of metastasis. Journal of Internal Medicine, 2013, 274, 113-126.	2.7	546

#	Article	IF	CITATIONS
863	Physicochemical properties of exogenous molecules correlated with their biological efficacy as protectors against carcinogenesis and inflammation. International Reviews in Physical Chemistry, 2013, 32, 393-434.	0.9	7
864	Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma. Clinical and Experimental Metastasis, 2013, 30, 969-976.	1.7	30
865	A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2013, 31, 910-917.	1.2	26
866	Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts. Cancer Chemotherapy and Pharmacology, 2013, 71, 1147-1157.	1.1	30
867	Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor Beta. Molecular Imaging and Biology, 2013, 15, 212-221.	1.3	27
868	Imaging integrin $\hat{l}\pm v\hat{l}^2$ 3 positive glioma with a novel RGD dimer probe and the impact of antiangiogenic agent (Endostar) on its tumor uptake. Cancer Letters, 2013, 335, 75-80.	3.2	21
869	Snail/beta-catenin signaling protects breast cancer cells from hypoxia attack. Experimental Cell Research, 2013, 319, 3150-3159.	1.2	20
870	Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer. Cancer Letters, 2013, 331, 99-104.	3.2	19
871	Role of Collagen Matrix in Tumor Angiogenesis and Glioblastoma Multiforme Progression. American Journal of Pathology, 2013, 183, 1293-1305.	1.9	143
872	CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels. Biomaterials, 2013, 34, 9496-9508.	5.7	68
873	Vitronectinâ€"Master controller or micromanager?. IUBMB Life, 2013, 65, 807-818.	1.5	76
874	Vascular endothelial growth factor singleâ€nucleotide polymorphism in gall bladder cancer. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1678-1685.	1.4	10
875	PHD4 Stimulates Tumor Angiogenesis in Osteosarcoma Cells via TGF-α. Molecular Cancer Research, 2013, 11, 1337-1348.	1.5	20
876	Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer. International Journal of Molecular Sciences, 2013, 14, 15885-15909.	1.8	105
877	Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells. Journal of Translational Medicine, 2013, 11, 257.	1.8	15
878	Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients. International Journal of Clinical Oncology, 2013, 18, 689-695.	1.0	5
879	A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 140, 331-339.	1.1	22
880	Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 751-759.	1.2	34

#	Article	IF	Citations
881	The antiangiogenic activities of ethanolic crude extracts of four Salvia species. BMC Complementary and Alternative Medicine, 2013, 13, 358.	3.7	24
882	Gene and isoform expression signatures associated with tumor stage in kidney renal clear cell carcinoma. BMC Systems Biology, 2013, 7, S7.	3.0	19
883	IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2013, 32, 97.	3.5	69
884	The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinical-pathological features and survival in pancreatic adenocarcinomas. Diagnostic Pathology, 2013, 8, 170.	0.9	14
885	Association Between Postoperative Complications and Clinical Cancer Outcomes. Annals of Surgical Oncology, 2013, 20, 4063-4066.	0.7	18
886	The role of vascular epithelial growth factor receptor–tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials. Current Medical Research and Opinion, 2013, 29, 1691-1699.	0.9	4
888	Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells. Expert Opinion on Therapeutic Targets, 2013, 17, 337-349.	1.5	89
889	Early Tumor Development Captured Through Nondestructive, High Resolution Differential Phase Contrast X-ray Imaging. Radiation Research, 2013, 180, 448-454.	0.7	3
890	Solution structure of the major G-quadruplex formed in the human VEGF promoter in K+: insights into loop interactions of the parallel G-quadruplexes. Nucleic Acids Research, 2013, 41, 10584-10592.	6.5	148
891	Multiphase modelling of vascular tumour growth in two spatial dimensions. Journal of Theoretical Biology, 2013, 316, 70-89.	0.8	51
892	Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent. Investigational New Drugs, 2013, 31, 126-135.	1.2	18
893	Multifunctional Magnetic Resonance Imaging Probes. Recent Results in Cancer Research, 2013, 187, 151-190.	1.8	6
894	Aerosol delivery of lentivirus-mediated O-glycosylation mutant osteopontin suppresses lung tumorigenesis in K-ras LA1 mice. Cellular Oncology (Dordrecht), 2013, 36, 15-26.	2.1	14
896	12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway. Journal of Ethnopharmacology, 2013, 146, 724-733.	2.0	22
897	Sunitinib as an anti-endometriotic agent. European Journal of Pharmaceutical Sciences, 2013, 49, 732-736.	1.9	19
898	GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism: Clinical and Experimental, 2013, 62, 1279-1286.	1.5	70
899	Angiogenesis, mediated by miR-21, is involved arsenite-induced carcinogenesis. Toxicology Letters, 2013, 223, 35-41.	0.4	36
900	Contrast-enhanced high-frequency ultrasound imaging of early stage liver metastasis in a preclinical mouse model. Cancer Letters, 2013, 339, 208-213.	3.2	20

#	Article	IF	CITATIONS
901	Targeting tumor neovasculature in non-small-cell lung cancer. Critical Reviews in Oncology/Hematology, 2013, 86, 130-142.	2.0	31
902	Time trends in survival from cancer of unknown primary: Small steps forward. European Journal of Cancer, 2013, 49, 2403-2410.	1.3	34
903	DPMA, a deoxypodophyllotoxin derivative, induces apoptosis and anti-angiogenesis in non-small cell lung cancer A549 cells. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6650-6655.	1.0	14
904	Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice. Cancer Letters, 2013, 337, 210-217.	3.2	89
905	Sonodynamic therapy inhibits angiogenesis and tumor growth in a xenograft mouse model. Cancer Letters, 2013, 335, 93-99.	3.2	77
906	The <scp>F</scp> â€prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma. Pathology International, 2013, 63, 37-44.	0.6	15
907	Tumor Dormancy and Cancer Stem Cells: Two Sides of the Same Coin?. Advances in Experimental Medicine and Biology, 2013, 734, 145-179.	0.8	108
908	MSCs in Solid Tumors and Hematological Malignancies: From Basic Biology to Therapeutic Applications. , 2013, , 209-235.		0
909	The novel tumor suppressor NOL7 post-transcriptionally regulates thrombospondin-1 expression. Oncogene, 2013, 32, 4377-4386.	2.6	9
910	Decorin induces rapid secretion of thrombospondinâ€1 in basal breast carcinoma cells via inhibition of <scp>R</scp> as homolog gene family, memberÂA/ <scp>R</scp> hoâ€associated coiledâ€coil containing protein kinaseÂ1. FEBS Journal, 2013, 280, 2353-2368.	2.2	45
911	Ecological photodynamic therapy: New trend to disrupt the intricate networks within tumor ecosystem. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1835, 86-99.	3.3	14
912	Targeted Therapy for Metastatic Colorectal Cancer: Role of Aflibercept. Clinical Colorectal Cancer, 2013, 12, 73-85.	1.0	33
913	<i>In Vivo</i> Gastric Cancer Targeting and Imaging Using Novel Symmetric Cyanine Dye-Conjugated GX1 Peptide Probes. Bioconjugate Chemistry, 2013, 24, 1134-1143.	1.8	29
914	Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2962-2967.	1.0	50
915	Modulation of $\hat{l}\pm v\hat{l}^2$ 3- and $\hat{l}\pm 5\hat{l}^2$ 1-integrin-mediated adhesion by dehydro- \hat{l}^2 -amino acids containing peptidomimetics. European Journal of Medicinal Chemistry, 2013, 66, 258-268.	2.6	19
916	Maslinic acid inhibits the metastatic capacity of DU145 human prostate cancer cells: possible mediation via hypoxia-inducible factor- \hat{l}_{\pm} signalling. British Journal of Nutrition, 2013, 109, 210-222.	1.2	38
917	Regulatory Roles of Metabolites in Cell Signaling Networks. Journal of Genetics and Genomics, 2013, 40, 367-374.	1.7	21
918	Novel cis-restricted \hat{l}^2 -lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro. Oncology Reports, 2013, 29, 585-594.	1.2	19

#	Article	IF	CITATIONS
919	<scp>SERPINA</scp> 3 <scp>K</scp> induces apoptosis in human colorectal cancer cells via activating the <scp>F</scp> as <scp>L</scp> /caspaseâ€8 signaling pathway. FEBS Journal, 2013, 280, 3244-3255.	2.2	28
920	Angiopoietins in angiogenesis. Cancer Letters, 2013, 328, 18-26.	3.2	523
921	Tumor-derived microvesicles: The metastasomes. Medical Hypotheses, 2013, 80, 75-82.	0.8	21
922	Targeting Ca ²⁺ transport in cancer: close reality or long perspective?. Expert Opinion on Therapeutic Targets, 2013, 17, 225-241.	1.5	50
923	Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2013, 11, 306.	0.8	59
924	Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis, 2013, 16, 289-295.	3.7	49
925	Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials. Annals of Oncology, 2013, 24, 2943-2952.	0.6	46
926	Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression. Cancer Prevention Research, 2013, 6, 1128-1139.	0.7	63
927	The Role of IL- $1\hat{l}^2$ in the Early Tumor Cellâ \in "Induced Angiogenic Response. Journal of Immunology, 2013, 190, 3500-3509.	0.4	171
928	Blood Outgrowth Endothelial Cells Increase Tumor Growth Rates and Modify Tumor Physiology: Relevance for Therapeutic Targeting. Cancers, 2013, 5, 205-217.	1.7	9
929	Gene Expression of VEGF-A and VEGF-C in Peripheral Blood Mononuclear Cells of Iranian Patients with Acute Myeloid Leukemia. Turkish Journal of Haematology, 2013, 30, 137-143.	0.2	7
930	Mesenchymal stem cells overexpressing PEDF decrease the angiogenesis of gliomas. Bioscience Reports, 2013, 33, e00019.	1.1	22
931	Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta $Oncol\tilde{A}^3$ gica, 2013, 52, 1202-1212.	0.8	40
932	Inhibition of angiogenesis. Anti-Cancer Drugs, 2013, 24, 781-791.	0.7	35
933	Increased plasma levels of soluble vascular endothelial growth factor receptor 1 (sFlt-1) in women by moderate exercise and increased plasma levels of vascular endothelial growth factor in overweight/obese women. European Journal of Cancer Prevention, 2013, 22, 83-89.	0.6	16
934	Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Research, 2013, 23, 243-253.	0.6	36
935	A diffusion-compensated model for the analysis of DCE-MRI data: theory, simulations and experimental results. Physics in Medicine and Biology, 2013, 58, 1983-1998.	1.6	20
936	The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth. Molecular Cancer Therapeutics, 2013, 12, 2055-2066.	1.9	11

#	Article	IF	CITATIONS
937	TRAF6 Upregulates Expression of HIF-1 \hat{l} ± and Promotes Tumor Angiogenesis. Cancer Research, 2013, 73, 4950-4959.	0.4	85
938	Effect of Green Tea Extract on Hepatocellular Carcinoma. , 2013, , 791-802.		0
939	Synstatin: a selective inhibitor of the syndecanâ€1â€coupled <scp>IGF</scp> 1 <scp>R</scp> â€'αvβ3 integrin complex in tumorigenesis and angiogenesis. FEBS Journal, 2013, 280, 2207-2215.	2.2	96
940	Subcompartmentalization of extracellular extravascular space (EES) into permeability and leaky space with local arterial input function (AIF) results in improved discrimination between highâ€and lowâ€grade glioma using dynamic contrastâ€enhanced (DCE) MRI. Journal of Magnetic Resonance Imaging, 2013. 38. 677-688.	1.9	29
941	The Practicality of Nanoceria-PAN-Based ⁶⁸ Ge/ ⁶⁸ Ga Generator Toward Preparation of ⁶⁸ Ga-Labeled Cyclic RGD Dimer as a Potential PET Radiotracer for Tumor Imaging. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 77-83.	0.7	19
942	MicroRNAs Regulate Tumor Angiogenesis Modulated by Endothelial Progenitor Cells. Cancer Research, 2013, 73, 341-352.	0.4	122
943	Hypoxia-mediated regulation of macrophage functions in pathophysiology. International Immunology, 2013, 25, 67-75.	1.8	69
944	Chemotherapy of advanced non-small-cell lung cancer: current landscape. Clinical Investigation, 2013, 3, 265-279.	0.0	0
945	Role of the nervous system in cancer metastasis. Oncology Letters, 2013, 5, 1101-1111.	0.8	74
946	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in adult human sarcoma cell lines. International Journal of Oncology, 2013, 43, 39-49.	1.4	10
947	Tanshinone VI Inhibits the Expression of Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1. International Journal of Immunopathology and Pharmacology, 2013, 26, 977-982.	1.0	4
948	Endothelialâ€rich microenvironment supports growth and branching morphogenesis of prostate epithelial cells. Prostate, 2013, 73, 884-896.	1.2	9
949	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human lung cancer and mesothelioma cell lines. International Journal of Oncology, 2013, 42, 1883-1889.	1.4	10
950	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in pediatric human sarcoma cell lines. International Journal of Oncology, 2013, 43, 1027-1035.	1.4	9
951	Integrin $\hat{l}\pm\langle sub\rangle v\langle sub\rangle \hat{l}^2\langle sub\rangle 3\langle sub\rangle$ -Targeted Radiotracer $\langle sup\rangle 99m\langle sup\rangle Tc-3P-RGD\langle sub\rangle 2\langle sub\rangle$ Useful for Noninvasive Monitoring of Breast Tumor Response to Antiangiogenic Linifanib Therapy but not Anti-Integrin $\hat{l}\pm\langle sub\rangle v\langle sub\rangle \hat{l}^2\langle sub\rangle 3\langle sub\rangle RGD\langle sub\rangle 2\langle sub\rangle Therapy. Theranostics, 2013, 3, 816-830.$	4.6	27
952	Clinicopathological significance of platelet-derived growth factor B, platelet-derived growth factor recpertor-Î ² , and E-cadherin expression in gastric carcinoma. Wspolczesna Onkologia, 2013, 2, 150-155.	0.7	23
953	Human Apurinic/Apyrimidinic Endonuclease siRNA Inhibits the Angiogenesis Induced by X-Ray Irradiation in Lung Cancer Cells. International Journal of Medical Sciences, 2013, 10, 870-882.	1.1	28
954	Impact of VEGF-C Gene Polymorphisms and Environmental Factors on Oral Cancer Susceptibility in Taiwan. PLoS ONE, 2013, 8, e60283.	1.1	18

#	Article	IF	CITATIONS
955	Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4. PLoS ONE, 2013, 8, e67294.	1.1	50
956	Knockdown of the Sodium-Dependent Phosphate Co-Transporter 2b (NPT2b) Suppresses Lung Tumorigenesis. PLoS ONE, 2013, 8, e77121.	1.1	37
957	The Tumor Microenvironment Contribution to Development, Growth, Invasion and Metastasis of Head and Neck Squamous Cell Carcinomas. Journal of Cancer, 2013, 4, 66-83.	1.2	262
958	Update on oncolytic viral therapy & Depth amp; ndash; targeting angiogenesis. OncoTargets and Therapy, 2013, 6, 1031.	1.0	16
959	Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. OncoTargets and Therapy, 2013, 6, 925.	1.0	25
960	Modes of Neovascularization in Tumors and Clinical Translation of Antiangiogenic Therapy. , 2014, , 2926-2957.		1
961	A Biomimetic Collagen Derived Peptide Exhibits Anti-Angiogenic Activity in Triple Negative Breast Cancer. PLoS ONE, 2014, 9, e111901.	1.1	12
962	Comprehensive Evaluation of the Anti-Angiogenic and Anti-Neoplastic Effects of Endostar on Liver Cancer through Optical Molecular Imaging. PLoS ONE, 2014, 9, e85559.	1.1	10
963	SHARP1 Suppresses Angiogenesis of Endometrial Cancer by Decreasing Hypoxia-Inducible Factor- $1\hat{l}_{\pm}$ Level. PLoS ONE, 2014, 9, e99907.	1.1	24
964	Roles of PI3K/Akt and c-Jun Signaling Pathways in Human Papillomavirus Type 16 Oncoprotein-Induced HIF- $1\hat{1}\pm$, VEGF, and IL-8 Expression and In Vitro Angiogenesis in Non-Small Cell Lung Cancer Cells. PLoS ONE, 2014, 9, e103440.	1.1	85
965	Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination with Chemotherapy Agents in Mouse Tumor Models. PLoS ONE, 2014, 9, e107823.	1.1	16
966	Endothelial Cells Provide a Notch-Dependent Pro-Tumoral Niche for Enhancing Breast Cancer Survival, Stemness and Pro-Metastatic Properties. PLoS ONE, 2014, 9, e112424.	1.1	68
967	Prognostic Value of Microvessel Density in Hepatocellular Carcinoma Patients: A Meta-Analysis. International Journal of Biological Markers, 2014, 29, 279-287.	0.7	13
968	A Novel Poly-Naphthol Compound ST104P Suppresses Angiogenesis by Attenuating Matrix Metalloproteinase-2 Expression in Endothelial Cells. International Journal of Molecular Sciences, 2014, 15, 16611-16627.	1.8	11
969	Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer. BioMed Research International, 2014, 2014, 1-11.	0.9	61
970	68Ga-Labeled Cyclic NGR Peptide for MicroPET Imaging of CD13 Receptor Expression. Molecules, 2014, 19, 11600-11612.	1.7	26
971	Imaging Integrin $\hat{l}\pm v\hat{l}^23$ and NRP-1 Positive Gliomas with a Novel Fluorine-18 Labeled RGD-ATWLPPR Heterodimeric Peptide Probe. Molecular Imaging and Biology, 2014, 16, 781-792.	1.3	41
972	Correlation of antiangiogenic, antioxidant and cytotoxic activities of some Sudanese medicinal plants with phenolic and flavonoid contents. BMC Complementary and Alternative Medicine, 2014, 14, 406.	3.7	51

#	Article	IF	CITATIONS
973	Suppression of tumor angiogenesis by targeting the protein neddylation pathway. Cell Death and Disease, 2014, 5, e1059-e1059.	2.7	64
974	Localization-delocalization matrices and electron density-weighted adjacency matrices: new electronic fingerprinting tools for medicinal computational chemistry. Future Medicinal Chemistry, 2014, 6, 1475-1479.	1.1	7
975	Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Research, 2014, 42, 2945-2957.	6.5	45
976	FHIT Suppresses Epithelial-Mesenchymal Transition (EMT) and Metastasis in Lung Cancer through Modulation of MicroRNAs. PLoS Genetics, 2014, 10, e1004652.	1.5	56
977	Development of Novel Anti-Cancer Strategies Based on Angiogenesis Inhibition. , 2014, , 147-190.		0
978	Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept. Gastroenterology Research and Practice, 2014, 2014, 1-13.	0.7	44
979	From Plasminogen to Plasmin: Role of Plasminogen Receptors in Human Cancer. International Journal of Molecular Sciences, 2014, 15, 21229-21252.	1.8	59
980	Bone marrow mononuclear cell angiogenic competency is suppressed by a high-salt diet. American Journal of Physiology - Cell Physiology, 2014, 306, C123-C131.	2.1	9
981	Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Expert Opinion on Biological Therapy, 2014, 14, 1319-1332.	1.4	12
982	Toxic Damage Increases Angiogenesis and Metastasis in Fibrotic Livers via PECAM-1. BioMed Research International, 2014, 2014, 1-11.	0.9	17
983	Targeting chemokine pathways in esophageal adenocarcinoma. Cell Cycle, 2014, 13, 3320-3327.	1.3	26
984	Recombinant Human Kallistatin Inhibits Angiogenesis by Blocking VEGF Signaling Pathway. Journal of Cellular Biochemistry, 2014, 115, 575-584.	1.2	17
985	Metastatic Tumors to the Jaws and Mouth. Head and Neck Pathology, 2014, 8, 463-474.	1.3	134
986	PPARδ deficiency disrupts hypoxiaâ€mediated tumorigenic potential of colon cancer cells. Molecular Carcinogenesis, 2014, 53, 926-937.	1.3	22
987	Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostaneâ€mediated thromboxane <scp>A</scp> ₂ receptor activation. British Journal of Pharmacology, 2014, 171, 3115-3131.	2.7	119
988	Imaging Biomarkers and Surrogate Endpoints in Oncology Clinical Trials. , 2014, , 29-42.		1
989	Role of nontoxigenic Clostridium novyi in solid tumor therapy. Reviews in Medical Microbiology, 2014, 25, 71-76.	0.4	7
990	Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 3123-3136.	1.9	29

#	ARTICLE	IF	CITATIONS
991	Stem Cell Therapy and Breast Cancer Treatment: Review of Stem Cell Research and Potential Therapeutic Impact Against Cardiotoxicities Due to Breast Cancer Treatment. Frontiers in Oncology, 2014, 4, 299.	1.3	10
992	Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth. Cancers, 2014, 6, 2330-2342.	1.7	7
993	A gene link-based method for identifying differential gene pathways. , 2014, , .		0
994	Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor. Biomaterials, 2014, 35, 5572-5579.	5.7	48
995	Wogonin inhibits H2O2-induced angiogenesis via suppressing Pl3K/Akt/NF-κB signaling pathway. Vascular Pharmacology, 2014, 60, 110-119.	1.0	36
996	9-Hydroxypheophorbide α-mediated photodynamic therapy induces matrix metalloproteinase-2 (MMP-2) and MMP-9 down-regulation in Hep-2 cells via ROS-mediated suppression of the ERK pathway. Photodiagnosis and Photodynamic Therapy, 2014, 11, 55-62.	1.3	14
997	PKA turnover by the REG \hat{I}^3 -proteasome modulates FoxO1 cellular activity and VEGF-induced angiogenesis. Journal of Molecular and Cellular Cardiology, 2014, 72, 28-38.	0.9	28
998	Tumor perfusionâ€related parameter of diffusionâ€weighted magnetic resonance imaging: Correlation with histological microvessel density. Magnetic Resonance in Medicine, 2014, 71, 1554-1558.	1.9	115
999	Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Medical Oncology, 2014, 31, 786.	1.2	48
1000	Periodicity in tumor vasculature targeting kinetics of ligand-functionalized nanoparticles studied by dynamic contrast enhanced magnetic resonance imaging and intravital microscopy. Angiogenesis, 2014, 17, 93-107.	3.7	14
1001	Treatment-related mortality with aflibercept in cancer patients: a meta-analysis. European Journal of Clinical Pharmacology, 2014, 70, 461-467.	0.8	11
1002	Isthmin targets cell-surface GRP78 and triggers apoptosis via induction of mitochondrial dysfunction. Cell Death and Differentiation, 2014, 21, 797-810.	5.0	61
1003	Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2014, 70, 531-538.	0.8	10
1004	Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core–shell nanoparticles. Biomaterials, 2014, 35, 5028-5038.	5.7	129
1005	Inflammatory Angiogenesis and the Tumor Microenvironment as Targets for Cancer Therapy and Prevention. Cancer Treatment and Research, 2014, 159, 401-426.	0.2	33
1006	In Vivo Volumetric Photoacoustic Molecular Angiography and Therapeutic Monitoring with Targeted Plasmonic Nanostars. Small, 2014, 10, 1585-1593.	5.2	157
1007	CXCR2â€mediated tumorâ€associated neutrophil recruitment is regulated by IFNâ€Î². International Journal of Cancer, 2014, 134, 1346-1358.	2.3	152
1008	Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: From Pathophysiology to Prevention and Treatment Based on Long-Acting Nitric Oxide Donors. American Journal of Hypertension, 2014, 27, 3-13.	1.0	45

#	Article	IF	Citations
1009	Human DNA Tumor Viruses and Oncogenesis. , 2014, , 121-137.		0
1010	The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women. Medical Oncology, 2014, 31, 336.	1.2	10
1011	15â€LOXâ€1 suppression of hypoxiaâ€induced metastatic phenotype and HIFâ€1 α expression in human colon cancer cells. Cancer Medicine, 2014, 3, 472-484.	1.3	20
1012	Pyridoxine-derived bicyclic amido-, ureido-, and carbamato-pyridinols: synthesis and antiangiogenic activities. Organic and Biomolecular Chemistry, 2014, 12, 8702-8710.	1.5	9
1013	Highâ€Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis. Particle and Particle Systems Characterization, 2014, 31, 1141-1150.	1.2	31
1014	Nitric oxide in cancer metastasis. Cancer Letters, 2014, 353, 1-7.	3.2	146
1015	FITC-Conjugated Cyclic RGD Peptides as Fluorescent Probes for Staining Integrin α _v β ₃ /α _v β ₅ in Tumor Tissues. Bioconjugate Chemistry, 2014 25, 1925-1941.	1,1.8	68
1016	Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity. ACS Medicinal Chemistry Letters, 2014, 5, 673-678.	1.3	30
1017	Understanding the Pathobiology of Head and Neck Squamous Cell Carcinoma. Current Oral Health Reports, 2014, 1, 196-203.	0.5	2
1018	Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors. European Journal of Medicinal Chemistry, 2014, 84, 698-707.	2.6	38
1019	Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. European Journal of Clinical Pharmacology, 2014, 70, 893-906.	0.8	49
1020	The â^'1154 G/A VEGF gene polymorphism is associated with the incidence of basal cell carcinoma in patients from northern Poland. Archives of Dermatological Research, 2014, 306, 539-544.	1.1	4
1021	The role of Chinese medicine in clinical oncology. Chinese Journal of Integrative Medicine, 2014, 20, 3-10.	0.7	19
1022	The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials. Tumor Biology, 2014, 35, 7675-7683.	0.8	10
1023	Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication. Molecular Cancer, 2014, 13, 102.	7.9	20
1024	Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study. Digestive and Liver Disease, 2014, 46, 561-567.	0.4	16
1025	Lipid droplets may lay a spacial foundation for vasculogenic mimicry formation in hepatocellular carcinoma. Medical Hypotheses, 2014, 83, 56-59.	0.8	6
1026	Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 161-179.	3.3	131

#	Article	IF	CITATIONS
1027	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncology, The, 2014, 15, 620-630.	5.1	96
1028	A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis. Cancer Letters, 2014, 342, 70-81.	3.2	23
1029	Circulating pro―and antiâ€angiogenic mediators in patients infected with hepatitis C at different stages of hepatocellular carcinoma. Journal of Medical Virology, 2014, 86, 1120-1129.	2.5	6
1030	Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. Cellular and Molecular Life Sciences, 2014, 71, 1417-1438.	2.4	25
1031	MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neuro-Oncology, 2014, 16, 1341-1353.	0.6	120
1032	Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma. Seminars in Oncology, 2014, 41, 217-234.	0.8	226
1033	Melanoma metastasis: new concepts and evolving paradigms. Oncogene, 2014, 33, 2413-2422.	2.6	120
1034	Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26. Clinical and Experimental Medicine, 2014, 14, 203-213.	1.9	12
1035	Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene, 2014, 33, 679-689.	2.6	358
1037	Anisi stellati fructus extract attenuates the in vitro and in vivo metastatic and angiogenic potential of malignant cancer cells by downregulating proteolytic activity and pro-angiogenic factors. International Journal of Oncology, 2014, 45, 1937-1948.	1.4	9
1038	Suprabasin as a novel tumor endothelial cell marker. Cancer Science, 2014, 105, 1533-1540.	1.7	37
1040	Correlation of Tumor-Infiltrative Lymphocyte Subtypes Alteration with Neoangiogenesis before and after Neoadjuvant Chemotherapy Treatment in Breast Cancer Patients. International Journal of Biological Markers, 2014, 29, 193-203.	0.7	6
1041	Extract of Cordyceps militaris inhibits angiogenesis and suppresses tumor growth of human malignant melanoma cells. International Journal of Oncology, 2014, 45, 209-218.	1.4	31
1042	Downregulation of VEGF expression attenuates malignant biological behavior of C6 glioma stem cells. International Journal of Oncology, 2014, 44, 1581-1588.	1.4	11
1043	Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 720-727.	1.3	12
1044	<scp>MMP</scp> s and angiogenesis affect the metastatic potential of a human vulvar leiomyosarcoma cell line. Journal of Cellular and Molecular Medicine, 2015, 19, 2098-2107.	1.6	4
1045	Effect of a nutrient mixture on the localization of extracellular matrix proteins in HeLa human cervical cancer xenografts in female nude mice. Experimental and Therapeutic Medicine, 2015, 10, 901-906.	0.8	7
1046	Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. Journal of Extracellular Vesicles, 2015, 4, 27522.	5.5	228

#	Article	IF	CITATIONS
1047	Cigarette smoke modulates PC3 prostate cancer cell migration by altering adhesion molecules and the extracellular matrix. Molecular Medicine Reports, 2015, 12, 6990-6996.	1.1	12
1048	Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production. Scientific Reports, 2014, 4, 6994.	1.6	41
1049	Association between the expression of T-cadherin and vascular endothelial growth factor and the prognosis of patients with gastric cancer. Molecular Medicine Reports, 2015, 12, 2075-2081.	1.1	9
1050	Deciphering the anti-angiogenic effect of endostatin/cyclophosphamide to normalize tumor micrangium through notch signaling pathway in colon cancer. World Journal of Surgical Oncology, 2015, 14, 10.	0.8	5
1051	Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma. Journal of Translational Medicine, 2015, 13, 365.	1.8	46
1052	CXCL12–CXCR7 axis is important for tumor endothelial cell angiogenic property. International Journal of Cancer, 2015, 137, 2825-2836.	2.3	64
1053	The Contribution of Angiogenesis to the Process of Metastasis. Cancer Journal (Sudbury, Mass), 2015, 21, 267-273.	1.0	377
1054	Tâ€cell immunoglobulin mucinâ€3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. Journal of Surgical Oncology, 2015, 112, 430-435.	0.8	56
1055	Dynamic contrast-enhanced MRI in mice: An investigation of model parameter uncertainties. Magnetic Resonance in Medicine, 2015, 73, 1979-1987.	1.9	5
1056	Adventures within the speckled band: heterogeneity, angiogenesis, and balanced inflammation in the tuberculous granuloma. Immunological Reviews, 2015, 264, 276-287.	2.8	46
1057	The role of the metastasis suppressor gene <scp>KAI</scp> 1 in melanoma angiogenesis. Pigment Cell and Melanoma Research, 2015, 28, 696-706.	1.5	11
1058	Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways. Current Cancer Drug Targets, 2015, 15, 14-26.	0.8	18
1059	In vitro and in vivo anti-angiogenic activity of girinimbine isolated from Murraya koenigii. Drug Design, Development and Therapy, 2015, 9, 1281.	2.0	11
1060	Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. OncoTargets and Therapy, 2015, 8, 2361.	1.0	3
1061	Prophylactic Administration of Fucoidan Represses Cancer Metastasis by Inhibiting Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinases (MMPs) in Lewis Tumor-Bearing Mice. Marine Drugs, 2015, 13, 1882-1900.	2.2	85
1062	Overexpression of Trps1 contributes to tumor angiogenesis and poor prognosis of human osteosarcoma. Diagnostic Pathology, 2015, 10, 167.	0.9	20
1063	Prognostic Value of Serum IL-17 and VEGF Levels in Small Cell Lung Cancer. International Journal of Biological Markers, 2015, 30, 359-363.	0.7	22
1064	The Differential Expression of OCT4 Isoforms in Cervical Carcinoma. PLoS ONE, 2015, 10, e0118033.	1.1	41

#	Article	IF	CITATIONS
1065	Geraniol Suppresses Angiogenesis by Downregulating Vascular Endothelial Growth Factor (VEGF)/VEGFR-2 Signaling. PLoS ONE, 2015, 10, e0131946.	1.1	41
1066	RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer. Drug Design, Development and Therapy, 2015, 9, 4613.	2.0	6
1067	A Hypothesis Concerning the Biphasic Dose-response of Tumors to Angiostatin and Endostatin. Dose-Response, 2015, 13, dose-response.1.	0.7	5
1068	Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy. Journal of Ophthalmology, 2015, 2015, 1-12.	0.6	16
1069	Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-12.	0.5	52
1070	Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma. Oncotarget, 2015, 6, 44806-44818.	0.8	3
1071	The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget, 2015, 6, 4633-4648.	0.8	10
1072	Pancreatic cancer stromal biology and therapy. Genes and Diseases, 2015, 2, 133-143.	1.5	110
1073	Nanoparticles for inhibition of in vitro tumour angiogenesis: synergistic actions of ligand function and laser irradiation. Biomaterials Science, 2015, 3, 733-741.	2.6	24
1074	Linifanib: current status and future potential in cancer therapy. Expert Review of Anticancer Therapy, 2015, 15, 677-687.	1.1	21
1075	Physical supports from liver cancer cells are essential for differentiation and remodeling of endothelial cells in a HepG2-HUVEC co-culture model. Scientific Reports, 2015, 5, 10801.	1.6	38
1076	Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF. Applied Biochemistry and Biotechnology, 2015, 176, 1985-1995.	1.4	29
1077	Systems biology of the microvasculature. Integrative Biology (United Kingdom), 2015, 7, 498-512.	0.6	16
1078	Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers. International Journal of Pharmaceutics, 2015, 493, 380-389.	2.6	26
1079	Polymorphisms and Plasma Levels of Tissue Inhibitor of Metalloproteinase-3. Medicine (United States), 2015, 94, e2092.	0.4	31
1080	Myo19 is an Outer Mitochondrial Membrane Motor and Effector of Starvation Induced Filopodia. Journal of Cell Science, 2016, 129, 543-56.	1.2	46
1081	Optical-resolution photoacoustic microscopy of the metabolic rate of oxygen in a mouse renal tumor model. Proceedings of SPIE, 2015, , .	0.8	3
1082	Angiogenesis modulation by Plectranthus amboinicus leaf extract and its fractions on chorioallantoic membrane and tumor induced angiogenesis. Oriental Pharmacy and Experimental Medicine, 2015, 15, 257-276.	1.2	1

#	Article	IF	CITATIONS
1083	Imaging of the dispersion coefficient of Ultrasound contrast agents by Wiener system identification for prostate cancer localization. , 2015 , , .		2
1084	Study of prognostic significance of marrow angiogenesis assessment in patients with de novo acute leukemia. Hematology, 2015, 20, 504-510.	0.7	7
1085	Targeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2. Cell Reports, 2015, 10, 1066-1081.	2.9	132
1086	CecropinXJ inhibits the proliferation of human gastric cancer BGC823 cells and induces cell death in vitro and in vivo. International Journal of Oncology, 2015, 46, 2181-2193.	1.4	20
1087	Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human colorectal, pancreatic and hepatic carcinoma cell lines. International Journal of Oncology, 2015, 47, 370-376.	1.4	11
1088	Widdrol, a sesquiterpene isolated from Juniperus chinensis, inhibits angiogenesis by targeting vascular endothelial growth factor receptor 2 signaling. Oncology Reports, 2015, 34, 1178-1184.	1.2	10
1089	Identification of immediate early response protein 2 as a regulator of angiogenesis through the modulation of endothelial cell motility and adhesion. International Journal of Molecular Medicine, 2015, 36, 1104-1110.	1.8	15
1090	Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. International Journal of Cancer, 2015, 137, 744-749.	2.3	37
1091	iTRAQ-based proteomic identification of proteins involved in anti-angiogenic effects of Panduratin A on HUVECs. Phytomedicine, 2015, 22, 203-212.	2.3	8
1092	Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics. Current Neurology and Neuroscience Reports, 2015, 15, 506.	2.0	114
1093	Bevacizumab: A dose review. Critical Reviews in Oncology/Hematology, 2015, 94, 311-322.	2.0	32
1094	F-18 Labeled RGD Probes Based on Bioorthogonal Strain-Promoted Click Reaction for PET Imaging. ACS Medicinal Chemistry Letters, 2015, 6, 402-407.	1.3	35
1095	Angiogenesis in diabetes and obesity. Reviews in Endocrine and Metabolic Disorders, 2015, 16, 67-75.	2.6	91
1096	The lymph node microenvironment and its role in the progression of metastatic cancer. Seminars in Cell and Developmental Biology, 2015, 38, 98-105.	2.3	140
1097	Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer. European Journal of Surgical Oncology, 2015, 41, 228-235.	0.5	42
1098	Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy. Journal of Urology, 2015, 193, 479-483.	0.2	46
1099	Comparison study of in vivo dose response to laser-driven versus conventional electron beam. Radiation and Environmental Biophysics, 2015, 54, 155-166.	0.6	27
1100	Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo. Cancer Chemotherapy and Pharmacology, 2015, 75, 465-474.	1.1	6

#	Article	IF	CITATIONS
1101	Advanced targeted nanomedicine. Journal of Biotechnology, 2015, 202, 88-97.	1.9	54
1102	In vivo imaging of Aminopeptidase N (CD13) receptors in experimental renal tumors using the novel radiotracer 68Ga-NOTA-c(NGR). European Journal of Pharmaceutical Sciences, 2015, 69, 61-71.	1.9	44
1103	Design, synthesis and anticancer activity of furochromone and benzofuran derivatives targeting VEGFR-2 tyrosine kinase. RSC Advances, 2015, 5, 25312-25324.	1.7	22
1104	Integrin $\hat{l}\pm\langle\text{sub}\rangle\nu\langle/\text{sub}\rangle\hat{l}^2\langle\text{sub}\rangle3\langle/\text{sub}\rangle$ as a Promising Target to Image Neoangiogenesis Using In-House Generator-Produced Positron Emitter $\langle\text{sup}\rangle68\langle/\text{sup}\rangle\text{Ga-Labeled DOTA-Arginine-Glycine-Aspartic Acid}$ (RGD) Ligand. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 217-224.	0.7	13
1105	Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model. Magnetic Resonance Imaging, 2015, 33, 737-760.	1.0	12
1106	Quantitative Contrast-Enhanced Ultrasonic Imaging Reflects Microvascularization in Hepatocellular Carcinoma and Prognosis after Resection. Ultrasound in Medicine and Biology, 2015, 41, 2621-2630.	0.7	7
1107	Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials. Critical Reviews in Oncology/Hematology, 2015, 94, 323-336.	2.0	24
1108	G-quadruplex DNAzyme-based electrochemiluminescence biosensing strategy for VEGF165 detection: Combination of aptamer–target recognition and T7 exonuclease-assisted cycling signal amplification. Biosensors and Bioelectronics, 2015, 74, 98-103.	5.3	58
1109	Toward a mathematical theory of Keller–Segel models of pattern formation in biological tissues. Mathematical Models and Methods in Applied Sciences, 2015, 25, 1663-1763.	1.7	698
1110	Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation. International Journal of Radiation Biology, 2015, 91, 771-776.	1.0	9
1111	Upregulation of Nuclear Heat Shock Factor 1ÂContributes to Tumor Angiogenesis and PoorÂSurvival in Patients With Non–Small CellÂLung Cancer. Annals of Thoracic Surgery, 2015, 100, 465-472.	0.7	20
1112	Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis. Angiogenesis, 2015, 18, 449-462.	3.7	42
1113	Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate <i>VEGFR2</i> in breast cancer cells. Genes and Development, 2015, 29, 1298-1315.	2.7	115
1114	The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. Scientific Reports, 2015, 5, 9054.	1.6	56
1115	Angiogenesis in Breast Cancer and its Correlation with Estrogen, Progesterone Receptors and other Prognostic Factors. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, EC05-7.	0.8	12
1116	The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opinion on Therapeutic Targets, 2015, 19, 1361-1377.	1.5	72
1117	Antineoplastic impact of leishmanial sphingolipid in tumour growth with regulation of angiogenic event and inflammatory response. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 869-882.	2.2	7
1118	cRGDyK-modified camretastain A4-loaded graphene oxide nanosheets for targeted anticancer drug delivery. RSC Advances, 2015, 5, 40258-40268.	1.7	5

#	Article	IF	CITATIONS
1119	Breast cancer cells promote a notch-dependent mesenchymal phenotype in endothelial cells participating to a pro-tumoral niche. Journal of Translational Medicine, 2015, 13, 27.	1.8	43
1120	Anti-inflammatory, antiangiogenic, and apoptosis-inducing activity of DLBS1442, a bioactive fraction of Phaleria macrocarpa, in a RL95-2 cell line as a molecular model of endometriosis. International Journal of Women's Health, 2015, 7, 161.	1.1	19
1121	Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. Survey of Ophthalmology, 2015, 60, 524-535.	1.7	48
1122	AECHL-1, a novel triterpenoid, targets tumor neo-vasculature and impairs the endothelial cell cytoskeleton. Angiogenesis, 2015, 18, 283-299.	3.7	15
1123	Activation of the mTOR signaling pathway in breast cancer MCF-7 cells by a peptide derived from Porphyra yezoensis. Oncology Reports, 2015, 33, 19-24.	1.2	34
1124	High-calorie diet exacerbates prostate neoplasia in mice with haploinsufficiency of Pten tumor suppressor gene. Molecular Metabolism, 2015, 4, 186-198.	3.0	14
1125	Anti-VEGF Molecular Targeted Therapies in Common Solid Malignancies: Comprehensive Update for Radiologists. Radiographics, 2015, 35, 455-474.	1.4	34
1126	On the derivation of angiogenesis tissue models: From the micro-scale to the macro-scale. Mathematics and Mechanics of Solids, 2015, 20, 268-279.	1.5	3
1127	Blockage of LMP1-modulated store-operated Ca2+ entry reduces metastatic potential in nasopharyngeal carcinoma cell. Cancer Letters, 2015, 360, 234-244.	3.2	26
1128	Incidence and risk of xerosis with targeted anticancer therapies. Journal of the American Academy of Dermatology, 2015, 72, 656-667.	0.6	39
1129	Synthesis of oxadiazole–morpholine derivatives and manifestation of the repressed CD31 Microvessel Density (MVD) as tumoral angiogenic parameters in Dalton's Lymphoma. Bioorganic Chemistry, 2015, 60, 136-146.	2.0	28
1130	Proteomic analysis of exosomes from nasopharyngeal carcinoma cell identifies intercellular transfer of angiogenic proteins. International Journal of Cancer, 2015, 137, 1830-1841.	2.3	84
1131	The human Nox4: gene, structure, physiological function and pathological significance. Journal of Drug Targeting, 2015, 23, 888-896.	2.1	81
1132	Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene, 2015, 34, 5997-6006.	2.6	100
1133	Evaluation of Tc-99Âm Labeled Dimeric GX1 Peptides for Imaging of Colorectal Cancer Vasculature. Molecular Imaging and Biology, 2015, 17, 661-670.	1.3	14
1134	Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma. Toxicology and Applied Pharmacology, 2015, 286, 112-123.	1.3	49
1135	Neutrophils: important contributors to tumor progression and metastasis. Cancer and Metastasis Reviews, 2015, 34, 735-751.	2.7	185
1136	VEGF Splicing and the Role of VEGF Splice Variants: From Physiological-Pathological Conditions to Specific Pre-mRNA Splicing. Methods in Molecular Biology, 2015, 1332, 3-23.	0.4	25

#	Article	IF	CITATIONS
1137	URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-Î⁰B signaling pathway. BMC Cancer, 2015, 15, 368.	1.1	17
1138	Design of optimal light delivery system for co-registered transvaginal ultrasound and photoacoustic imaging of ovarian tissue. Photoacoustics, 2015, 3, 114-122.	4.4	32
1139	Glioma Angiogenesis and Perfusion Imaging: Understanding the Relationship between Tumor Blood Volume and Leakiness with Increasing Glioma Grade. American Journal of Neuroradiology, 2015, 36, 2030-2035.	1.2	36
1140	Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis. Biochemical and Biophysical Research Communications, 2015, 465, 239-244.	1.0	26
1141	Intraâ€epithelially entrapped blood vessels in ameloblastoma. Journal of Oral Pathology and Medicine, 2015, 44, 378-385.	1.4	4
1142	Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1850-1858.	3.3	43
1143	Obesity and cancer phenotype: Is angiogenesis a missed link?. Life Sciences, 2015, 139, 16-23.	2.0	13
1144	Amniotic Membrane in Cancer. , 2015, , 139-152.		2
1145	Mechanisms of Cancer Cell Dormancyâ€"Another Hallmark of Cancer?. Cancer Research, 2015, 75, 5014-5022.	0.4	168
1146	Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 2422-2438.	1.1	133
1147	Height and drinking status in relation to risk of anemia in rural adult healthy Japanese men: the Nagasaki Islands study. Aging Male, 2015, 18, 100-105.	0.9	14
1149	A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. Annals of Oncology, 2015, 26, 2341-2346.	0.6	30
1150	Bioactive Benzofuran derivatives: A review. European Journal of Medicinal Chemistry, 2015, 97, 483-504.	2.6	407
1151	Enhanced Recovery After Surgery Protocols for Open Hepatectomyâ€"Physiology, Immunomodulation, and Implementation. Journal of Gastrointestinal Surgery, 2015, 19, 387-399.	0.9	62
1152	Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Cancer Letters, 2015, 356, 721-732.	3.2	72
1153	In vivo molecular imaging of gastric cancer in human-murine xenograft models with confocal laser endomicroscopy using a tumor vascular homing peptide. Cancer Letters, 2015, 356, 891-898.	3.2	18
1154	Fas/FasL Complex Promotes Proliferation and Migration of Brain Endothelial Cells Via FADD–FLIP–TRAF–NF-κB Pathway. Cell Biochemistry and Biophysics, 2015, 71, 1319-1323.	0.9	13
1155	Synergy of bone marrow transplantation and curcumin ensue protective effects at early onset of diabetes in mice 在早期å•病的糖尿病å°é¼ä¸ä½¿ç"¨éª¨é«"ç§»æ∰Œå§œé»"ç´è³å•æ²»ç——å…æo	e‰aa€Eä¿⊛ -	æŠ <mark>\$</mark> 1/2œç""

#	Article	IF	CITATIONS
1156	Nanomaterials for Theranostics: Recent Advances and Future Challenges. Chemical Reviews, 2015, 115, 327-394.	23.0	1,063
1157	A reason for intermittent fasting to suppress the awakening of dormant breast tumors. BioSystems, 2015, 127, 1-6.	0.9	5
1158	Interception of host angiogenic signalling limits mycobacterial growth. Nature, 2015, 517, 612-615.	13.7	239
1159	The zebrafish/tumor xenograft angiogenesis assay as a tool for screening anti-angiogenic miRNAs. Cytotechnology, 2015, 67, 969-975.	0.7	26
1160	Hypoxia and angiogenesis: from primary tumor to bone metastasis., 2015,, 177-189.		1
1161	Altered calcium signaling in cancer cells. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2502-2511.	1.4	256
1162	Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. OncoTargets and Therapy, 2016, 9, 2421.	1.0	13
1163	Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes. International Journal of Nanomedicine, 2016, 11, 991.	3.3	21
1164	Bone marrow blood vessels: normal and neoplastic niche. Oncology Reviews, 2016, 10, 306.	0.8	9
1165	Helicobacter pylori-infected MSCs acquire a pro-inflammatory phenotype and induce human gastric cancer migration by promoting EMT in gastric cancer cells. Oncology Letters, 2016, 11, 449-457.	0.8	12
1166	Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer. Oncotarget, 2016, 7, 85437-85449.	0.8	26
1167	Expression and prognostic significance of contactin 1 in human hepatocellular carcinoma. OncoTargets and Therapy, 2016, 9, 387.	1.0	18
1168	Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model. Oncotarget, 2016, 7, 5258-5272.	0.8	37
1169	Targeting angiogenesis in gastrointestinal tumors: current challenges. Translational Gastroenterology and Hepatology, 2016, 1, 67-67.	1.5	15
1170	An Aqueous Extract of Marine Microalgae Exhibits Antimetastatic Activity through Preferential Killing of Suspended Cancer Cells and Anticolony Forming Activity. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-8.	0.5	23
1171	Appraisals of Bangladeshi Medicinal Plants Used by Folk Medicine Practitioners in the Prevention and Management of Malignant Neoplastic Diseases. International Scholarly Research Notices, 2016, 2016, 1-12.	0.9	12
1172	Growth Hormone-Releasing Hormone and Its Analogues: Significance for MSCs-Mediated Angiogenesis. Stem Cells International, 2016, 2016, 1-12.	1.2	16
1173	Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates. Disease Markers, 2016, 2016, 1-11.	0.6	29

#	Article	IF	CITATIONS
1174	Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review. OncoTargets and Therapy, 2016, 9, 3695.	1.0	12
1175	Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget, 2016, 7, 67661-67673.	0.8	43
1176	The in Vitro and in Vivo Antitumor Activities of Tetracyclic Triterpenoids Compounds Actein and 26-Deoxyactein Isolated from Rhizome of Cimicifuga foetida L Molecules, 2016, 21, 1001.	1.7	9
1177	Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer. Molecules, 2016, 21, 1308.	1.7	9
1178	A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice. International Journal of Cancer, 2016, 138, 1013-1023.	2.3	91
1179	Noncoding RNAs in Tumor Angiogenesis. Advances in Experimental Medicine and Biology, 2016, 927, 217-241.	0.8	33
1180	Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone. Journal of Surgical Oncology, 2016, 113, 515-521.	0.8	9
1181	Sigmoid Colon Perforation Related to Bevacizumab in a Patient With Glioblastoma. American Journal of Therapeutics, 2016, 23, e241-e242.	0.5	2
1182	Inhibition of hypoxia inducible factor- $\hat{1}$ attenuates abdominal aortic aneurysm progression through the down-regulation of matrix metalloproteinases. Scientific Reports, 2016, 6, 28612.	1.6	62
1183	GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1214-H1224.	1.5	14
1184	Impact of single-nucleotide polymorphisms on radiation pneumonitis in cancer patients. Molecular and Clinical Oncology, 2016, 4, 3-10.	0.4	17
1185	RUNX3 inhibits the metastasis and angiogenesis of colorectal cancer. Oncology Reports, 2016, 36, 2601-2608.	1.2	35
1186	Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract. BMC Complementary and Alternative Medicine, 2016, 16, 277.	3.7	7
1187	Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan. Scientific Reports, 2016, 6, 28039.	1.6	112
1188	Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. Cancer and Metastasis Reviews, 2016, 35, 413-426.	2.7	44
1189	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 461-465.	1.1	37
1190	Effect of recombinant human endostatin onradiotherapy for esophagus cancer. Asian Pacific Journal of Tropical Medicine, 2016, 9, 86-90.	0.4	9
1191	Review: the Contribution of both Nature and Nurture to Carcinogenesis and Progression in Solid Tumours. Cancer Microenvironment, 2016, 9, 63-69.	3.1	25

#	Article	IF	CITATIONS
1192	Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy. Journal of Controlled Release, 2016, 228, 107-119.	4.8	45
1193	Influence of Exposure to Chronic Persistent Low-Dose Ionizing Radiation on the Tumor Biology of Clear-Cell Renal-Cell Carcinoma. An Immunohistochemical and Morphometric Study of Angiogenesis and Vascular Related Factors. Pathology and Oncology Research, 2016, 22, 807-815.	0.9	5
1194	Naringenin exerts anti-angiogenic effects in human endothelial cells: Involvement of ERRÎ \pm /VEGF/KDR signaling pathway. FÃ \neg toterapÃ \neg â, 2016, 111, 78-86.	1.1	41
1195	The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells. Cancer Chemotherapy and Pharmacology, 2016, 77, 1087-1096.	1.1	20
1196	5-Hydroxy-7-azaindolin-2-one, a novel hybrid of pyridinol and sunitinib: design, synthesis and cytotoxicity against cancer cells. Organic and Biomolecular Chemistry, 2016, 14, 4829-4841.	1.5	26
1197	Neuronavigation-assisted trajectory planning for deep brain biopsy with susceptibility-weighted imaging. Acta Neurochirurgica, 2016, 158, 1355-1362.	0.9	9
1198	Mutually Supportive Mechanisms of Inflammation and Vascular Remodeling. International Review of Cell and Molecular Biology, 2016, 326, 201-278.	1.6	28
1199	The multifaceted roles of fatty acid synthesis in cancer. Nature Reviews Cancer, 2016, 16, 732-749.	12.8	1,022
1200	Overexpression of CXCR7 induces angiogenic capacity of human hepatocellular carcinoma cells via the AKT signaling pathway. Oncology Reports, 2016, 36, 2275-2281.	1.2	21
1201	\hat{l}^2 2 -Adrenoceptors on tumor cells play a critical role in stress-enhanced metastasis in a mouse model of breast cancer. Brain, Behavior, and Immunity, 2016, 57, 106-115.	2.0	77
1202	Understanding the antiangiogenic effect of metronomic chemotherapy through a simple mathematical model. Physica A: Statistical Mechanics and Its Applications, 2016, 464, 251-266.	1,2	8
1203	Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2016, 81, 33-40.	1.1	15
1204	Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 78, 727-733.	1.1	2
1205	Targeted Therapy of Colorectal Cancer. Oncology Research and Treatment, 2016, 39, 796-802.	0.8	38
1206	In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT-116 xenograft model in nude mice. Oncology Reports, 2016, 36, 2951-2959.	1,2	6
1207	Endothelial progenitor cells promote tumor growth and progression by enhancing new vessel formation. Oncology Letters, 2016, 12, 793-799.	0.8	28
1208	Tumor endothelial cells express high pentraxin 3 levels. Pathology International, 2016, 66, 687-694.	0.6	11
1209	Tumor Growth Suppression Induced by Biomimetic Silk Fibroin Hydrogels. Scientific Reports, 2016, 6, 31037.	1.6	62

#	Article	IF	CITATIONS
1210	Synthesis and Characterization of Injectable Sulfonate-Containing Hydrogels. Biomacromolecules, 2016, 17, 4064-4074.	2.6	20
1211	Ethanol extract of Lophatheri Herba exhibits anti-cancer activity in human cancer cells by suppression of metastatic and angiogenic potential. Scientific Reports, 2016, 6, 36277.	1.6	18
1212	Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide. Scientific Reports, 2016, 6, 19800.	1.6	45
1213	Pien Tze Huang suppresses VEGF-C-mediated lymphangiogenesis in colorectal cancer. Oncology Reports, 2016, 36, 3568-3576.	1.2	19
1214	Forward-viewing photoacoustic imaging probe with bundled ultra-thin hollow optical fibers. Journal of Optics (United Kingdom), 2016, 18, 074015.	1.0	9
1215	Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab. Medicine (United States), 2016, 95, e4232.	0.4	16
1216	Targeting Angiogenesis in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 182-189.	1.0	29
1217	Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer. Medicine (United States), 2016, 95, e3752.	0.4	7
1218	Modifying the tumor microenvironment using nanoparticle therapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2016, 8, 891-908.	3.3	30
1219	Utilizing Zebrafish to Identify Antiâ€(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges. Microcirculation, 2016, 23, 389-405.	1.0	11
1220	EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway. Journal of Experimental and Clinical Cancer Research, 2016, 35, 65.	3.5	23
1221	Activation of multiple angiogenic signaling pathways in hemangiopericytoma. Brain Tumor Pathology, 2016, 33, 200-208.	1.1	6
1222	Suppression of HSP27 increases the anti-tumor effects of quercetin in human leukemia U937 cells. Molecular Medicine Reports, 2016, 13, 689-696.	1.1	44
1223	Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy. Chemical Society Reviews, 2016, 45, 6250-6269.	18.7	365
1224	Distinct association of VEGF-A polymorphisms with laryngeal and nasopharyngeal cancer. Meta Gene, 2016, 10, 90-94.	0.3	16
1225	Correlation between angiogenic/inflammatory mediators in Wister rat model of liver dysplasia. Journal of Immunoassay and Immunochemistry, 2016, 37, 472-484.	0.5	5
1226	Platycodin D inhibits B16F10 melanoma metastasis via antiangiogenic activity. RSC Advances, 2016, 6, 10606-10614.	1.7	8
1227	Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma. Human Pathology, 2016, 51, 75-85.	1.1	34

#	Article	IF	CITATIONS
1228	Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. European Journal of Medicinal Chemistry, 2016, 108, 495-504.	2.6	68
1229	Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model. Magnetic Resonance Imaging, 2016, 34, 177-182.	1.0	17
1230	Targeting metastasis. Nature Reviews Cancer, 2016, 16, 201-218.	12.8	1,111
1231	Blocking the FGF/FGFR system as a â¿¿two-compartmentâ¿¿ antiangiogenic/antitumor approach in cancer therapy. Pharmacological Research, 2016, 107, 172-185.	3.1	69
1232	Angiogenesis in melanoma: an update with a focus on current targeted therapies. Journal of Clinical Pathology, 2016, 69, 472-483.	1.0	55
1233	Tumor angiogenesisâ€"characteristics of tumor endothelial cells. International Journal of Clinical Oncology, 2016, 21, 206-212.	1.0	119
1234	Polysaccharides from Korean Citrus hallabong peels inhibit angiogenesis and breast cancer cell migration. International Journal of Biological Macromolecules, 2016, 85, 522-529.	3.6	44
1235	In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy. International Journal of Pharmaceutics, 2016, 503, 150-162.	2.6	23
1236	Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration. Tissue Engineering - Part B: Reviews, 2016, 22, 341-357.	2.5	8
1237	Neutrophils: Critical components in experimental animal models of cancer. Seminars in Immunology, 2016, 28, 197-204.	2.7	41
1238	Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence. Annals of Surgical Oncology, 2016, 23, 1760-1767.	0.7	12
1239	Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Seminars in Immunopathology, 2016, 38, 167-183.	2.8	96
1240	Pilot prospective evaluation of 18F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1047-1055.	3.3	25
1241	Realistic biological approaches for improving thermoradiotherapy. International Journal of Hyperthermia, 2016, 32, 14-22.	1.1	10
1242	Heterogeneity of tumor endothelial cells and drug delivery. Advanced Drug Delivery Reviews, 2016, 99, 140-147.	6.6	88
1243	Molecular and Cellular Biology. , 2016, , 41-50.e2.		1
1244	STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Letters, 2016, 370, 125-135.	3.2	225
1245	Drug delivery approaches for the treatment of glioblastoma multiforme. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1365-1373.	1.9	36

#	Article	IF	CITATIONS
1246	3D bioprinting: improving in vitro in v	1.2	123
1247	A novel delivery vector for targeted delivery of the antiangiogenic drug paclitaxel to angiogenic blood vessels: TLTYTWS-conjugated PEG–PLA nanoparticles. Journal of Nanoparticle Research, 2017, 19, 1.	0.8	6
1248	Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics, 2017, 14, 307-320.	2.1	294
1249	⁶⁸ Ga-Chelation and comparative evaluation of N,N′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) conjugated NGR and RGD peptides as tumor targeted molecular imaging probes. MedChemComm, 2017, 8, 673-679.	3.5	22
1250	Circulating endothelial cells, circulating endothelial progenitor cells, and von Willebrand factor in pregnancies complicated by hypertensive disorders. American Journal of Reproductive Immunology, 2017, 77, e12625.	1,2	22
1251	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: Gl carcinomas., 2017, 174, 145-172.		22
1252	Anal study in immunocompetent women with human papillomavirus related lower genital tract pathology. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 211, 15-20.	0.5	6
1253	Polyketides from the endophytic fungus Phomopsis sp. sh917 by using the one strain/many compounds strategy. Tetrahedron, 2017, 73, 3577-3584.	1.0	25
1254	A monomeric water-soluble NIR-absorbing porphyrin derivative as in vivo photoacoustic tomography contrast agent., 2017,,.		0
1255	Arctigenin, a lignan from Arctium lappa L., inhibits metastasis of human breast cancer cells through the downregulation of MMP-2/â^9 and heparanase in MDA-MB-231 cells. Oncology Reports, 2017, 37, 179-184.	1.2	76
1256	Endothelial cell markers from clinician's perspective. Experimental and Molecular Pathology, 2017, 102, 303-313.	0.9	68
1257	Endophytic fungi from mangrove inhibit lung cancer cell growth and angiogenesis in vitro. Oncology Reports, 2017, 37, 1793-1803.	1.2	9
1258	WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma. Cell Death and Disease, 2017, 8, e2750-e2750.	2.7	60
1259	Intratumoral Cancer Cell Intravasation Can Occur Independent of Invasion into the Adjacent Stroma. Cell Reports, 2017, 19, 601-616.	2.9	72
1260	Overexpressed HSPA2 correlates with tumor angiogenesis and unfavorable prognosis in pancreatic carcinoma. Pancreatology, 2017, 17, 457-463.	0.5	23
1261	An Optimized 3D Coculture Assay for Preclinical Testing of Pro- and Antiangiogenic Drugs. SLAS Discovery, 2017, 22, 602-613.	1.4	12
1262	Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis. British Journal of Cancer, 2017, 116, 1329-1339.	2.9	35
1263	Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State. Cancer Research, 2017, 77, 2564-2569.	0.4	87

#	Article	IF	CITATIONS
1264	The CNGRCLLII(KLAKLAK)2 peptide shows cytotoxicity against HUVECs by inducing apoptosis: An in vitro and in vivo study. Tumor Biology, 2017, 39, 101042831770164.	0.8	0
1266	NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4. Biochemical and Biophysical Research Communications, 2017, 488, 1-5.	1.0	16
1267	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. European Journal of Cancer, 2017, 70, 111-121.	1.3	70
1268	Correlation Between Microvessel Density and Morphological Features in Skin Squamous Cell Carcinoma. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2017, 38, 63-73.	0.2	2
1269	Synergistic Suppression of Tumor Angiogenesis by the Co-delivering of Vascular Endothelial Growth Factor Targeted siRNA and Candesartan Mediated by Functionalized Carbon Nanovectors. ACS Applied Materials & Samp; Interfaces, 2017, 9, 23353-23369.	4.0	53
1270	The effect of RCAN1 on the biological behaviors of small cell lung cancer. Tumor Biology, 2017, 39, 101042831770040.	0.8	14
1271	Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharmaceutical Journal, 2017, 25, 638-643.	1.2	49
1272	Vascular-homing peptides for cancer therapy. Biomedicine and Pharmacotherapy, 2017, 92, 187-195.	2.5	28
1273	Natural Compounds Are Smart Players in Context to Anticancer Potential of Receptor Tyrosine Kinases: An In Silico and In Vitro Advancement. Translational Medicine Research, 2017, , 177-202.	0.0	1
1274	Modulation of mammary tumor vascularization by mast cells: Ultrasonographic and histopathological approaches. Life Sciences, 2017, 176, 35-41.	2.0	7
1275	Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. Journal of Neuro-Oncology, 2017, 134, 495-504.	1.4	160
1276	The chemokine receptor CXCR4 promotes granuloma formation by sustaining a mycobacteria-induced angiogenesis programme. Scientific Reports, 2017, 7, 45061.	1.6	31
1277	MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF. Oncogene, 2017, 36, 3986-4000.	2.6	118
1278	Pericytes, an overlooked player in vascular pathobiology. , 2017, 171, 30-42.		165
1279	Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer. Neoplasia, 2017, 19, 8-16.	2.3	17
1280	Salivary biomarkers in the diagnosis of breast cancer: A review. Critical Reviews in Oncology/Hematology, 2017, 110, 62-73.	2.0	72
1281	Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 119, 50-58.	2.0	17
1282	Vitamins and regulation of angiogenesis: [A, B1, B2, B3, B6, B9, B12, C, D, E, K]. Journal of Functional Foods, 2017, 38, 180-196.	1.6	22

#	Article	IF	CITATIONS
1283	Human neutrophil elastase mediates fibrinolysis shutdown through competitive degradation of plasminogen and generation of angiostatin. Journal of Trauma and Acute Care Surgery, 2017, 83, 1053-1061.	1.1	24
1284	Spermatogenesis., 2017, , 135-160.		0
1285	Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression. Scientific Reports, 2017, 7, 11864.	1.6	32
1286	CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis. Scientific Reports, 2017, 7, 10666.	1.6	20
1287	Ticagrelor breaks up the tumor-platelet party. Blood, 2017, 130, 1177-1178.	0.6	10
1288	Increased PD-L1 expression and IL-6 secretion characterize human lung tumor-derived perivascular-like cells that promote vascular leakage in a perfusable microvasculature model. Scientific Reports, 2017, 7, 10636.	1.6	35
1289	PhID: An Open-Access Integrated Pharmacology Interactions Database for Drugs, Targets, Diseases, Genes, Side-Effects, and Pathways. Journal of Chemical Information and Modeling, 2017, 57, 2395-2400.	2.5	9
1290	Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis. Future Medicinal Chemistry, 2017, 9, 1709-1729.	1.1	18
1291	HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. International Journal of Oncology, 2017, 51, 715-723.	1.4	33
1292	Comprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells. Scientific Reports, 2017, 7, 9789.	1.6	59
1293	Combining 2D angiogenesis and 3D osteosarcoma microtissues to improve vascularization. Experimental Cell Research, 2017, 360, 138-145.	1.2	28
1294	MCPIP1 Downregulation in Clear Cell Renal Cell Carcinoma Promotes Vascularization and Metastatic Progression. Cancer Research, 2017, 77, 4905-4920.	0.4	60
1295	Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes. Molecular Cancer Therapeutics, 2017, 16, 2452-2461.	1.9	35
1296	Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging. Angiogenesis, 2017, 20, 547-555.	3.7	26
1297	Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis. International Journal of Clinical Oncology, 2017, 22, 807-816.	1.0	3
1298	Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer. Scientific Reports, 2017, 7, 1796.	1.6	51
1299	Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis. Cancer Chemotherapy and Pharmacology, 2017, 80, 487-495.	1.1	21
1300	STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade. Oncolmmunology, 2017, 6, e1361088.	2.1	30

#	Article	IF	Citations
1301	Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Oncogene, 2017, 36, 6627-6639.	2.6	93
1302	Antitumoral effects of γCdcPLI, a PLA2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell. Scientific Reports, 2017, 7, 7077.	1.6	17
1303	Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Seminars in Cancer Biology, 2017, 47, 185-195.	4.3	114
1304	Radiolabeled Anti-Adenosine Triphosphate Synthase Monoclonal Antibody as a Theragnostic Agent Targeting Angiogenesis. Molecular Imaging, 2017, 16, 153601211773739.	0.7	6
1305	Oral Cancer Stem Cells Microenvironment. Advances in Experimental Medicine and Biology, 2017, 1041, 207-233.	0.8	11
1306	Emerging Nanomedical Solutions for Angiogenesis Regulation. Advanced Drug Delivery Reviews, 2017, 119, 1-2.	6.6	2
1307	A Contrastâ€Enhanced Ultrasonographic Study About the Impact of Longâ€term Exercise Training on Mammary Tumor Vascularization. Journal of Ultrasound in Medicine, 2017, 36, 2459-2466.	0.8	6
1308	Targeted Disruption of JCAD (Junctional Protein Associated With Coronary Artery Disease)/KIAA1462, a Coronary Artery Disease–Associated Gene Product, Inhibits Angiogenic Processes In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1667-1673.	1.1	25
1309	Microfluidic technologies for anticancer drug studies. Drug Discovery Today, 2017, 22, 1654-1670.	3.2	63
1310	Recent synthetic and medicinal perspectives of tryptanthrin. Bioorganic and Medicinal Chemistry, 2017, 25, 4533-4552.	1.4	112
1311	Spheroids as vascularization units: From angiogenesis research to tissue engineering applications. Biotechnology Advances, 2017, 35, 782-791.	6.0	78
1312	Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway. Journal of Experimental and Clinical Cancer Research, 2017, 36, 27.	3.5	101
1313	Novel small peptides derived from VEGF125-136: potential drugs for radioactive diagnosis and therapy in A549 tumor-bearing nude mice. Scientific Reports, 2017, 7, 4278.	1.6	11
1314	Entropy of Ultrasound-Contrast-Agent Velocity Fields for Angiogenesis Imaging in Prostate Cancer. IEEE Transactions on Medical Imaging, 2017, 36, 826-837.	5.4	26
1315	Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. Investigational New Drugs, 2017, 35, 79-86.	1.2	3
1316	A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Annals of Oncology, 2017, 28, 121-127.	0.6	24
1317	Cupressus sempervirens extract inhibited human basal cell carcinoma tumorigenesis, local invasion, and angiogenic property. Comparative Clinical Pathology, 2017, 26, 203-211.	0.3	7
1318	Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer and Metastasis Reviews, 2017, 36, 159-177.	2.7	103

#	Article	IF	CITATIONS
1319	Informatics for cancer immunotherapy. Annals of Oncology, 2017, 28, xii56-xii73.	0.6	19
1320	The Role of E-Cadherin/β-Catenin in Hydroxysafflor Yellow A Inhibiting Adhesion, Invasion, Migration and Lung Metastasis of Hepatoma Cells. Biological and Pharmaceutical Bulletin, 2017, 40, 1706-1715.	0.6	18
1321	Targeting Membrane Lipid a Potential Cancer Cure?. Frontiers in Pharmacology, 2017, 8, 12.	1.6	91
1322	CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. OncoTargets and Therapy, 2017, Volume 10, 3817-3825.	1.0	56
1323	Loss of Complement Factor H in Plasma Increases Endothelial Cell Migration. Journal of Cancer, 2017, 8, 2184-2190.	1.2	12
1324	Multimodality Imaging in Tumor Angiogenesis: Present Status and Perspectives. International Journal of Molecular Sciences, 2017, 18, 1864.	1.8	33
1325	G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts. International Journal of Molecular Sciences, 2017, 18, 2713.	1.8	27
1326	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. International Journal of Molecular Sciences, 2017, 18, 85.	1.8	25
1327	Differential effects of sulforaphane in regulation of angiogenesis in a co-culture model of endothelial cells and pericytes. Oncology Reports, 2017, 37, 2905-2912.	1.2	8
1328	Vasohibin-1 inhibits angiogenesis and suppresses tumor growth in renal cell carcinoma. Oncology Reports, 2017, 38, 1021-1028.	1.2	7
1329	Luminescent/magnetic PLGA-based hybrid nanocomposites: a smart nanocarrier system for targeted codelivery and dual-modality imaging in cancer theranostics. International Journal of Nanomedicine, 2017, Volume 12, 4299-4322.	3.3	50
1330	Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications. PLoS ONE, 2017, 12, e0181484.	1.1	46
1331	Role of Nitric Oxide in Cancer Stem Cell Regulation and Metastasis. , 2017, , 179-189.		0
1332	Computational investigation of sphingosine kinase 1 (SphK1) and calcium dependent ERK1/2 activation downstream of VEGFR2 in endothelial cells. PLoS Computational Biology, 2017, 13, e1005332.	1.5	26
1333	Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 76.	1.6	22
1334	The small vesicular culprits: the investigation of extracellular vesicles as new targets for cancer treatment. Clinical and Translational Medicine, 2017, 6, 45.	1.7	29
1335	Sema3A drastically suppresses tumor growth in oral cancer Xenograft model of mice. BMC Pharmacology & Samp; Toxicology, 2017, 18, 55.	1.0	18
1336	In vivo antitumor potential of extracts from different parts of Bauhinia variegata linn. Against b16f10 melanoma tumour model in c57bl/6 mice. Applied Cancer Research, 2017, 37, .	1.0	13

#	Article	IF	CITATIONS
1337	Dynamics of angiogenesis and cellularity in rabbit VX2 tumors using contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging. Oncology Letters, 2018, 15, 2978-2984.	0.8	4
1338	On the validity of the first-pass binding model for quantitative ultrasound molecular imaging: Comparison between BR55 and Sonovue. , 2017, , .		0
1339	Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal. Oncotarget, 2017, 8, 36137-36148.	0.8	137
1340	An FGF8b-mimicking peptide with potent antiangiogenic activity. Molecular Medicine Reports, 2017, 16, 894-900.	1.1	4
1341	Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer. Oncotarget, 2017, 8, 1141-1155.	0.8	11
1342	The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and -9 in angiogenesis, metastasis, and prognosis of endometrial cancer. OncoTargets and Therapy, 2017, Volume 10, 4617-4624.	1.0	86
1343	Improved Tumor Targeting and Longer Retention Time of NIR Fluorescent Probes Using Bioorthogonal Chemistry. Theranostics, 2017, 7, 3794-3802.	4.6	34
1344	Survivin expression, HPV positivity and microvessel density in oropharyngeal carcinomas and relationship with survival time. Archives of Medical Science, 2017, 6, 1467-1473.	0.4	7
1345	Bioconverted Orostachys japonicas Extracts Suppress Angiogenic Activity of Ms-1 Endothelial Cells. International Journal of Molecular Sciences, 2017, 18, 2615.	1.8	13
1346	The Role of NOX4 and TRX2 in Angiogenesis and Their Potential Cross-Talk. Antioxidants, 2017, 6, 42.	2.2	32
1347	Redox activated polymeric nanoparticles in tumor therapy., 2017,, 327-354.		4
1348	Functional role of Kv1.1 and Kv1.3 channels in the neoplastic progression steps of three cancer cell lines, elucidated by scorpion peptides. International Journal of Biological Macromolecules, 2018, 111, 1146-1155.	3.6	39
1349	PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway. Cell Death and Disease, 2018, 9, 375.	2.7	37
1350	Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response. Oncology Letters, 2018, 15, 3437-3446.	0.8	17
1351	Pituitary adenylate cyclase-activating polypeptide ameliorates vascular dysfunction induced by hyperglycaemia. Diabetes and Vascular Disease Research, 2018, 15, 277-285.	0.9	10
1352	Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1223-1227.	1.0	11
1353	A putative G-quadruplex structure in the proximal promoter of VEGFR-2 has implications for drug design to inhibit tumor angiogenesis. Journal of Biological Chemistry, 2018, 293, 8947-8955.	1.6	21
1354	Activation of <scp>AMPK</scp> by simvastatin inhibited breast tumor angiogenesis via impeding <scp>HIF</scp> â€Îαâ€induced proâ€angiogenic factor. Cancer Science, 2018, 109, 1627-1637.	1.7	46

#	Article	IF	CITATIONS
1355	Doxorubicin-DNA adduct entrenched and motif tethered artificial virus encased in pH-responsive polypeptide complex for targeted cancer therapy. Materials Science and Engineering C, 2018, 89, 387-400.	3.8	12
1356	Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment. Science China Life Sciences, 2018, 61, 380-391.	2.3	15
1357	The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review. Biomedicine and Pharmacotherapy, 2018, 102, 1127-1144.	2.5	42
1358	MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma. Molecular and Cellular Biochemistry, 2018, 448, 61-69.	1.4	38
1359	Recent advances in anti-angiogenic nanomedicines for cancer therapy. Nanoscale, 2018, 10, 5393-5423.	2.8	69
1360	LYG-202 inhibits activation of endothelial cells and angiogenesis through CXCL12/CXCR7 pathway in breast cancer. Carcinogenesis, 2018, 39, 588-600.	1.3	33
1361	Suppression of Metastasis by Primary Tumor and Acceleration of Metastasis Following Primary Tumor Resection: A Natural Law?. Bulletin of Mathematical Biology, 2018, 80, 519-539.	0.9	24
1362	LTBP3 promotes early metastatic events during cancer cell dissemination. Oncogene, 2018, 37, 1815-1829.	2.6	17
1363	Repeated photon and C-ion irradiations in vivo have different impact on alteration of tumor characteristics. Scientific Reports, 2018, 8, 1458.	1.6	10
1364	\hat{l}^2 1,4-Galactosyltransferase V activates Notch1 signaling in glioma stem-like cells and promotes their transdifferentiation into endothelial cells. Journal of Biological Chemistry, 2018, 293, 2219-2230.	1.6	13
1365	Protein neddylation and its alterations in human cancers for targeted therapy. Cellular Signalling, 2018, 44, 92-102.	1.7	167
1366	3D Image Analysis of theÂMicrovasculature in Healthy and Diseased Tissues. Methods in Molecular Biology, 2018, 1731, 193-212.	0.4	0
1367	GV1001 Induces Apoptosis by Reducing Angiogenesis in Renal Cell Carcinoma Cells Both In Vitro and In Vivo. Urology, 2018, 113, 129-137.	0.5	8
1368	Dual-targeted nanomedicines for enhanced tumor treatment. Nano Today, 2018, 18, 65-85.	6.2	90
1369	LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene, 2018, 37, 4094-4109.	2.6	275
1370	Overexpression of miR-133 decrease primary endothelial cells proliferation and migration via FGFR1 targeting. Experimental Cell Research, 2018, 369, 11-16.	1.2	5
1371	Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2–/– mice and human cholangiocarcinoma tumorigenesis. Hepatology, 2018, 68, 1042-1056.	3.6	50
1372	Dissecting Oncogenic RTK Pathways in Colorectal Cancer Initiation and Progression. Methods in Molecular Biology, 2018, 1765, 27-42.	0.4	4

#	Article	IF	CITATIONS
1373	Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles. Journal of Controlled Release, 2018, 277, 35-47.	4.8	113
1374	Effects of cryopreservation on adipose tissueâ€derived microvascular fragments. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1020-1030.	1.3	24
1375	Liposomeâ€encapsulated chemotherapy: Current evidence for its use in companion animals. Veterinary and Comparative Oncology, 2018, 16, E1-E15.	0.8	13
1376	Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review. Irish Journal of Medical Science, 2018, 187, 333-336.	0.8	7
1377	Abnormalities of tumor endothelial cells and cancer progression. Oral Science International, 2018, 15, 1-6.	0.3	12
1378	CCR6 promotes tumor angiogenesis via the AKT/NF-κB/VEGF pathway in colorectal cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 387-397.	1.8	59
1379	ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene, 2018, 37, 1005-1019.	2.6	49
1380	Multiparametric characterization of response to antiâ€angiogenic therapy using USPIO contrastâ€enhanced MRI in combination with dynamic contrastâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2018, 47, 1589-1600.	1.9	11
1381	Therapeutic potency of pharmacological adenosine receptor agonist/antagonist in angiogenesis, current status and perspectives. Journal of Pharmacy and Pharmacology, 2018, 70, 191-196.	1.2	16
1382	Comparative evaluation of ⁶⁸ Gaâ€labeled <scp>NODAGA</scp> , <scp> DOTAGA</scp> , and <scp>HBED</scp> â€scp>CCâ€conjugated <scp>cNGR</scp> peptide chelates as tumorâ€targeted molecular imaging probes. Chemical Biology and Drug Design, 2018, 91, 781-788.	1.5	18
1383	Laser scanning laser diode photoacoustic microscopy system. Photoacoustics, 2018, 9, 1-9.	4.4	50
1384	Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Advanced Materials, 2018, 30, e1801362.	11.1	415
1385	MicroRNAâ€'424 suppresses the proliferation of hemangiomaâ€'derived endothelial cells by targeting VEGFRâ€'2. Molecular Medicine Reports, 2018, 18, 4065-4071.	1.1	7
1386	CXCR7 silencing inhibits the migration and invasion of human tumor endothelial cells derived from hepatocellular carcinoma by suppressing STAT3. Molecular Medicine Reports, 2018, 18, 1644-1650.	1.1	9
1387	Genetic variation determines VEGF-A plasma levels in cancer patients. Scientific Reports, 2018, 8, 16332.	1.6	10
1388	Predicting drug delivery efficiency into tumor tissues through molecular simulation of transport in complex vascular networks. Journal of Controlled Release, 2018, 292, 221-234.	4.8	15
1389	Factors Associated With Small Aggressive Non–Small Cell Lung Cancers in the National Lung Screening Trial: A Validation Study. JNCI Cancer Spectrum, 2018, 2, pkx010.	1.4	1
1390	Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model. EJNMMI Research, 2018, 8, 54.	1.1	12

#	Article	IF	CITATIONS
1391	Treatment with Src inhibitor dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model. Tumor & Microenvironment, 2018, 1, 30.	0.7	6
1392	The oncometabolite dâ€'2â€'hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway. International Journal of Oncology, 2019, 54, 753-763.	1.4	11
1393	Anoikisâ€'resistant human osteosarcoma cells display significant angiogenesis by activating the Src kinaseâ€'mediated MAPK pathway. Oncology Reports, 2019, 41, 235-245.	1.2	12
1394	Isoliquiritin Apioside Suppresses in vitro Invasiveness and Angiogenesis of Cancer Cells and Endothelial Cells. Frontiers in Pharmacology, 2018, 9, 1455.	1.6	21
1395	Peptideâ€Based Multifunctional Nanomaterials for Tumor Imaging and Therapy. Advanced Functional Materials, 2018, 28, 1804492.	7.8	94
1396	FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA. Cancer Letters, 2018, 439, 78-90.	3.2	44
1397	Cyclopropane Modification of Trehalose Dimycolate Drives Granuloma Angiogenesis and Mycobacterial Growth through Vegf Signaling. Cell Host and Microbe, 2018, 24, 514-525.e6.	5.1	34
1398	Malignant Lesions. , 2018, , 185-214.		0
1399	The real-time ultrasonography for fusion image in glioma neurosugery. Clinical Neurology and Neurosurgery, 2018, 175, 84-90.	0.6	9
1400	RGD-modified nanoliposomes containing quercetin for lung cancer targeted treatment. OncoTargets and Therapy, 2018, Volume 11, 5397-5405.	1.0	27
1401	Molecular mechanisms of the action of Arctigenin in cancer. Biomedicine and Pharmacotherapy, 2018, 108, 403-407.	2.5	60
1402	Expression of vascular endothelial growth factor (VEGF) in equine sarcoid. BMC Veterinary Research, 2018, 14, 266.	0.7	9
1403	Effects of auriculasin on vascular endothelial growth factor (VEGF)-induced angiogenesis via regulation of VEGF receptor 2 signaling pathways in vitro and in vivo. Food and Chemical Toxicology, 2018, 121, 612-621.	1.8	20
1404	Successful treatment of relapsed testicular embryonal rhabdomyosarcoma with Endostar and traditional chemotherapy: a case report. OncoTargets and Therapy, 2018, Volume 11, 5287-5291.	1.0	3
1405	Contribution of Tumor Endothelial Cells in Cancer Progression. International Journal of Molecular Sciences, 2018, 19, 1272.	1.8	182
1406	Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 382-394.	0.7	2
1407	Vascular Endothelial Growth Factor Enhances Compensatory Lung Growth in Piglets. Surgery, 2018, 164, 1279-1286.	1.0	5
1408	Efficacy and safety of rhâ€endostatin (Endostar) combined with pemetrexed/cisplatin followed by rhâ€endostatin plus pemetrexed maintenance in nonâ€small cell lung cancer: A retrospective comparison with standard chemotherapy. Thoracic Cancer, 2018, 9, 1354-1360.	0.8	14

#	Article	IF	CITATIONS
1409	Establishment of a detection assay for DNA endonuclease activity and its application in the screening and prognosis of malignant lymphoma. BMC Biochemistry, 2018, 19, 6.	4.4	7
1410	Stretching Reduces Tumor Growth in a Mouse Breast Cancer Model. Scientific Reports, 2018, 8, 7864.	1.6	48
1411	Lymphangiogenesis, lymphatic systemomics, and cancer: context, advances and unanswered questions. Clinical and Experimental Metastasis, 2018, 35, 419-424.	1.7	9
1412	Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer. Oncogene, 2018, 37, 4903-4920.	2.6	52
1413	Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study. Oncology Letters, 2018, 15, 8627-8634.	0.8	13
1414	Plant-Derived Compounds in Cancer Therapy: Traditions of Past and Drugs of Future. , 2018, , 91-127.		5
1415	FOXP3 inhibits angiogenesis by downregulating VEGF in breast cancer. Cell Death and Disease, 2018, 9, 744.	2.7	45
1416	Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. International Journal of Oncology, 2018, 52, 2051-2060.	1.4	18
1417	A Catecholâ€Type Resveratrol Analog Manifests Antiangiogenic Action by Constructing an Efficient Catalytic Redox Cycle with Intracellular Copper Ions and NQO1. Molecular Nutrition and Food Research, 2018, 62, e1700969.	1.5	9
1418	Overview and Critical Appraisal of Arterial Spin Labelling Technique in Brain Perfusion Imaging. Contrast Media and Molecular Imaging, 2018, 2018, 1-15.	0.4	25
1419	Novel Mutations in the Asparagine Synthetase Gene (ASNS) Associated With Microcephaly. Frontiers in Genetics, 2018, 9, 245.	1.1	15
1420	Anti-angiogenic and anticancer effects of baicalein derivatives based on transgenic zebrafish model. Bioorganic and Medicinal Chemistry, 2018, 26, 4481-4492.	1.4	20
1421	Computational modeling of synergistic interaction between $\hat{l}\pm V\hat{l}^23$ integrin and VEGFR2 in endothelial cells: Implications for the mechanism of action of angiogenesis-modulating integrin-binding peptides. Journal of Theoretical Biology, 2018, 455, 212-221.	0.8	19
1422	An optimized LC-MS/MS method for determination of HYNIC-3PRGD2, a new promising imaging agent for tumor targeting, in rat plasma and its application. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1095, 142-148.	1.2	1
1423	Targeting the Metastatic Bone Microenvironment by MicroRNAs. Frontiers in Endocrinology, 2018, 9, 202.	1.5	24
1424	Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review. Nutrients, 2018, 10, 645.	1.7	178
1425	Single and Multiphoton Responsive Nanomaterials for the Investigation of Cancer Microenvironment. , 2018, , 63-95.		0
1426	Recombinant TSR1 of ADAMTS5 Suppresses Melanoma Growth in Mice via an Anti-angiogenic Mechanism. Cancers, 2018, 10, 192.	1.7	20

#	Article	IF	CITATIONS
1427	Aneuploid CTC and CEC. Diagnostics, 2018, 8, 26.	1.3	32
1428	Serum exosomes contain ECRG4 mRNA that suppresses tumor growth via inhibition of genes involved in inflammation, cell proliferation, and angiogenesis. Cancer Gene Therapy, 2018, 25, 248-259.	2.2	67
1429	Tissue Engineering to Improve Immature Testicular Tissue and Cell Transplantation Outcomes: One Step Closer to Fertility Restoration for Prepubertal Boys Exposed to Gonadotoxic Treatments. International Journal of Molecular Sciences, 2018, 19, 286.	1.8	46
1430	Integrin \hat{l}^21 is an essential factor in vasculogenic mimicry of human cancer cells. Cancer Science, 2018, 109, 2490-2496.	1.7	61
1431	Phytoestrogens as a Natural Source for the Possible Colon Cancer Treatment. , 2018, , 259-281.		0
1432	With Great Age Comes Great Metastatic Ability: Ovarian Cancer and the Appeal of the Aging Peritoneal Microenvironment. Cancers, 2018, 10, 230.	1.7	27
1433	Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations. BMC Cancer, 2018, 18, 264.	1.1	43
1434	Modeling and Analysis of a Nonlinear Age-Structured Model for Tumor Cell Populations with Quiescence. Journal of Nonlinear Science, 2018, 28, 1763-1791.	1.0	18
1435	Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology. International Journal of Molecular Sciences, 2018, 19, 2311.	1.8	70
1436	Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization. Drug Delivery and Translational Research, 2018, 8, 1508-1526.	3.0	28
1437	Synthesis and in vitro experiments of carcinoma vascular endothelial targeting polymeric nano-micelles combining small particle size and supermagnetic sensitivity. International Journal of Medical Sciences, 2018, 15, 498-506.	1.1	10
1438	Single-breath-hold photoacoustic computed tomography of the breast. Nature Communications, 2018, 9, 2352.	5.8	290
1439	Development of the renal vasculature. Seminars in Cell and Developmental Biology, 2019, 91, 132-146.	2.3	34
1440	ADAMTS5 acts as a tumor suppressor by inhibiting migration, invasion and angiogenesis in human gastric cancer. Gastric Cancer, 2019, 22, 287-301.	2.7	27
1441	Observation of the early blood vessels of cutaneous malignant melanoma using Swept Source Optical Coherence Tomography Angiography (SS-OCTA). Journal of Innovative Optical Health Sciences, 2019, 12, 1942005.	0.5	2
1442	Embolization of iliac metastasis during lenvatinib treatment in patient with advanced Hýrthle cell thyroid carcinoma. Future Oncology, 2019, 15, 35-40.	1.1	4
1443	Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis. International Journal of Molecular Sciences, 2019, 20, 3928.	1.8	4
1444	Metal ions and the extracellular matrix in tumor migration. FEBS Journal, 2019, 286, 2950-2964.	2.2	32

#	ARTICLE	IF	CITATIONS
1445	Capsaicinoids: Multiple effects on angiogenesis, invasion and metastasis in human cancers. Biomedicine and Pharmacotherapy, 2019, 118, 109317.	2.5	36
1446	Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions. Cancer Research, 2019, 79, 4567-4576.	0.4	79
1447	Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer, 2019, 125, 4139-4147.	2.0	299
1448	C-glyco"RGD―as αIIbβ3 and αvβ integrin ligands for imaging applications: Synthesis, in vitro evaluation and molecular modeling. Bioorganic and Medicinal Chemistry, 2019, 27, 4101-4109.	1.4	6
1449	<p>Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes</p> . International Journal of Nanomedicine, 2019, Volume 14, 5911-5924.	3.3	29
1450	An improved kit formulation for oneâ€pot synthesis of [^{99m} Tc]Tcâ€HYNICâ€E[c(RGDfK)] ₂ for routine clinical use in cancer imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 823-834.	0.5	3
1451	PTBP3 contributes to colorectal cancer growth and metastasis via translational activation of HIF- $1\hat{l}_{\pm}$. Journal of Experimental and Clinical Cancer Research, 2019, 38, 301.	3.5	30
1452	Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene, 2019, 38, 6095-6108.	2.6	40
1453	PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway. Angiogenesis, 2019, 22, 507-519.	3.7	30
1454	Synthesis and biological evaluation of novel benzylidene-succinimide derivatives as noncytotoxic antiangiogenic inhibitors with anticolorectal cancer activity inÂvivo. European Journal of Medicinal Chemistry, 2019, 179, 805-827.	2.6	22
1455	Quantitative characterization of viscoelastic fracture induced by time-dependent intratumoral pressure in a 3D model tumor. Biomicrofluidics, 2019, 13, 054107.	1.2	1
1456	Dietary 2-deoxy-D-glucose impairs tumour growth and metastasis by inhibiting angiogenesis. European Journal of Cancer, 2019, 123, 11-24.	1.3	12
1457	Comparison of 68Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold. Nuclear Medicine and Biology, 2019, 78-79, 1-10.	0.3	17
1458	In Vivo Biodistribution of Engineered Lipid Microbubbles in Rodents. ACS Omega, 2019, 4, 13371-13381.	1.6	8
1459	Expression and Characterization of Human Vascular Endothelial Growth Factor Produced in SiHa Cells Transduced with Adenoviral Vector. Protein Journal, 2019, 38, 693-703.	0.7	3
1460	The contrary intracellular and extracellular functions of PEDF in HCC development. Cell Death and Disease, 2019, 10, 742.	2.7	11
1461	Reshaping Prostate Tumor Microenvironment To Suppress Metastasis <i>via</i> Cancer-Associated Fibroblast Inactivation with Peptide-Assembly-Based Nanosystem. ACS Nano, 2019, 13, 12357-12371.	7.3	107
1462	Risk of Venous Thromboembolic Events in Patients With Cancer Treated With Aflibercept: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. American Journal of Therapeutics, 2019, 26, e549-e552.	0.5	6

#	Article	IF	CITATIONS
1463	The antitumor efficacy of monomeric disintegrin obtustatin in S-180 sarcoma mouse model. Investigational New Drugs, 2019, 37, 1044-1051.	1.2	13
1464	Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation. Chemical Biology and Drug Design, 2019, 93, 934-948.	1.5	15
1465	The natural history of renal cell carcinoma with pulmonary metastases illuminated through mathematical modeling. Mathematical Biosciences, 2019, 309, 118-130.	0.9	3
1466	ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription. Oncogene, 2019, 38, 3812-3823.	2.6	23
1467	Hypoxic cancer–associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. Science Signaling, 2019, 12, .	1.6	83
1468	Glycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis. Cells, 2019, 8, 544.	1.8	64
1469	Revisiting hypoxia therapies for tuberculosis. Clinical Science, 2019, 133, 1271-1280.	1.8	20
1470	Non-contact co-culture with human vascular endothelial cells promotes epithelial-to-mesenchymal transition of cervical cancer SiHa cells by activating the NOTCH1/LOX/SNAIL pathway. Cellular and Molecular Biology Letters, 2019, 24, 39.	2.7	19
1471	Crosstalk between cancer and immune cells: Role of tumorâ€associated macrophages in the tumor microenvironment. Cancer Medicine, 2019, 8, 4709-4721.	1.3	211
1472	Diosmetin inhibits tumor development and block tumor angiogenesis in skin cancer. Biomedicine and Pharmacotherapy, 2019, 117, 109091.	2.5	43
1473	Long-term pulmonary exposure to multi-walled carbon nanotubes promotes breast cancer metastatic cascades. Nature Nanotechnology, 2019, 14, 719-727.	15.6	131
1474	VEGFR1+ Metastasis–Associated Macrophages Contribute to Metastatic Angiogenesis and Influence Colorectal Cancer Patient Outcome. Clinical Cancer Research, 2019, 25, 5674-5685.	3.2	34
1475	CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration. Life Sciences, 2019, 231, 116543.	2.0	50
1476	Breast Cancer Brain Metastasis Response to Radiation After Microbubble Oxygen Delivery in a Murine Model. Journal of Ultrasound in Medicine, 2019, 38, 3221-3228.	0.8	26
1477	Optoacoustic imaging of the breast: correlation with histopathology and histopathologic biomarkers. European Radiology, 2019, 29, 6728-6740.	2.3	17
1478	Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation. Journal of Experimental and Clinical Cancer Research, 2019, 38, 235.	3.5	84
1479	Correlations between quantitative parameters of contrast-enhanced ultrasound and vasculogenic mimicry in murine tumor model: a novel noninvasive technique for assessment?. Biological Procedures Online, 2019, 21, 11.	1.4	4
1480	Rare case of a giant duodenal ulcer penetrating the pancreas during antiangiogenic treatment. BMJ Case Reports, 2019, 12, e228612.	0.2	3

#	Article	IF	CITATIONS
1481	Deep Learning for Super-resolution Vascular Ultrasound Imaging., 2019, , .		43
1482	Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and Akt pathways. International Journal of Oncology, 2019, 54, 2069-2079.	1.4	27
1483	Precise closure of single blood vessels via multiphoton absorption–based photothermolysis. Science Advances, 2019, 5, eaan9388.	4.7	9
1484	Gambogic acid impairs tumor angiogenesis by targeting YAP/STAT3 signaling axis. Phytotherapy Research, 2019, 33, 1579-1591.	2.8	15
1485	Endothelial Cell-Derived TGF- \hat{l}^2 Promotes Epithelial-Mesenchymal Transition via CD133 in HBx-Infected Hepatoma Cells. Frontiers in Oncology, 2019, 9, 308.	1.3	24
1486	Herbacetin suppressed MMP9 mediated angiogenesis of malignant melanoma through blocking EGFR-ERK/AKT signaling pathway. Biochimie, 2019, 162, 198-207.	1.3	39
1487	Phloretin suppresses metastasis by targeting protease and inhibits cancer stemness and angiogenesis in human cervical cancer cells. Phytomedicine, 2019, 62, 152964.	2.3	34
1488	Tumor-induced neoangiogenesis and receptor tyrosine kinases – Mechanisms and strategies for acquired resistance. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 1217-1225.	1.1	9
1489	Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue. Cancers, 2019, 11, 469.	1.7	165
1490	Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression. International Journal of Oncology, 2019, 54, 1555-1566.	1.4	21
1491	miR-622 inhibits angiogenesis by suppressing the CXCR4–VEGFA axis in colorectal cancer. Gene, 2019, 699, 37-42.	1.0	39
1492	Nonâ€Anticoagulant Heparin Prodrug Loaded Biodegradable and Injectable Thermoresponsive Hydrogels for Enhanced Antiâ€Metastasis Therapy. Macromolecular Bioscience, 2019, 19, 1800409.	2.1	22
1493	Photoacoustic imaging with low-cost sources; A review. Photoacoustics, 2019, 14, 1-11.	4.4	90
1494	PMEPA1/TMEPAI knockout impairs tumour growth and lung metastasis in MDA-MB-231 cells without changing monolayer culture cell growth. Journal of Biochemistry, 2019, 165, 411-414.	0.9	13
1495	A Current Review of Spatial Fractionation: Back to the Future?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 177-187.	0.4	90
1496	Bombesin conjugated solid lipid nanoparticles for improved delivery of epigallocatechin gallate for breast cancer treatment. Chemistry and Physics of Lipids, 2019, 224, 104770.	1.5	50
1497	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Diagnostic Tool in the Assessment of Tumour Angiogenesis in Urinary Bladder Cancer. Canadian Association of Radiologists Journal, 2019, 70, 254-263.	1.1	12
1498	Efficacy of Combined VEGFR1-3, PDGFÎ \pm /β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	3.2	10

#	Article	IF	CITATIONS
1499	Tumorâ€derived exosomes: Implication in angiogenesis and antiangiogenesis cancer therapy. Journal of Cellular Physiology, 2019, 234, 16885-16903.	2.0	92
1500	The emerging roles of macrophages in cancer metastasis and response to chemotherapy. Journal of Leukocyte Biology, 2019, 106, 259-274.	1.5	80
1501	Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Current Oncology Reports, 2019, 21, 22.	1.8	26
1502	Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells. Molecules, 2019, 24, 623.	1.7	7
1503	Dynamic Modeling of the Angiogenic Switch and Its Inhibition by Bevacizumab. Complexity, 2019, 2019, 1-18.	0.9	8
1504	Correlation of vascular endothelial growth factor and vascular endothelial growth factor receptor-1 levels in serum and thyroid nodules with histopathological and radiological variables. Journal of Laboratory Physicians, 2019, 11, 051-057.	0.4	7
1505	7-epi-Clusianone, a Multi-Targeting Natural Product with Potential Chemotherapeutic, Immune-Modulating, and Anti-Angiogenic Properties. Molecules, 2019, 24, 4415.	1.7	19
1506	GV1001 inhibits cell viability and induces apoptosis in castration-resistant prostate cancer cells through the AKT/NF-κB/VEGF pathway. Journal of Cancer, 2019, 10, 6269-6277.	1.2	10
1507	Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options. Frontiers in Endocrinology, 2019, 10, 782.	1.5	31
1508	Preparation of truncated tissue factor antineuropilin-1 monoclonal antibody conjugate and identification of its selective thrombosis in tumor blood vessels. Anti-Cancer Drugs, 2019, 30, 441-450.	0.7	3
1509	The metabolic engine of endothelial cells. Nature Metabolism, 2019, 1, 937-946.	5.1	70
1510	Extracellular Vesicles From Pathological Microenvironment Induce Endothelial Cell Transformation and Abnormal Angiogenesis via Modulation of TRPV4 Channels. Frontiers in Cell and Developmental Biology, 2019, 7, 344.	1.8	12
1511	Adipose tissue, angiogenesis and angio-MIR under physiological and pathological conditions. European Journal of Cell Biology, 2019, 98, 53-64.	1.6	14
1512	Melanoma tumour vasculature heterogeneity: from mice models to human. Journal of Cancer Research and Clinical Oncology, 2019, 145, 589-597.	1.2	9
1513	Nanotheranostics-Based Imaging for Cancer Treatment Monitoring. Bioanalysis, 2019, , 395-428.	0.1	4
1514	Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism: Clinical and Experimental, 2019, 92, 121-135.	1.5	821
1515	Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer. Oncogene, 2019, 38, 2092-2107.	2.6	66
1516	Aspirin suppresses tumor cell-induced angiogenesis and their incongruity. Journal of Cell Communication and Signaling, 2019, 13, 491-502.	1.8	15

#	Article	IF	CITATIONS
1517	TAZ Expression on Endothelial Cells Is Closely Related to Blood Vascular Density and VEGFR2 Expression in Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2019, 78, 172-180.	0.9	11
1518	Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer, 2019, 19, 47-57.	1.1	8
1519	Optimizing immune cell therapies with artificial intelligence. Journal of Theoretical Biology, 2019, 461, 34-40.	0.8	12
1520	Tricyclic antidepressant amitriptyline inhibits autophagic flux and prevents tube formation in vascular endothelial cells. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 370-384.	1.2	9
1521	Deletion of <i>Atm</i> in Tumor but not Endothelial Cells Improves Radiation Response in a Primary Mouse Model of Lung Adenocarcinoma. Cancer Research, 2019, 79, 773-782.	0.4	28
1522	Thymidine kinase-1/CD31 double immunostaining for identifying activated tumor vessels. Biotechnic and Histochemistry, 2019, 94, 60-64.	0.7	9
1523	<scp>LOXL</scp> 2 promotes vasculogenic mimicry and tumour aggressiveness in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2019, 23, 1363-1374.	1.6	38
1524	Caspase-11 regulates the tumour suppressor function of STAT1 in a murine model of colitis-associated carcinogenesis. Oncogene, 2019, 38, 2658-2674.	2.6	21
1525	The element-free Galerkin method based on moving least squares and moving Kriging approximations for solving two-dimensional tumor-induced angiogenesis model. Engineering With Computers, 2020, 36, 1517-1537.	3.5	23
1526	Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer. Free Radical Biology and Medicine, 2020, 157, 154-175.	1.3	47
1527	Combined microwave ablation and antiangiogenic therapy to increase local efficacy. Minimally Invasive Therapy and Allied Technologies, 2020, 29, 107-113.	0.6	2
1528	Risk of hand-foot skin reaction associated with vascular endothelial growth factor–tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients. Journal of the American Academy of Dermatology, 2020, 83, 788-796.	0.6	21
1529	A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstÂline induction chemotherapy in extensiveÂ-stage small cell lung cancer. Investigational New Drugs, 2020, 38, 148-159.	1.2	22
1530	Maternally expressed gene 3 in metabolic programming. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2020, 1863, 194396.	0.9	9
1531	Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Seminars in Cancer Biology, 2020, 65, 13-27.	4.3	170
1532	Antitumor Activity of Propolis: Recent Advances in Cellular Perspectives, Animal Models and Possible Applications. Food Reviews International, 2020, 36, 429-455.	4.3	18
1533	Intravoxel incoherent motion diffusion-weighted imaging assessment of microvascular characteristics in the murine embryonal rhabdomyosarcoma model. Acta Radiologica, 2020, 61, 260-266.	0.5	9
1534	Variation in energy metabolism arising from the effect of the tumor microenvironment on cell biological behaviors of bladder cancer cells and endothelial cells. BioFactors, 2020, 46, 64-75.	2.6	8

#	Article	IF	CITATIONS
1535	Effects of an isatin derivative on tumor cell migration and angiogenesis. RSC Advances, 2020, 10, 1191-1197.	1.7	8
1536	DKC1 enhances angiogenesis by promoting HIF- $1\hat{l}\pm$ transcription and facilitates metastasis in colorectal cancer. British Journal of Cancer, 2020, 122, 668-679.	2.9	57
1537	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro-Oncology, 2020, 22, 705-717.	0.6	47
1538	Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomedicine and Pharmacotherapy, 2020, 121, 109604.	2.5	330
1539	Dynamic contrast-enhanced magnetic resonance imaging for monitoring the anti-angiogenesis efficacy in a C6 glioma rat model. Acta Radiologica, 2020, 61, 973-982.	0.5	3
1540	Contraction for large perturbations of traveling waves in a hyperbolic–parabolic system arising from a chemotaxis model. Mathematical Models and Methods in Applied Sciences, 2020, 30, 387-437.	1.7	19
1541	Novel engineered TRAILâ€based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance. International Journal of Cancer, 2020, 147, 1117-1130.	2.3	7
1542	Involvement of Long Non-Coding RNAs (IncRNAs) in Tumor Angiogenesis. Non-coding RNA, 2020, 6, 42.	1.3	30
1543	In vivo assessment of aminopeptidase N (APN/CD13) specificity of different 68Ga-labelled NGR derivatives using PET/MRI imaging. International Journal of Pharmaceutics, 2020, 589, 119881.	2.6	11
1544	Circ_0072088 Promotes Proliferation, Migration, and Invasion of Esophageal Squamous Cell Cancer by Absorbing miR-377. Journal of Oncology, 2020, 2020, 1-14.	0.6	19
1545	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Medicine, 2020, 12, 86.	3.6	63
1546	Myricitrin inhibits vascular endothelial growth factor-induced angiogenesis of human umbilical vein endothelial cells and mice. Biomedicine and Pharmacotherapy, 2020, 130, 110726.	2.5	6
1547	Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy. Journal of Cerebral Blood Flow and Metabolism, 2020, 41, 0271678X2096185.	2.4	10
1548	Novel VEGFRâ€2 inhibitors with an <i>N</i> â€acylhydrazone scaffold. Archiv Der Pharmazie, 2020, 353, e2000130.	2.1	3
1549	Hydrostatic pressure promotes endothelial tube formation through aquaporin 1 and Ras-ERK signaling. Communications Biology, 2020, 3, 152.	2.0	24
1550	S1PR1 and VEGFR2 $\hat{a}\in$ a synergy that promotes tumor angiogenesis?. Molecular and Cellular Oncology, 2020, 7, 1746131.	0.3	3
1551	The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas. Cancer Genomics and Proteomics, 2020, 17, 715-727.	1.0	10
1553	Angiogenesis-Related Functions of Wnt Signaling in Colorectal Carcinogenesis. Cancers, 2020, 12, 3601.	1.7	32

#	Article	IF	CITATIONS
1554	Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas. Frontiers in Medicine, 2020, 7, 584250.	1.2	16
1555	<i>In Vivo</i> Imaging of Hypoxia and Neoangiogenesis in Experimental Syngeneic Hepatocellular Carcinoma Tumor Model Using Positron Emission Tomography. BioMed Research International, 2020, 2020, 1-10.	0.9	5
1556	Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors. ACS Omega, 2020, 5, 18872-18886.	1.6	20
1557	Clinicopathological Evaluation of the Potential Anatomic Pathways of Systemic Metastasis from Primary Breast Cancer Suggests an Orderly Spread Through the Regional Lymph Nodes. Annals of Surgical Oncology, 2020, 27, 4810-4818.	0.7	14
1558	Novel mechanistic targets of forkhead box Q1 transcription factor in human breast cancer cells. Molecular Carcinogenesis, 2020, 59, 1116-1128.	1.3	7
1559	Biological Properties, Bioactive Constituents, and Pharmacokinetics of Some Capsicum spp. and Capsaicinoids. International Journal of Molecular Sciences, 2020, 21, 5179.	1.8	110
1560	Chinese herbal medicines for prevention and treatment of colorectal cancer: From molecular mechanisms to potential clinical applications. Journal of Integrative Medicine, 2020, 18, 369-384.	1.4	30
1561	Anticancer Effect of Capsaicin and Its Analogues. , 0, , .		5
1562	A Prognostic Model Based on Six Metabolism-Related Genes in Colorectal Cancer. BioMed Research International, 2020, 2020, 1-16.	0.9	15
1563	Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. Cells, 2020, 9, 1896.	1.8	73
1564	Metabolomics revealed the influence of breast cancer on lymphatic endothelial cell metabolism, metabolic crosstalk, and lymphangiogenic signaling in co-culture. Scientific Reports, 2020, 10, 21244.	1.6	10
1565	Hypoxic exosomes orchestrate tumorigenesis: molecular mechanisms and therapeutic implications. Journal of Translational Medicine, 2020, 18, 474.	1.8	53
1566	Mathematical Model Predicts Effective Strategies to Inhibit VEGF-eNOS Signaling. Journal of Clinical Medicine, 2020, 9, 1255.	1.0	14
1567	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1214.	1.7	26
1568	<p>Exosomal IncRNA RAMP2-AS1 Derived from Chondrosarcoma Cells Promotes Angiogenesis Through miR-2355-5p/VEGFR2 Axis</p> . OncoTargets and Therapy, 2020, Volume 13, 3291-3301.	1.0	50
1569	Oridonin exhibits anti-angiogenic activity in human umbilical vein endothelial cells by inhibiting VEGF-induced VEGFR-2 signaling pathway. Pathology Research and Practice, 2020, 216, 153031.	1.0	10
1570	Long non-coding RNA HNF1A-AS1 upregulates OTX1 to enhance angiogenesis in colon cancer via the binding of transcription factor PBX3. Experimental Cell Research, 2020, 393, 112025.	1.2	20
1571	Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 3753.	1.8	7

#	Article	IF	CITATIONS
1572	Chinese Dragon's Blood EtOAc Extract Inhibits Liver Cancer Growth Through Downregulation of Smad3. Frontiers in Pharmacology, 2020, 11, 669.	1.6	12
1573	Hypoxia-induced epithelial to mesenchymal transition in cancer. Cancer Letters, 2020, 487, 10-20.	3.2	86
1574	Angiogenic biomaterials to promote therapeutic regeneration and investigate disease progression. Biomaterials, 2020, 255, 120207.	5.7	34
1575	Tumor cells derived-exosomes as angiogenenic agents: possible therapeutic implications. Journal of Translational Medicine, 2020, 18, 249.	1.8	82
1576	A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. Lung Cancer, 2020, 146, 12-18.	0.9	21
1577	Proapoptotic and Antiangiogenic Activities of <i>Arctium Lappa</i> L. on Breast Cancer Cell Lines. Scientifica, 2020, 2020, 1-14.	0.6	11
1578	How are MCPIP1 and cytokines mutually regulated in cancer-related immunity?. Protein and Cell, 2020, 11, 881-893.	4.8	8
1579	Indoor dust extracellular vesicles promote cancer lung metastasis by inducing tumour necrosis factorâ€Î±. Journal of Extracellular Vesicles, 2020, 9, 1766821.	5 . 5	9
1580	Multimodal Decorations of Mesoporous Silica Nanoparticles for Improved Cancer Therapy. Pharmaceutics, 2020, 12, 527.	2.0	40
1581	Molecular insights and novel approaches for targeting tumor metastasis. International Journal of Pharmaceutics, 2020, 585, 119556.	2.6	55
1582	Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivo. Scientific Reports, 2020, 10, 5133.	1.6	19
1583	Angiogenesis in obesity. Biomedicine and Pharmacotherapy, 2020, 126, 110103.	2.5	38
1584	Discovery of small molecules targeting GRP78 for antiangiogenic and anticancer therapy. European Journal of Medicinal Chemistry, 2020, 193, 112228.	2.6	10
1585	Endosialin (TEM1) as a Diagnostic, Progression, and Prognostic Serum Marker for Patients With Colorectal Cancerâ€"A Preliminary Study. Cancer Control, 2020, 27, 107327482090335.	0.7	6
1586	Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value. International Journal of Molecular Sciences, 2020, 21, 1671.	1.8	34
1587	Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis. Experimental Cell Research, 2020, 390, 111934.	1.2	10
1588	Discovery of tetrandrine derivatives as tumor migration, invasion and angiogenesis inhibitors. Bioorganic Chemistry, 2020, 101, 104025.	2.0	7
1589	Aneuploid Circulating Tumor-Derived Endothelial Cell (CTEC): A Novel Versatile Player in Tumor Neovascularization and Cancer Metastasis. Cells, 2020, 9, 1539.	1.8	42

#	Article	IF	CITATIONS
1590	The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nature Cancer, 2020, 1, 672-680.	5.7	132
1591	Human DNA tumor viruses and oncogenesis. , 2020, , 131-151.		2
1592	Automated volumetric radiomic analysis of breast cancer vascularization improves survival prediction in primary breast cancer. Scientific Reports, 2020, 10, 3664.	1.6	16
1593	Mushroom: A New Resource for Anti-Angiogenic Therapeutics. Food Reviews International, 2022, 38, 88-109.	4.3	12
1594	Recapitulating and Deciphering Tumor Microenvironment by Using 3D Printed Plastic Brick–Like Microfluidic Cell Patterning. Advanced Healthcare Materials, 2020, 9, e1901713.	3.9	7
1595	Role of Apelin/APJ axis in cancer development and progression. Advances in Medical Sciences, 2020, 65, 202-213.	0.9	45
1596	Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity. Pharmaceutical Development and Technology, 2020, 25, 640-648.	1.1	9
1597	Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo. Journal of Ethnopharmacology, 2020, 256, 112664.	2.0	8
1598	HemoSYS: A Toolkit for Image-based Systems Biology of Tumor Hemodynamics. Scientific Reports, 2020, 10, 2372.	1.6	5
1599	Medicinal inorganic chemistry: New perspectives and targets for the periodic table. Advances in Inorganic Chemistry, 2020, 75, 57-86.	0.4	7
1600	Fucoidan from Laminaria japonica exerts antitumor effects on angiogenesis and micrometastasis in triple-negative breast cancer cells. International Journal of Biological Macromolecules, 2020, 149, 600-608.	3.6	58
1601	Evaluation of Hypoxia-Inducible Factor-1 Alpha (HIF- $1\hat{l}\pm$) in Equine Sarcoid: An Immunohistochemical and Biochemical Study. Pathogens, 2020, 9, 58.	1.2	5
1602	Synergism of 4HPR and SAHA increases anti-tumor actions in glioblastoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2020, 25, 217-232.	2.2	8
1603	The Effect of Laser and Ultrasound Synchronization in Photo-Mediated Ultrasound Therapy. IEEE Transactions on Biomedical Engineering, 2020, 67, 3363-3370.	2.5	16
1604	Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. Angiogenesis, 2020, 23, 279-298.	3.7	30
1605	Physics in nanomedicine: Phenomena governing the <i>in vivo</i> performance of nanoparticles. Applied Physics Reviews, 2020, 7, .	5.5	36
1606	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Experimental Hematology and Oncology, 2020, 9, 7.	2.0	11
1607	<p>Matrix Stiffness and Colorectal Cancer</p> . OncoTargets and Therapy, 2020, Volume 13, 2747-2755.	1.0	42

#	Article	IF	CITATIONS
1608	Hypoxia-Driven Immune Escape in the Tumor Microenvironment. Cells, 2020, 9, 992.	1.8	156
1609	Green Chemistry Synthesis of Silver Nanoparticles and Their Potential Anticancer Effects. Cancers, 2020, 12, 855.	1.7	166
1610	Parallels of Resistance between Angiogenesis and Lymphangiogenesis Inhibition in Cancer Therapy. Cells, 2020, 9, 762.	1.8	25
1611	Allogenic mouse cell vaccine inhibits lung cancer progression by inhibiting angiogenesis. Human Vaccines and Immunotherapeutics, 2021, 17, 35-50.	1.4	2
1612	The oncogenic potential of NANOG: An important cancer induction mediator. Journal of Cellular Physiology, 2021, 236, 2443-2458.	2.0	35
1613	Preoperative normalized iodine concentration derived from spectral CT is correlated with early recurrence of hepatocellular carcinoma after curative resection. European Radiology, 2021, 31, 1872-1882.	2.3	6
1614	Gastric carcinogenesis: a comprehensive review of the angiogenic pathways. Clinical Journal of Gastroenterology, 2021, 14, 14-25.	0.4	18
1615	FOXM1D potentiates PKM2â€mediated tumor glycolysis and angiogenesis. Molecular Oncology, 2021, 15, 1466-1485.	2.1	30
1616	Current status of targeted microbubbles in diagnostic molecular imaging of pancreatic cancer. Bioengineering and Translational Medicine, 2021, 6, e10183.	3.9	15
1617	The vascular landscape of human cancer. Journal of Clinical Investigation, 2021, 131, .	3.9	26
1618	Long Noncoding RNAs and Human Cancer. , 2021, , 338-347.		0
1619	The tumorigenic and therapeutic functions of exosomes in colorectal cancer: Opportunity and challenges. Cell Biochemistry and Function, 2021, 39, 468-477.	1.4	12
1620	Bioactive lipids in cancers. , 2021, , 31-45.		0
1621	Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. Journal of Cancer, 2021, 12, 2694-2701.	1.2	8
1622	Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer. Oncology Research, 2021, 28, 929-944.	0.6	9
1623	Microvessel density as a prognostic indicator of prostate cancer: A systematic review and meta-analysis. Open Medicine (Poland), 2021, 16, 882-891.	0.6	0
1624	Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy–refractory extensive-stage SCLC: a real-world retrospective study. International Journal of Clinical Oncology, 2021, 26, 670-683.	1.0	4
1625	Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies. Translational Oncology, 2021, 14, 100984.	1.7	9

#	Article	IF	CITATIONS
1626	Microfluidic System to Analyze the Effects of Interleukin 6 on Lymphatic Breast Cancer Metastasis. Frontiers in Bioengineering and Biotechnology, 2020, 8, 611802.	2.0	17
1627	Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature. Frontiers in Oncology, 2020, 10, 612802.	1.3	31
1628	Beneficial Actions of Orostachys japonica and Its Compounds against Tumors via MAPK Signaling Pathways. Nutrients, 2021, 13, 555.	1.7	5
1629	Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 662318.	1.3	7
1630	Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer. Thoracic Cancer, 2021, 12, 1347-1357.	0.8	21
1631	LRH1 Acts as an Oncogenic Driver in Human Osteosarcoma and Pan-Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 643522.	1.8	5
1632	Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse. Seminars in Cancer Biology, 2022, 78, 17-22.	4.3	19
1633	Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment. Gut, 2022, 71, 509-520.	6.1	41
1634	Correlation between endothelial CXCR7 expression and clinicopathological factors in oral squamous cell carcinoma. Pathology International, 2021, 71, 383-391.	0.6	6
1635	Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy. Cancers, 2021, 13, 1100.	1.7	35
1636	Mechanistic Targets and Nutritionally Relevant Intervention Strategies to Break Obesity–Breast Cancer Links. Frontiers in Endocrinology, 2021, 12, 632284.	1.5	7
1637	Pien Tze Huang (PZH) as a Multifunction Medicinal Agent in Traditional Chinese Medicine (TCM): a review on cellular, molecular and physiological mechanisms. Cancer Cell International, 2021, 21, 146.	1.8	17
1638	Vascular endothelial growth factor (VEGF-2578 CÂ>ÂA) gene polymorphism as a genetic biomarker for breast cancer: A case control study. Gene Reports, 2021, 22, 101007.	0.4	0
1639	Assessment of Tumor Response in Mice with Ovarian Peritoneal Carcinomatosis using Doppler Ultrasound of the Superior Mesenteric Artery and Celiac Trunk. Ultrasound in Medicine and Biology, 2021, 47, 759-768.	0.7	1
1640	Recent Advances in Anti-Metastatic Approaches of Herbal Medicines in 5 Major Cancers: From Traditional Medicine to Modern Drug Discovery. Antioxidants, 2021, 10, 527.	2.2	16
1641	Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma. Oncotarget, 2021, 12, 638-648.	0.8	2
1642	MiR-205 Promotes the Viability, Migration, and Tube Formation of Cervical Cancer Cells In Vitro by Targeting GATA3. Cancer Biotherapy and Radiopharmaceuticals, 2021, , .	0.7	1
1643	Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer. BMC Cancer, 2021, 21, 255.	1.1	28

#	Article	IF	CITATIONS
1644	Microvascular Structural Alterations in Cancer Patients Treated With Antiangiogenic Drugs. Frontiers in Cardiovascular Medicine, 2021, 8, 651594.	1.1	4
1645	Nanovaccineâ€Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy. Small, 2021, 17, e2006000.	5.2	53
1646	A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab. Journal of Cancer Research and Clinical Oncology, 2022, 148, 487-496.	1.2	8
1647	MicroRNAs and angiogenesis: a new era for the management of colorectal cancer. Cancer Cell International, 2021, 21, 221.	1.8	33
1648	Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 4584.	1.8	29
1649	IARS2 regulates proliferation, migration, and angiogenesis of human umbilical vein endothelial cells. Revista Da Associação Médica Brasileira, 2021, 67, 555-560.	0.3	0
1650	Chewing Behavior Attenuates the Tumor Progression-Enhancing Effects of Psychological Stress in a Breast Cancer Model Mouse. Brain Sciences, 2021, 11, 479.	1,1	3
1651	Clinical Value of Detecting Tumor Endothelial Marker 8 (ANTXR1) as a Biomarker in the Diagnosis and Prognosis of Colorectal Cancer. Cancer Management and Research, 2021, Volume 13, 3113-3122.	0.9	13
1652	The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer. Nutrients, 2021, 13, 1212.	1.7	27
1653	Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin/FAK Signaling Axis. Pharmaceuticals, 2021, 14, 521.	1.7	9
1654	Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis. Nature Communications, 2021, 12, 2773.	5.8	35
1655	Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients. Materials, 2021, 14, 2440.	1.3	14
1656	Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Frontiers in Oncology, 2021, 11, 637823.	1.3	8
1657	Accelerated and Improved Vascular Maturity after Transplantation of Testicular Tissue in Hydrogels Supplemented with VEGF- and PDGF-Loaded Nanoparticles. International Journal of Molecular Sciences, 2021, 22, 5779.	1.8	17
1658	Exosomal microRNAs in hepatocellular carcinoma. Cancer Cell International, 2021, 21, 254.	1.8	5
1659	Thebaine Derivatives as a New Regulator of Tumor Angiogenesis. Polycyclic Aromatic Compounds, 2022, 42, 4501-4519.	1.4	0
1660	Sweet Cherries as Anti-Cancer Agents: From Bioactive Compounds to Function. Molecules, 2021, 26, 2941.	1.7	12
1661	Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. British Journal of Cancer, 2021, 125, 528-533.	2.9	12

#	Article	IF	Citations
1662	Study on novel PtNP–sorafenib and its interaction with VEGFR2. Journal of Biochemistry, 2021, 170, 411-417.	0.9	2
1663	PARP1 Is Targeted by miR-519a-3p and Promotes the Migration, Invasion, and Tube Formation of Ovarian Cancer Cells. Cancer Biotherapy and Radiopharmaceuticals, 2021, , .	0.7	3
1664	Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status. International Journal of Molecular Sciences, 2021, 22, 5544.	1.8	17
1665	Angiopoietin inhibitors: A review on targeting tumor angiogenesis. European Journal of Pharmacology, 2021, 899, 174021.	1.7	64
1666	Thyroid Hormone Enhances Angiogenesis and the Warburg Effect in Squamous Cell Carcinomas. Cancers, 2021, 13, 2743.	1.7	11
1667	Comprehensive Analysis of Differentially Expressed Long Noncoding RNA-mRNA in the Adenoma-Carcinoma Sequence of DNA Mismatch Repair Proficient Colon Cancer. Journal of Oncology, 2021, 2021, 1-15.	0.6	0
1668	Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?. Frontiers in Oncology, 2021, 11, 683570.	1.3	19
1669	Cancer-secreted exosomal miR-21-5p induces angiogenesis and vascular permeability by targeting KRIT1. Cell Death and Disease, 2021, 12, 576.	2.7	71
1670	A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy. Matrix Biology, 2021, 100-101, 118-149.	1.5	18
1671	Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and transcriptional activities of ECs in CC. Molecular Therapy - Nucleic Acids, 2021, 24, 682-694.	2.3	51
1672	Numerical evaluation reveals the effect of branching morphology on vessel transport properties during angiogenesis. PLoS Computational Biology, 2021, 17, e1008398.	1.5	6
1673	The Inflammatory Profile of the Tumor Microenvironment, Orchestrated by Cyclooxygenase-2, Promotes Epithelial-Mesenchymal Transition. Frontiers in Oncology, 2021, 11, 686792.	1.3	30
1674	Tumor vasculature-targeting nanomedicines. Acta Biomaterialia, 2021, 134, 1-12.	4.1	18
1675	Bispecific antibodies: A guide to model informed drug discovery and development. Heliyon, 2021, 7, e07649.	1.4	3
1676	The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling. Nature Communications, 2021, 12, 4308.	5.8	45
1677	Pharmacognosy and In-vivo anticancer potential of an indigenous marine macroalga, Ulvafasciata Delile from Visakhapatnam coast, India. Advances in Traditional Medicine, 2021, 21, 433-442.	1.0	4
1678	Evaluation of Integrin $\hat{l}\pm v\hat{l}^23$ Expression in Murine Xenograft Models: [68Ga]Ga-DOTA-C(RGDfK) PET Study with Immunohistochemical Confirmation. Diagnostics, 2021, 11, 1295.	1.3	2
1679	Structure-activity relationships of natural quinone vegfrecine analogs with potent activity against VEGFR-1 and -2 tyrosine kinases. Journal of Antibiotics, 2021, 74, 734-742.	1.0	1

#	Article	IF	CITATIONS
1680	DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma. Experimental Cell Research, 2021, 405, 112656.	1.2	14
1681	Micro-positron emission tomography imaging of angiogenesis based on 18F-RGD for assessing liver metastasis of colorectal cancer. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 345-351.	0.6	0
1682	FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells. BMC Biology, 2021, 19, 173.	1.7	53
1683	Discovery of potent thieno[2,3-d]pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations. Bioorganic Chemistry, 2021, 113, 105019.	2.0	29
1684	Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma. Aging, 2021, 13, 20793-20807.	1.4	2
1685	Crotoxin Inhibits Endothelial Cell Functions in Two- and Three-dimensional Tumor Microenvironment. Frontiers in Pharmacology, 2021, 12, 713332.	1.6	6
1686	Single-cell transcriptional profiling reveals the heterogeneity in embryonal rhabdomyosarcoma. Medicine (United States), 2021, 100, e26775.	0.4	1
1687	Anoikis resistant gastric cancer cells promote angiogenesis and peritoneal metastasis through C/EBPÎ ² -mediated PDGFB autocrine and paracrine signaling. Oncogene, 2021, 40, 5764-5779.	2.6	41
1688	Potential Roles of Iridoid Glycosides and Their Underlying Mechanisms against Diverse Cancer Growth and Metastasis: Do They Have an Inhibitory Effect on Cancer Progression?. Nutrients, 2021, 13, 2974.	1.7	25
1689	A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient. Medicine (United States), 2021, 100, e26801.	0.4	0
1690	Fumagillin Attenuates Spinal Angiogenesis, Neuroinflammation, and Pain in Neuropathic Rats after Chronic Constriction Injury. Biomedicines, 2021, 9, 1187.	1.4	10
1691	SC1 limits tube formation, branching, migration, expansion and induce apoptosis of endothelial cells. Vascular Pharmacology, 2021, 141, 106903.	1.0	2
1692	Dependence receptors: new targets for cancer therapy. EMBO Molecular Medicine, 2021, 13, e14495.	3.3	17
1693	Progranulin: A proangiogenic factor in visceral adipose tissue in tumoral and non‑tumoral visceral pathology. Experimental and Therapeutic Medicine, 2021, 22, 1337.	0.8	1
1694	Blood Vessels and Peripheral Nerves as Key Players in Cancer Progression and Therapy Resistance. Cancers, 2021, 13, 4471.	1.7	10
1695	Identification of soluble tissueâ€'derived biomarkers from human thyroid tissue explants maintained on a microfluidic device. Oncology Letters, 2021, 22, 780.	0.8	6
1696	Recapitulating the Cancer Microenvironment Using Bioprinting Technology for Precision Medicine. Micromachines, 2021, 12, 1122.	1.4	7
1697	Heterogeneous microenvironmental stiffness regulates pro-metastatic functions of breast cancer cells. Acta Biomaterialia, 2021, 131, 326-340.	4.1	56

#	ARTICLE	IF	CITATIONS
1698	Roles of Non-coding RNAs and Angiogenesis in Glioblastoma. Frontiers in Cell and Developmental Biology, 2021, 9, 716462.	1.8	38
1699	Non-coding RNAs in Regulating Tumor Angiogenesis. Frontiers in Cell and Developmental Biology, 2021, 9, 751578.	1.8	6
1700	Structure features, selenylation modification, and improved anti-tumor activity of a polysaccharide from Eriobotrya japonica. Carbohydrate Polymers, 2021, 273, 118496.	5.1	44
1701	A Correlative Study Between IVIM-DWI Parameters and the Expression Levels of Ang-2 and TKT in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 594366.	1.3	10
1702	Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma. Blood Cancer Journal, 2021, 11, 2.	2.8	29
1703	Flow-adapted vascular systems: mimicking the vascular network to predict clinical response to radiation. , 2021, , 129-146.		0
1705	Cancer Metastasis. , 2006, , 244-253.		1
1706	Vascular Leukocytes: a Population with Angiogenic and Immunossuppressive Properties Highly Represented in Ovarian Cancer., 2007, 590, 185-193.		20
1707	The Clinical Utility of Bevacizumab. , 2008, , 375-385.		2
1708	The Search for Genes Which Influence Prostate Cancer Metastasis: A Moving Target?. Cancer Metastasis - Biology and Treatment, 2008, , 21-61.	0.1	2
1709	Cellular and Molecular Mechanisms of Retinal Angiogenesis. , 2008, , 1-39.		2
1710	Adoptive immunotherapy for human cancers: Flagmen signal first "open road―then "roadblocks.―A narrative synopsis. , 2008, , 1-23.		1
1711	Memory T-Cell Responses and Survival in Human Cancer: Remember to Stay Alive. Advances in Experimental Medicine and Biology, 2010, 684, 166-177.	0.8	9
1712	The Basic Biology of Metastasis. Cancer Treatment and Research, 2004, 118, 1-21.	0.2	22
1713	Applications of Small-Animal Molecular Imaging in Drug Development., 2014,, 715-752.		1
1714	Strategies for siRNA Navigation to Desired Cells. Methods in Molecular Biology, 2015, 1218, 201-216.	0.4	4
1715	Tumor Angiogenesis: Methods to Analyze Tumor Vasculature and Vessel Normalization in Mouse Models of Cancer. Methods in Molecular Biology, 2015, 1267, 349-365.	0.4	9
1717	Fluorescent Imaging of Tumors. , 2007, , 281-302.		5

#	ARTICLE	IF	Citations
1718	Positron Emission Tomography Imaging of Blood Flow and Hypoxia in Tumors., 2007,, 47-71.		5
1719	In vitro Footprinting of Promoter Regions Within Supercoiled Plasmid DNA. Methods in Molecular Biology, 2010, 613, 223-233.	0.4	11
1720	Targeted Delivery of Antisense Oligonucleotides and siRNAs into Mammalian Cells. Methods in Molecular Biology, 2009, 487, 1-22.	0.4	7
1721	Eph Receptors and Ephrins: Role in Vascular Development and Tumor Angiogenesis. , 2008, , 121-134.		1
1722	Noninvasive Tracer Techniques to Characterize Angiogenesis. Handbook of Experimental Pharmacology, 2008, , 323-339.	0.9	7
1723	Molecular Signaling Pathways in Nasopharyngeal Cancer. Medical Radiology, 2010, , 27-40.	0.0	2
1725	Models of inflammatory processes in cancer. , 2006, , 83-102.		3
1726	Antibody-Based Therapies for Solid Tumors. , 2011, , 245-256.		1
1728	Retinal Metastases. , 2006, , 641-650.		2
1730	Combination curcumin and (â^')-epigallocatechin-3-gallate inhibits colorectal carcinoma microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway. Oncogenesis, 2017, 6, e384-e384.	2.1	81
1731	Vascular toxicity associated with anti-angiogenic drugs. Clinical Science, 2020, 134, 2503-2520.	1.8	33
1732	The Effects of Stiffness, Fluid Viscosity, and Geometry of Microenvironment in Homeostasis, Aging, and Diseases: A Brief Review. Journal of Biomechanical Engineering, 2020, 142, .	0.6	24
1733	Computer-aided detection of basal cell carcinoma through blood content analysis in dermoscopy images. , 2018, , .		3
1734	Impaired Angiogenesis in the Aged. Science of Aging Knowledge Environment: SAGE KE, 2004, 2004, 7pe-7.	0.9	72
1735	Connecting (T)issues: How Research in Fascia Biology Can Impact Integrative Oncology. Cancer Research, 2016, 76, 6159-6162.	0.4	34
1736	Ultrasonic Analysis of Peptide- and Antibody-Targeted Microbubble Contrast Agents for Molecular Imaging of α _v β ₃ -Expressing Cells. Molecular Imaging, 2004, 3, 125-134.	0.7	115
1737	Metastasis regulation by PPARD expression in cancer cells. JCI Insight, 2017, 2, e91419.	2.3	58
1738	Double target for tumor mass destruction. Journal of Clinical Investigation, 2003, 111, 1277-1280.	3.9	42

#	Article	IF	CITATIONS
1739	Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. Journal of Clinical Investigation, 2004, 114, 898-907.	3.9	141
1740	Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo. Journal of Clinical Investigation, 2006, 116, 1596-1605.	3.9	78
1741	Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. Journal of Clinical Investigation, 2008, 118, 1380-1389.	3.9	130
1742	Targeting prion-like protein doppel selectively suppresses tumor angiogenesis. Journal of Clinical Investigation, 2016, 126, 1251-1266.	3.9	24
1743	Carbohydrate-binding protein CLEC14A regulates VEGFR-2– and VEGFR-3–dependent signals during angiogenesis and lymphangiogenesis. Journal of Clinical Investigation, 2016, 127, 457-471.	3.9	27
1744	Î"Np63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. Journal of Clinical Investigation, 2018, 128, 5095-5109.	3.9	102
1745	Photoacoustic imaging of cells in a three-dimensional microenvironment. Journal of Biomedical Science, 2020, 27, 3.	2.6	26
1746	Oridonin Suppresses Human Gastric Cancer Growth <i>in Vitro</i> and <i>in Vivo</i> <i>via</i> Inhibition of VEGF, Integrin Î ² 3, and PCNA. Biological and Pharmaceutical Bulletin, 2020, 43, 1035-1045.	0.6	12
1747	PERK Regulates the Proliferation and Development of Insulin-Secreting Beta-Cell Tumors in the Endocrine Pancreas of Mice. PLoS ONE, 2009, 4, e8008.	1.1	50
1748	A Novel Xenograft Model in Zebrafish for High-Resolution Investigating Dynamics of Neovascularization in Tumors. PLoS ONE, 2011, 6, e21768.	1.1	101
1749	In Vivo Evolution of Tumor-Derived Endothelial Cells. PLoS ONE, 2012, 7, e37138.	1.1	28
1750	Aminoimidazole Carboxamide Ribonucleotide (AICAR) Inhibits the Growth of Retinoblastoma In Vivo by Decreasing Angiogenesis and Inducing Apoptosis. PLoS ONE, 2013, 8, e52852.	1.1	48
1751	Bmi-1 Promotes Glioma Angiogenesis by Activating NF-κB Signaling. PLoS ONE, 2013, 8, e55527.	1.1	45
1752	Dynamic Quantitative Intravital Imaging of Glioblastoma Progression Reveals a Lack of Correlation between Tumor Growth and Blood Vessel Density. PLoS ONE, 2013, 8, e72655.	1.1	23
1753	Tryptanthrin Inhibits Angiogenesis by Targeting the VEGFR2-Mediated ERK1/2 Signalling Pathway. PLoS ONE, 2013, 8, e82294.	1.1	49
1754	HIF-1 Alpha Overexpression Correlates with Poor Overall Survival and Disease-Free Survival in Gastric Cancer Patients Post-Gastrectomy. PLoS ONE, 2014, 9, e90678.	1.1	44
1755	Associations of VEGF-C Genetic Polymorphisms with Urothelial Cell Carcinoma Susceptibility Differ between Smokers and Non-Smokers in Taiwan. PLoS ONE, 2014, 9, e91147.	1.1	15
1756	Oridonin Inhibits Tumor Growth and Metastasis through Anti-Angiogenesis by Blocking the Notch Signaling. PLoS ONE, 2014, 9, e113830.	1.1	49

#	Article	IF	CITATIONS
1757	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS ONE, 2015, 10, e0134731.	1.1	38
1759	COL18A1 is highly expressed during human adipocyte differentiation and the SNP c.1136C > T in its "frizzled" motif is associated with obesity in diabetes type 2 patients. Anais Da Academia Brasileira De Ciencias, 2008, 80, 167-177.	0.3	21
1760	Anti-cancer activities of Brassica juncea leaves in vitro. EXCLI Journal, 2016, 15, 699-710.	0.5	17
1761	Exosomes derived from cancerous and non-cancerous cells regulate the anti-tumor response in the tumor microenvironment. Genes and Cancer, 2018, 9, 87-100.	0.6	76
1762	Functional intratumoral lymphatics in patient-derived xenograft models of squamous cell carcinoma of the uterine cervix: implications for lymph node metastasis. Oncotarget, 2016, 7, 56986-56997.	0.8	20
1763	Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue. Oncotarget, 2013, 4, 1472-1483.	0.8	17
1764	Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound. Oncotarget, 2017, 8, 7801-7813.	0.8	22
1765	MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status. Oncotarget, 2017, 8, 8484-8498.	0.8	44
1766	Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget, 2017, 8, 42076-42086.	0.8	35
1767	Opioids: Modulators of angiogenesis in wound healing and cancer. Oncotarget, 2017, 8, 25783-25796.	0.8	46
1768	CD147 overexpression may serve as a promising diagnostic and prognostic marker for gastric cancer: evidence from original research and literature. Oncotarget, 2017, 8, 30888-30899.	0.8	6
1769	RNAi-mediated inhibition of Lgr5 leads to decreased angiogenesis in gastric cancer. Oncotarget, 2017, 8, 31581-31591.	0.8	10
1770	Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget, 2017, 8, 64471-64480.	0.8	57
1771	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget, 2017, 8, 43555-43570.	0.8	10
1772	Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget, 2017, 8, 51492-51506.	0.8	38
1773	Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis. Oncotarget, 2014, 5, 3066-3075.	0.8	33
1774	Metformin inhibits esophageal squamous cell carcinoma-induced angiogenesis by suppressing JAK/STAT3 signaling pathway. Oncotarget, 2017, 8, 74673-74687.	0.8	30
1775	A cassaine diterpene alkaloid, $3\hat{i}^2$ -acetyl-nor-erythrophlamide, suppresses VEGF-induced angiogenesis and tumor growth via inhibiting eNOS activation. Oncotarget, 2017, 8, 92346-92358.	0.8	12

#	Article	IF	CITATIONS
1776	A novel action mechanism for MPTOG013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression. Oncotarget, 2014, 5, 9838-9850.	0.8	11
1777	Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis. Oncotarget, 2018, 9, 28445-28455.	0.8	7
1778	Targeted therapies for advanced non-small cell lung cancer. Oncotarget, 2018, 9, 37589-37607.	0.8	52
1779	Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget, 2019, 10, 5523-5533.	0.8	11
1780	Dual effects of collagenase-3 on melanoma: metastasis promotion and disruption of vasculogenic mimicry. Oncotarget, 2015, 6, 8890-8899.	0.8	21
1781	The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma. Oncotarget, 2015, 6, 29111-29128.	0.8	34
1782	The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG. Oncotarget, 2016, 7, 27243-27254.	0.8	11
1783	<i>In vivo</i> screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget, 2016, 7, 33237-33245.	0.8	44
1784	Repositioning the Old Fungicide Ciclopirox for New Medical Uses. Current Pharmaceutical Design, 2016, 22, 4443-4450.	0.9	41
1785	Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma. Mini-Reviews in Medicinal Chemistry, 2016, 16, 430-454.	1.1	42
1786	The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress. Current Molecular Medicine, 2016, 16, 533-544.	0.6	527
1787	Zebrafish-Based Screening Models for the Identification of Anti-Metastatic Drugs. Molecules, 2020, 25, 2407.	1.7	17
1788	Lymphangiogenic and angiogenic microvessel density in human primary sporadic colorectal carcinoma. World Journal of Gastroenterology, 2008, 14, 101.	1.4	34
1789	Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. World Journal of Gastroenterology, 2008, 14, 2461.	1.4	30
1790	Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. World Journal of Gastroenterology, 2008, 14, 7021.	1.4	11
1791	Inhibitory effect of antisense vascular endothelial growth factor 165 eukaryotic expression vector on proliferation of hepatocellular carcinoma cells. World Journal of Gastroenterology, 2004, 10, 535.	1.4	8
1792	Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model. World Journal of Gastroenterology, 2004, 10, 1191.	1.4	20
1793	Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World Journal of Gastroenterology, 2005, 11, 216.	1.4	19

#	Article	IF	CITATIONS
1794	Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis <i>in vivo</i> . World Journal of Gastroenterology, 2005, 11, 340.	1.4	27
1795	Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World Journal of Gastroenterology, 2004, 11 , 447.	1.4	25
1796	Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World Journal of Gastroenterology, 2006, 12, 2884.	1.4	51
1797	Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World Journal of Gastroenterology, 2006, 12, 3970.	1.4	42
1798	Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World Journal of Gastroenterology, 2006, 12, 4241.	1.4	72
1799	Hepatic tight junctions: From viral entry to cancer metastasis. World Journal of Gastroenterology, 2010, 16, 289.	1.4	31
1800	Molecule action mechanisms of NM-3 on human gastric cancer SGC-7901 cellsin vivoorin vitro. World Journal of Gastroenterology, 2003, 9, 2366.	1.4	8
1801	Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: An experimental study. World Journal of Gastroenterology, 2003, 9, 2445.	1.4	51
1802	Tumor-Associated Macrophage (TAM) and Angiogenesis in Human Colon Carcinoma. Open Access Macedonian Journal of Medical Sciences, 2015, 3, 209-214.	0.1	39
1803	Roles of fatty acid metabolism in tumourigenesis: Beyond providing nutrition (Review). Molecular Medicine Reports, 2018, 18, 5307-5316.	1.1	21
1804	Fisetin inhibits vascular endothelial growth factor‑induced angiogenesis in retinoblastoma cells. Oncology Letters, 2020, 20, 1239-1244.	0.8	15
1805	A novel definition of microvessel density in renal cell carcinoma: Angiogenesis plus vasculogenic mimicry. Oncology Letters, 2020, 20, 1-1.	0.8	7
1806	Modeling chemotaxis from \$L^2\$-closure moments in kinetic theory of active particles. Discrete and Continuous Dynamical Systems - Series B, 2013, 18, 847-863.	0.5	10
1807	Insights into Hypoxia: Non-invasive Assessment through Imaging Modalities and Its Application in Breast Cancer, Journal of Breast Cancer, 2019, 22, 155.	0.8	24
1808	Antimelanoma potential of eruca sativa seed oil and its bioactive principles. Indian Journal of Pharmaceutical Sciences, 2015, 77, 208.	1.0	8
1809	Metastatic tumors to the jaws and oral cavity. Journal of Oral and Maxillofacial Pathology, 2013, 17, 71.	0.3	101
1810	To evaluate immunoreactivity of cyclooxygenase-2 in cases of endometrial carcinoma and correlate it with expression of p53 and vascular endothelial growth factor. Journal of Cancer Research and Therapeutics, 2018, 14, 1366-1372.	0.3	9
1811	Zerumbone Suppresses Angiogenesis in HepG2 Cells through Inhibition of Matrix Metalloproteinase-9, Vascular Endothelial Growth Factor, and Vascular Endothelial Growth Factor Receptor Expressions. Pharmacognosy Magazine, 2018, 13, S731-S736.	0.3	10

#	Article	IF	CITATIONS
1812	Tumor Angiogenesis: Initiation and Targeting - Therapeutic Targeting of an FGF-Binding Protein, an Angiogenic Switch Molecule, and Indicator of Early Stages of Gastrointestinal Adenocarcinomas Cancer Research and Treatment, 2006, 38, 189.	1.3	19
1813	Novel therapeutic agents in the treatment of metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 99.	0.8	22
1814	Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. World Journal of Hepatology, 2015, 7, 1866.	0.8	24
1815	Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World Journal of Radiology, $2011, 3, 1$.	0.5	17
1816	Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer. BMB Reports, 2020, 53, 291-298.	1.1	38
1817	Genipin Inhibits Hypoxia-Induced Accumulation of HIF-1 $\hat{l}\pm$ and VEGF Expressions in Human Cervical Carcinoma Cells. Kosin Medical Journal, 2019, 34, 106.	0.1	3
1818	Characteristics of Invasive Breast Ductal Carcinoma, NOS, Diagnosed in a Tertiary Institution in the East Coast of Malaysia with a Focus on Tumor Angiogenesis. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4445-4452.	0.5	5
1819	Preclinical murine tumor models: A structural and functional perspective. ELife, 2020, 9, .	2.8	81
1820	Malignant Transformation in Glioma Steered by an Angiogenic Switch: Defining a Role for Bone Marrow-Derived Cells. Cureus, 2016, 8, e471.	0.2	10
1821	Construction and Evaluation of Robust Interpretation Models for Breast Cancer Metastasis Prediction. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 1344-1353.	1.9	4
1822	Endostar (<scp>rhâ€endostatin</scp>) improves efficacy of concurrent chemoradiotherapy for locally advanced <scp>nonâ€small</scp> cell lung cancer: A systematic review and <scp>metaâ€analysis</scp> . Thoracic Cancer, 2021, 12, 3208-3215.	0.8	9
1823	Regenerative Medicine and Angiogenesis; Focused on Cardiovascular Disease. Advanced Pharmaceutical Bulletin, 2021, , .	0.6	2
1824	Effect of Peptide Receptor Radionuclide Therapy in Combination with Temozolomide against Tumor Angiogenesis in a Glioblastoma Model. Cancers, 2021, 13, 5029.	1.7	1
1825	The Recruitment of Bone Marrow-Derived Cells to Sites of Pancreatic ^ ^beta;-cell Injury and the Restoration of Endocrine Function. The Showa University Journal of Medical Sciences, 2005, 17, 95-103.	0.1	0
1826	Applications to Gynecological Cancers. Medical Radiology, 2006, , 303-315.	0.0	0
1827	Pathogenesis of Vascular Diseases. , 2006, , 49-73.		0
1828	Particular Treatment Procedures. , 2008, , 293-326.		0
1829	Molecular Basis of Radiation Therapy. , 2008, , 593-604.		2

#	Article	IF	CITATIONS
1830	Genes and metastasis: experimental advances and clinical implications. , 2008, , 33-58.		0
1831	Noninvasive Determination of Angiogenesis. , 2008, , 211-223.		0
1832	Express \tilde{A} £o dos marcadores de angiog \tilde{A} ªnese fator VIII e CD-34 no adenocarcinoma g \tilde{A} ¡strico. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2008, 21, 25-32.	0.5	0
1833	Cancer Stem Cells and Oral Cavity Cancer Metastasis. , 2009, , 323-335.		0
1834	Breast Cancer Stem Cells. , 2009, , 167-192.		0
1835	Concepts and Mechanisms of Breast Cancer Metastasis. , 2009, , 549-564.		1
1836	What Are the Key Targeted Delivery Technologies of siRNA Now?. Methods in Molecular Biology, 2010, 629, 91-105.	0.4	2
1837	Extravasale Proteolyse: Funktion und Interaktion der Faktoren des fibrinolytischen Systems. , 2010, , 289-299.		0
1838	Dormancy of Disseminated Tumor Cells: Reciprocal Crosstalk with the Microenvironment. , 2010, , 229-254.		0
1839	Hemofiltrocytodiagnosis as a morphological method of malignant neoplasm detection. Bulletin of Siberian Medicine, 2010, 9, 170-172.	0.1	0
1840	Alcohol, Altered Protein Homeostasis, and Cancer., 2011, , 155-173.		0
1841	Principles of Classification and Diagnosis in Anatomic Pathology and the Inevitability of Problem Cases., 2011,, 95-120.		1
1842	Microparticle Dissemination of Biological Activities: Implications for Cancer Biology., 2012, , 211-243.		0
1843	GRB2 Signaling as a Molecular Target for Cancer. , 2012, , 1-22.		1
1844	P-Type Lectins: Cation-Independent Mannose-6-Phosphate Reeptors. , 2012, , 81-108.		0
1845	Intracellular Signaling Network as a Prime Chemotherapy Target of Green Tea Catechin, $(\hat{a} \in \text{``})$ -Epigallocatechin-3-gallate. , 2012, , 339-376.		1
1846	Molecular and Cellular Biology. , 2012, , 43-52.		0
1848	Molecular Immunotherapeutics and Vaccines for Renal Cell Carcinoma and Its Vasculature. , 2013, , 371-383.		0

#	Article	IF	CITATIONS
1849	Liver Metastases. , 2013, , 141-161.		0
1850	Hepatocellular Carcinoma Microvessel Density Quantitation with Image Analysis: Correlation with Prognosis. Journal of Analytical Oncology, 0, , .	0.1	O
1851	Angiogenic Switch., 2013,, 28-29.		0
1852	A Review of the Expression of Genes Involved in Sex Steroid Hormone Metabolism in Prostate Tissue: A Need for Epigenetic Information. Journal of Analytical Oncology, 0, , .	0.1	0
1853	Metronomic Chemotherapy in Pediatric Malignancies. , 2014, , 157-172.		0
1854	Advances in the Medical Management of Ovarian Cancer. , 2014, , 77-107.		O
1855	Tumor-Associated Macrophages. , 2014, , 425-443.		1
1857	Pharmacology and Clinical Development of New Molecularly Targeted Agents. Current Clinical Pathology, 2015, , 9-29.	0.0	0
1858	Peptide fluorescent probe by computer design for tumor diagnosis., 2015,,.		0
1859	Role of Mechanosensitive TRP Channels in Abnormal Vasculature of Tumors. , 2016, , 255-273.		0
1860	Neutrophil Activating Protein-2 (NAP-2)., 2016,, 213-220.		0
1861	Cancer Vaccines. , 2016, , 295-333.		0
1862	Significance of Cryobiopsy for Morphological and Immunohistochemical Analyses of Xenografted Human Lung Cancer Tissues and Functional Blood Vessels. , 2016, , 263-268.		0
1863	Host–Tumor Interactions in Brain Cancer Metastasis Leading to Drug Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 237-253.	0.1	0
1864	Antitumor and Antiangiogenic Effects of the Crude Oil of Nigella sativa L. in Tumor Tissues in BALB/c Mice. Zahedan Journal of Researches in Medical Sciences, 2016, In Press, .	0.1	0
1865	The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety. Oncotarget, 2016, 7, 68194-68205.	0.8	5
1866	The Immunosuppressed Patient., 2017,, 267-303.		0
1867	Role of Cancer Stem Cells in Oral Cancer. , 2017, , 487-529.		0

#	Article	IF	CITATIONS
1868	Role of Hypoxia-Inducible Factor (HIF) in Liver Cancer., 2017,, 465-478.		0
1870	Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. Oncotarget, 2017, 8, 93179-93185.	0.8	2
1871	Tumor Blood Vessels as Targets for Cancer Therapy. , 2019, , 41-56.		0
1872	Real-time photoacoustic sensing for photo-mediated ultrasound therapy. Optics Letters, 2019, 44, 4063.	1.7	9
1873	Contrast-Enhanced T1-Weighted Digital Subtraction for Increased Lesion Conspicuity and Quantifying Treatment Response in Malignant Gliomas., 2020,, 49-60.		0
1874	The Biology of Colorectal Liver Metastases. , 2020, , 7-20.		0
1875	Expression levels of circulatory mir-185-5p, vascular endothelial growth factor, and platelet-derived growth factor target genes in endometriosis. International Journal of Reproductive BioMedicine, 2020, 18, 347-358.	0.5	8
1876	Tumor budding index and microvessel density assessment in patients with endometrial cancer: A pilot study. Oncology Letters, 2020, 20, 2701-2710.	0.8	7
1877	Magnetic Resonance Imaging for Quantification of Brain Vascular Perfusion. Neuromethods, 2021, , 289-321.	0.2	0
1878	RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy. Journal of Controlled Release, 2021, 340, 221-242.	4.8	62
1879	Identification of modules based on integrative analysis for drug prediction in colorectal cancer. Gene Reports, 2021, 25, 101403.	0.4	0
1880	Cavitation induced shear and circumferential stresses on blood vessel walls during photo-mediated ultrasound therapy. AIP Advances, 2020, 10, 125227.	0.6	9
1881	Early Recurrence of Breast Cancer after the Primary Treatment: Analysis of Clinicopathological and Radiological Predictive Factors. Journal of the Korean Society of Radiology, 2020, 81, 395.	0.1	0
1882	Prediction of outcomes of hysteroresectoscopic endometrial destruction in patients with endometrial hyperplasia without atypia. Russian Journal of Human Reproduction, 2020, 26, 18.	0.1	1
1884	7‑Difluoromethyl‑5,4'‑dimethoxygenistein exerts anti‑angiogenic effects on acute promyelocytic leukemi HL‑60 cells by inhibiting the TLR4/NF‴κB signaling pathway. Molecular Medicine Reports, 2020, 21, 2251-2259.	a 1.1	2
1886	Angiogenesis and Lung Cancer. , 2005, , 13-30.		0
1888	Modeling Cancer as A Complex Adaptive System: Genetic Instability and Evolution., 2006,, 537-556.		0
1889	Heat Shock Proteins in the Progression of Cancer. , 2007, , 422-450.		0

#	Article	IF	CITATIONS
1890	Molecular Basis for Vascular Endothelial Growth Factor Expression in Tumor. , 2008, , 79-124.		0
1891	Double target for tumor mass destruction. Journal of Clinical Investigation, 2003, 111, 1277-1280.	3.9	17
1892	Control of Neovascularization and Cell Survival in the Eye by PEDF., 2006,, 215-231.		0
1893	Problems, Side Effects, and Disappointments in Clinical Cancer Gene Therapy., 2007, , 351-385.		1
1894	Clinical Angioblast Therapy. , 2007, , 245-258.		0
1895	Vandetanib (ZACTIMAâ,,¢; ZD6474): Preclinical and Clinical Development. , 2008, , 741-759.		O
1896	Thalidomide in Multiple Myeloma. , 2008, , 779-794.		0
1898	Molekulare Toxikologie., 2006,, 153-259.		0
1900	Why cancer and inflammation?. Yale Journal of Biology and Medicine, 2006, 79, 123-30.	0.2	267
1901	Antiangiogenic agents in first-line and second-line therapy for advanced colorectal cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, S22-8.	0.8	0
1902	Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma. Biologics: Targets and Therapy, 2007, 1, 321-4.	3.0	3
1903	Salivary protein factors are elevated in breast cancer patients. Molecular Medicine Reports, 2008, 1, 375-8.	1.1	48
1904	Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). Anticancer Research, 2009, 29, 1987-92.	0.5	6
1906	Heat shock protein 10 (Hsp10) in immune-related diseases: one coin, two sides. International Journal of Biochemistry and Molecular Biology, 2011, 2, 47-57.	0.1	38
1907	(68)Ga-Labeling of RGD peptides and biodistribution. International Journal of Clinical and Experimental Medicine, 2012, 5, 165-72.	1.3	18
1908	Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings. Translational Gastrointestinal Cancer, 2012, 1, 138-150.	3.0	22
1909	Systemic therapy for metastatic renal cell carcinoma: a review and update. Reviews in Urology, 2012, 14, 65-78.	0.9	18
1910	Relevant Networks involving the p53 Signalling Pathway in Renal Cell Carcinoma. International Journal of Biomedical Science, 2011, 7, 273-82.	0.5	O

#	Article	IF	Citations
1911	Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genomics and Proteomics, 2008, 5, 263-73.	1.0	12
1914	Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis. Iranian Journal of Medical Sciences, 2015, 40, 2-12.	0.3	13
1915	Does Chemotherapy Change Expression of VEGF A&C and MVD in Acute Myeloid Leukemia?. International Journal of Hematology-Oncology and Stem Cell Research, 2014, 8, 24-9.	0.3	7
1916	Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. International Journal of Clinical and Experimental Pathology, 2015, 8, 252-9.	0.5	5
1918	Inhibitory effect of midkine-binding peptide on tumor proliferation and migration. International Journal of Clinical and Experimental Pathology, 2015, 8, 5387-94.	0.5	4
1920	Morphological study and comprehensive cellular constituents of milky spots in the human omentum. International Journal of Clinical and Experimental Pathology, 2015, 8, 12877-84.	0.5	11
1921	Increased matrix metalloproteinase-2 expression and reduced tissue factor pathway inhibitor-2 expression correlate with angiogenesis and early postoperative recurrence of pancreatic carcinoma. American Journal of Translational Research (discontinued), 2015, 7, 2412-22.	0.0	13
1923	Revisiting the hallmarks of cancer. American Journal of Cancer Research, 2017, 7, 1016-1036.	1.4	292
1925	Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma. Canadian Veterinary Journal, 2017, 58, 1059-1064.	0.0	14
1926	LncRNA SUMO1P3 drives colon cancer growth, metastasis and angiogenesis. American Journal of Translational Research (discontinued), 2017, 9, 5461-5472.	0.0	31
1929	Long noncoding RNAs, emerging and versatile regulators of tumor-induced angiogenesis. American Journal of Cancer Research, 2019, 9, 1367-1381.	1.4	35
1930	TRIM11 promotes tumor angiogenesis via activation of STAT3/VEGFA signaling in lung adenocarcinoma. American Journal of Cancer Research, 2019, 9, 2019-2027.	1.4	9
1931	Assessment of diagnostic accuracy of perfusion MR imaging in primary and metastatic solitary malignant brain tumors. American Journal of Neuroradiology, 2005, 26, 2187-99.	1.2	88
1932	Associations between angiogenic factors and intravoxel incoherent motion-derived parameters in diffusion-weighted magnetic resonance imaging of breast cancer. Medicine (United States), 2021, 100, e27495.	0.4	0
1933	Inhibition of Src/STAT3 signaling-mediated angiogenesis is involved in the anti-melanoma effects of dioscin. Pharmacological Research, 2022, 175, 105983.	3.1	18
1934	Associations between angiogenic factors and intravoxel incoherent motion-derived parameters in diffusion-weighted magnetic resonance imaging of breast cancer. Medicine (United States), 2021, 100, e27495.	0.4	4
1935	Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. Clinical and Experimental Metastasis, 2022, 39, 159-179.	1.7	30
1936	Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal Transduction and Targeted Therapy, 2021, 6, 383.	7.1	143

#	Article	IF	Citations
1937	MicroRNA-140-3p represses the proliferation, migration, invasion and angiogenesis of lung adenocarcinoma cells via targeting TYMS (thymidylate synthetase). Bioengineered, 2021, 12, 11959-11977.	1.4	10
1938	The Significance of Perfusion-Weighted Magnetic Resonance Imaging in Evaluating the Pathological Biological Activity of Cerebral Alveolar Echinococcosis. Journal of Computer Assisted Tomography, 2021, Publish Ahead of Print, 131-139.	0.5	2
1939	FAK Regulates VEGFR2 Expression and Promotes Angiogenesis in Triple-Negative Breast Cancer. Biomedicines, 2021, 9, 1789.	1.4	22
1940	Suprabasin: Role in human cancers and other diseases. Molecular Biology Reports, 2022, 49, 1453-1461.	1.0	7
1941	Integrated Transcriptome Analysis Reveals the Impact of Photodynamic Therapy on Cerebrovascular Endothelial Cells. Frontiers in Oncology, 2021, 11, 731414.	1.3	3
1942	Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer. Frontiers in Oncology, 2021, 11, 772305.	1.3	18
1943	A Synopsis of Signaling Crosstalk of Pericytes and Endothelial Cells in Salivary Gland. Dentistry Journal, 2021, 9, 144.	0.9	6
1944	Tolerance and Pharmacokinetics of Recombinant Human Endostatin Administered as Single-Dose or Multiple-Dose Infusions in Patients With Advanced Solid Tumors: A Phase I Clinical Trial. Technology in Cancer Research and Treatment, 2021, 20, 153303382110644.	0.8	2
1945	Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2. Pharmaceutics, 2022, 14, 97.	2.0	10
1946	Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer. Frontiers in Pharmacology, 2021, 12, 824531.	1.6	20
1947	Hyperglycemia-induced oxidative stress promotes tumor metastasis by upregulating vWF expression in endothelial cells through the transcription factor GATA1. Oncogene, 2022, 41, 1634-1646.	2.6	9
1948	Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study. Radiotherapy and Oncology, 2022, 168, 95-103.	0.3	3
1949	LncRNAs and the Angiogenic Switch in Cancer: Clinical Significance and Therapeutic Opportunities. Genes, 2022, 13, 152.	1.0	14
1950	Apatinib as maintenance therapy following standard firstâ€line chemotherapy in extensive disease small cell lung cancer: A phase <scp>ll> singleâ€arm trial. Thoracic Cancer, 2022, 13, 557-562.</scp>	0.8	5
1951	PFKFB4 promotes angiogenesis via IL-6/STAT5A/P-STAT5 signaling in breast cancer. Journal of Cancer, 2022, 13, 212-224.	1.2	6
1952	Target c-Myc to treat pancreatic cancer. Cancer Biology and Therapy, 2022, 23, 34-50.	1.5	47
1953	Signaling Mechanisms and Pharmacological Modulators Governing Diverse Aquaporin Functions in Human Health and Disease. International Journal of Molecular Sciences, 2022, 23, 1388.	1.8	50
1954	Vasculogenic mimicry: A dynamic event of malignancy. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130084.	1.1	2

#	Article	IF	Citations
1955	Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect. Advanced Drug Delivery Reviews, 2022, 183, 114138.	6.6	33
1956	Endoglin Modulates TGF \hat{l}^2 R2 Induced VEGF and Proinflammatory Cytokine Axis Mediated Angiogenesis in Prolonged DEHP-Exposed Breast Cancer Cells. Biomedicines, 2022, 10, 417.	1.4	6
1957	Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor. Journal of the American Chemical Society, 2022, 144, 270-281.	6.6	39
1959	Methionine aminopeptidaseâ€'2 is a pivotal regulator of vasculogenic mimicry. Oncology Reports, 2021, 47, .	1.2	6
1960	Human study on cancer diagnostic probe (CDP) for realâ€time excising of breast positive cavity side margins based on tracing hypoxia glycolysis; checking diagnostic accuracy in nonâ€neoadjuvant cases. Cancer Medicine, 2022, 11, 1630-1645.	1.3	3
1961	Evaluation of the metabolism of PEP06, an endostatin-RGDRGD 30-amino-acid polypeptide and a promising novel drug for targeting tumor cells. Journal of Pharmaceutical Analysis, 2022, 12, 766-773.	2.4	1
1962	Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?. Journal of Nutrition, 2022, 152, 1381-1403.	1.3	14
1963	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. Frontiers in Oncology, 2022, 12, 849993.	1.3	1
1964	Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis. Neuro-Oncology, 2022, 24, 1509-1523.	0.6	12
1965	Tumor endothelial cellâ€induced CD8 ⁺ Tâ€cell exhaustion via GPNMB in hepatocellular carcinoma. Cancer Science, 2022, 113, 1625-1638.	1.7	18
1966	Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials. Melanoma Research, 2022, 32, 159-165.	0.6	1
1967	Modulating Tumour Hypoxia in Prostate Cancer Through Exercise: The Impact of Redox Signalling on Radiosensitivity. Sports Medicine - Open, 2022, 8, 48.	1.3	3
1968	Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis. Frontiers in Global Women S Health, 2022, 3, 856316.	1.1	19
1969	Nanotechnology-based multifunctional vaccines for cancer immunotherapy. Chemical Engineering Journal, 2022, 437, 135505.	6.6	13
1970	Osteosarcoma and Metastasis. Frontiers in Oncology, 2021, 11, 780264.	1.3	70
1971	Bispecific Antibodies for IFN-Î ² Delivery to ErbB2+ Tumors. Biomolecules, 2021, 11, 1915.	1.8	4
1972	NOX4: a potential therapeutic target for pancreatic cancer and its mechanism. Journal of Translational Medicine, 2021, 19, 515.	1.8	15
1973	LINCO1615 activates ZEB2 through competitively binding with miR-3653-3p to promote the carcinogenesis of colon cancer cells. Cell Cycle, 2022, 21, 228-246.	1.3	7

#	Article	IF	CITATIONS
1974	Interleukin-1 receptor antagonist inhibits metastatic potential by down-regulating CXCL12/CXCR4 signaling axis in colorectal cancer. Cell Communication and Signaling, 2021, 19, 122.	2.7	8
1975	Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review. Frontiers in Oncology, 2021, 11, 773905.	1.3	15
1976	A Fokker–Planck feedback control framework for optimal personalized therapies in colon cancer-induced angiogenesis. Journal of Mathematical Biology, 2022, 84, 23.	0.8	4
1977	The emerging role of photoacoustic imaging in clinical oncology. Nature Reviews Clinical Oncology, 2022, 19, 365-384.	12.5	115
1979	Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma. BMC Medical Genomics, 2022, 15, 81.	0.7	1
1980	A 3D finite element model to study the cavitation induced stresses on blood–vessel wall during the ultrasound-only phase of photo-mediated ultrasound therapy. AIP Advances, 2022, 12, 045020.	0.6	7
1981	Targeting Angiogenic Factors for the Treatment of Medulloblastoma. Current Treatment Options in Oncology, 2022, 23, 864-886.	1.3	2
1982	The antitumour activity of C21 steroidal glycosides and their derivatives of Baishouwu: A review. Journal of Ethnopharmacology, 2022, 293, 115300.	2.0	5
1988	SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Cell Research, 2022, 32, 638-658.	5.7	19
1989	Perspectives of SLIT/ROBO signaling in placental angiogenesis. Histology and Histopathology, 2010, 25, 1181-90.	0.5	24
1990	Significance of Vasohibin 1 in Cancer Patients: A Systematic Review and Meta analysis. Journal of Cancer Research and Therapeutics, 2022, .	0.3	0
1991	Upregulation of PNCK Promotes Metastasis and Angiogenesis via Activating NF-κB/VEGF Pathway in Nasopharyngeal Carcinoma. Journal of Oncology, 2022, 2022, 1-14.	0.6	4
1992	<i>EFNA1</i> in gastrointestinal cancer: Expression, regulation and clinical significance. World Journal of Gastrointestinal Oncology, 2022, 14, 973-988.	0.8	2
1993	DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma. Cell Death and Disease, 2022, 13, 456.	2.7	5
1994	Role of the Pro-Inflammatory Tumor Microenvironment in Extracellular Vesicle-Mediated Transfer of Therapy Resistance. Frontiers in Oncology, 2022, 12, .	1.3	7
1995	Production and optimization of a vasostatin-30 and vasoinhibin fusion protein that inhibits tumor angiogenesis and dissemination of breast cancer cells in a zebrafish model. Process Biochemistry, 2022, 119, 1-12.	1.8	1
1996	Dormancy in Breast Cancer, the Role of Autophagy, IncRNAs, miRNAs and Exosomes. International Journal of Molecular Sciences, 2022, 23, 5271.	1.8	12
1997	Peroxisome Proliferator-Activated Receptor \hat{l}^3 Ligands Improve the Antitumor Efficacy of Thrombospondin Peptide ABT510. Molecular Cancer Research, 2004, 2, 541-550.	1.5	55

#	Article	IF	CITATIONS
1998	Acquired αSMA Expression in Pericytes Coincides with Aberrant Vascular Structure and Function in Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 2448.	1.7	8
1999	Molecular Mechanism of Curcumin and Its Analogs as Multifunctional Compounds against Pancreatic Cancer. Nutrition and Cancer, 2022, 74, 3096-3108.	0.9	3
2000	Function and therapeutic development of exosomes for cancer therapy. Archives of Pharmacal Research, 2022, 45, 295-308.	2.7	15
2001	New perspectives on the origins and heterogeneity of mast cells. Nature Reviews Immunology, 2023, 23, 55-68.	10.6	41
2002	The protein biosynthesis inhibitor vioprolide A evokes anti-angiogenic and pro-survival actions by targeting NOP14 and decreasing VEGF receptor 2- and TAZ-signaling. Biomedicine and Pharmacotherapy, 2022, 152, 113174.	2.5	3
2003	Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study. Frontiers in Oncology, 0, 12, .	1.3	2
2004	Dimeric Gâ€quadruplex <scp>DNA</scp> Structure in the Proximal Promoter of <scp>VEGFR</scp> â€2 Reveals A New Drug Target to Inhibit Tumor Angiogenesis. Chinese Journal of Chemistry, 0, , .	2.6	2
2005	A Novel Overall Survival Prediction Signature Based on Comprehensive Research in Prostate Cancer Bone Metastases. Frontiers in Medicine, 0, 9, .	1.2	2
2006	Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation. Drug Delivery and Translational Research, 2023, 13, 105-134.	3.0	1
2007	Inhibition of Platelet-Derived Growth Factor Receptor Signaling Restricts the Growth of Human Breast Cancer in the Bone of Nude Mice. Clinical Cancer Research, 2005, 11, 306-314.	3.2	69
2009	Transcriptomic and Functional Evidence for Differential Effects of MCF-7 Breast Cancer Cell-Secretome on Vascular and Lymphatic Endothelial Cell Growth. International Journal of Molecular Sciences, 2022, 23, 7192.	1.8	5
2010	Atractylenolide III Attenuates Angiogenesis in Gastric Precancerous Lesions Through the Downregulation of Delta-Like Ligand 4. Frontiers in Pharmacology, 0, 13, .	1.6	6
2011	Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2. Molecules, 2022, 27, 4079.	1.7	10
2012	Graphene Quantum Dots – Hydrothermal Green Synthesis, Material Characterization and Prospects for Cervical Cancer Diagnosis Applications: A Review. ChemistrySelect, 2022, 7, .	0.7	5
2013	Probiotic Supplementation Suppresses Tumor Growth in an Experimental Colorectal Cancer Liver Metastasis Model. International Journal of Molecular Sciences, 2022, 23, 7674.	1.8	4
2014	FOXS1 Promotes Tumor Progression by Upregulating CXCL8 in Colorectal Cancer. Frontiers in Oncology, 0, 12, .	1.3	4
2015	$HIF-1\hat{1}\pm Inhibition$ Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR). Cancers, 2022, 14, 3273.	1.7	17
2016	Safety of endoscopy in patients undergoing treatments with antiangiogenic agents: A 5-year retrospective review. World Journal of Gastrointestinal Endoscopy, 2022, 14, 416-423.	0.4	O

#	Article	IF	CITATIONS
2017	Vascularization of Melanoma by Mobilization and Remodeling of Preexisting Latent Vessels to Patency. Cancer Research, 2005, 65, 913-918.	0.4	15
2018	The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient. , 2023, , 448-458.		0
2019	Changes in kinetic heterogeneity of breast cancer via computer-aided diagnosis on MRI predict the pathological response to neoadjuvant systemic therapy. European Radiology, 2023, 33, 440-449.	2.3	2
2020	Multispectral Image Analysis of Vasculatures in Sublingual Mucosa. , 2022, , .		3
2021	Modeling ATP-mediated endothelial cell elongation on line patterns. Biomechanics and Modeling in Mechanobiology, $0, \dots$	1.4	0
2022	Identify an innovative ferroptosisâ€related gene in hepatocellular carcinoma. Journal of Clinical Laboratory Analysis, 0, , .	0.9	3
2023	Replacement in angiogenesis research: Studying mechanisms of blood vessel development by animal-free in vitro, in vivo and in silico approaches. Frontiers in Physiology, $0,13,.$	1.3	5
2024	A comprehensive analysis of avian lymphoid leukosis-like lymphoma transcriptomes including identification of LncRNAs and the expression profiles. PLoS ONE, 2022, 17, e0272557.	1.1	0
2025	Different predictive values of microvessel density for biochemical recurrence among different <scp>PCa</scp> populations: A systematic review and metaâ€analysis. Cancer Medicine, 0, , .	1.3	1
2026	Mechanisms of white matter injury. , 2023, , 139-155.		0
2027	Overview of Breast DWI: Diagnosis of Suspicious Lesions Using DWI in Combination With Standard MRI., 2023,, 40-48.		0
2028	Metabolic Vestiges of Conflict Mediation in Modern Biology. , 2022, , 97-117.		0
2029	NF-kB Signaling in the Macroenvironment of Cancer Cachexia., 2022, , 119-135.		0
2031	Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188798.	3.3	2
2032	Inhaled Indomethacin-Loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC). Pharmaceutical Research, 2022, 39, 2801-2815.	1.7	7
2033	Prognostic value of angiogenic markers of endometrial cancer (literature review). Siberian Journal of Oncology, 2022, 21, 137-146.	0.1	0
2034	A phase <scp>II</scp> study of antiangiogenic therapy (Apatinib) plus chemotherapy as secondâ€ine treatment in advanced small cell lung cancer. Cancer Medicine, 2023, 12, 2979-2989.	1.3	2
2035	Targeting the (pro)renin receptor in cancers: from signaling to pathophysiological effects. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2595-2605.	1.2	1

#	Article	IF	CITATIONS
2036	The analysis of hormonal status and vascular and cell proliferation in endometrioid endometrial adenocarcinomas. Romanian Journal of Morphology and Embryology, 2022, 63, 113-120.	0.4	0
2037	Metformin and simvastatin synergistically suppress endothelin 1â€induced hypoxia and angiogenesis in multiple cancer types. Cancer Science, 2023, 114, 640-653.	1.7	8
2038	Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 10119.	1.8	2
2040	Adding recombinant AAVs to the cancer therapeutics mix. Molecular Therapy - Oncolytics, 2022, 27, 73-88.	2.0	2
2041	Vascular adhesion protein-1 (VAP-1) in vascular inflammatory diseases. Vasa - European Journal of Vascular Medicine, 2022, 51, 341-350.	0.6	5
2042	The anticancer effects of curcumin and clinical research progress on its effects on esophageal cancer. Frontiers in Pharmacology, $0,13,.$	1.6	6
2043	Liposomes Loaded with Amaranth Unsaponifiable Matter and Soybean Lunasin Prevented Melanoma Tumor Development Overexpressing Caspase-3 in an In Vivo Model. Pharmaceutics, 2022, 14, 2214.	2.0	0
2044	Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Network Open, 2022, 5, e2236626.	2.8	6
2045	Mechanisms of cancer metastasis. Seminars in Cancer Biology, 2022, 87, 17-31.	4.3	42
2046	Roles of follistatin-like protein 3 in human non-tumor pathophysiologies and cancers. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	3
2047	SOD3 Expression in Tumor Stroma Provides the Tumor Vessel Maturity in Oral Squamous Cell Carcinoma. Biomedicines, 2022, 10, 2729.	1.4	0
2048	Overexpression of ELL-associated factor 2 suppresses invasion, migration, and angiogenesis in colorectal cancer. World Journal of Gastrointestinal Oncology, 0, 14, 1949-1967.	0.8	3
2049	MECHANIZMY PROWADZĄCE DO ANGIOGEGNEZY W NOWOTWORACH. , 2019, 17, 60-65.		0
2050	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. International Journal of Molecular Sciences, 2022, 23, 13696.	1.8	0
2051	The RNA demethylase ALKBH5 promotes the progression and angiogenesis of lung cancer by regulating the stability of the LncRNA PVT1. Cancer Cell International, 2022, 22, .	1.8	14
2052	Knockdown of mediator complex subunit 27 suppresses gastric cancer cell metastasis and angiogenesis via Wnt/ \hat{l}^2 -catenin pathway. Tissue and Cell, 2022, 79, 101973.	1.0	3
2053	Non-clinical pharmacology and toxicology studies of bevacizumab biosimilar LY01008. European Journal of Pharmacology, 2022, 936, 175383.	1.7	1
2056	Extracellular vesicles as a novel approach for breast cancer therapeutics. Cancer Letters, 2023, 555, 216036.	3.2	2

#	Article	IF	CITATIONS
2057	Multiparametric ultrasound and machine learning for prostate cancer localization., 2022,,.		1
2058	Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation. Frontiers in Oncology, 0, 12, .	1.3	5
2059	Dickkopf-3: An Update on a Potential Regulator of the Tumor Microenvironment. Cancers, 2022, 14, 5822.	1.7	1
2060	Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study. Journal of Thoracic Disease, 2022, 14, 4416-4426.	0.6	2
2061	Molecular Features, Prognostic Value, and Cancer Immune Interactions of Angiogenesis-Related Genes in Ovarian Cancer. Reproductive Sciences, 0, , .	1.1	1
2062	Imaging perfusion changes in oncological clinical applications by hyperspectral imaging: a literature review. Radiology and Oncology, 2022, 56, 420-429.	0.6	6
2063	An Array SPRi Biosensor for Simultaneous VEGF-A and FGF-2 Determination in Biological Samples. Applied Sciences (Switzerland), 2022, 12, 12699.	1.3	3
2064	Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials, 2022, 12, 4494.	1.9	46
2065	Incorporating cross-voxel exchange for the analysis of dynamic contrast-enhanced imaging data: pre-clinical results. Physics in Medicine and Biology, 2022, 67, 245013.	1.6	0
2066	Nitric oxide and thyroid carcinoma: A review. Frontiers in Endocrinology, 0, 13, .	1.5	2
2067	Traditional Chinese medicine for transformation of gastric precancerous lesions to gastric cancer: A critical review. World Journal of Gastrointestinal Oncology, 0, 15, 36-54.	0.8	2
2068	Tumor hypoxia: From basic knowledge to therapeutic implications. Seminars in Cancer Biology, 2023, 88, 172-186.	4.3	21
2069	Targeted Cytokine Delivery for Cancer Treatment: Engineering and Biological Effects. Pharmaceutics, 2023, 15, 336.	2.0	3
2070	Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study. Korean Journal of Radiology, 2023, 24, 133.	1.5	9
2071	Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling. Molecules, 2023, 28, 943.	1.7	3
2072	Synthesis and Anti-Angiogenic Activity of Novel c(RGDyK) Peptide-Based JH-VII-139-1 Conjugates. Pharmaceutics, 2023, 15, 381.	2.0	1
2073	Aptamer-functionalized dendrimers for targeted cancer therapy., 2023,, 255-275.		1
2074	Histopathological Evaluation of Angiogenic Markers in Non-Hodgkin's Lymphoma. Journal of Laboratory Physicians, 0, , .	0.4	0

#	Article	IF	CITATIONS
2075	The effect of single bout and prolonged aerobic exercise on tumor hypoxia in mice. Journal of Applied Physiology, 2023, 134, 692-702.	1.2	3
2076	Emerging Graphene-Based Nanomaterials for Cancer Nanotheranostics. Materials Horizons, 2023, , 1091-1126.	0.3	1
2077	Molecular principles of tissue invasion and metastasis. American Journal of Physiology - Cell Physiology, 2023, 324, C971-C991.	2.1	4
2078	A robust lyophilized kit for convenient one-step formulation of [68Ga]Ga-DOTA-Eâ^2[c(RGDfK)]2 in hospital radiopharmacy for clinical PET imaging. Applied Radiation and Isotopes, 2023, 196, 110725.	0.7	O
2079	Exploring the molecular pathways and therapeutic implications of angiogenesis in neuropathic pain. Biomedicine and Pharmacotherapy, 2023, 162, 114693.	2.5	3
2081	Therapeutic Performance Evaluation of 213Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([213Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology. Pharmaceutics, 2023, 15, 491.	2.0	1
2082	Could senescence phenotypes strike the balance to promote tumor dormancy?. Cancer and Metastasis Reviews, 2023, 42, 143-160.	2.7	2
2083	Cascade-Responsive 2-DG Nanocapsules Encapsulate aV-siCPT1C Conjugates to Inhibit Glioblastoma through Multiple Inhibition of Energy Metabolism. ACS Applied Materials & Samp; Interfaces, 2023, 15, 10356-10370.	4.0	3
2084	A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy. Chinese Journal of Polymer Science (English Edition), 0, , .	2.0	2
2085	Preclinical In Vitro Investigation of MDM2 Inhibition in Combination with Antiangiogenic Therapy for Breast Cancer Treatment. Scientia Pharmaceutica, 2023, 91, 12.	0.7	2
2086	Development of Clioquinol Platinum(IV) Conjugates as Autophagy-Targeted Antimetastatic Agents. Journal of Medicinal Chemistry, 2023, 66, 3393-3410.	2.9	13
2087	Vascular endothelial growth factor and risk of malignant brain tumor: A genetic correlation and two-sample Mendelian randomization study. Frontiers in Oncology, $0,13,.$	1.3	0
2088	Angiotensin-converting enzyme insertion/deletion gene polymorphism in patients with laryngeal cancer. Acta Otorhinolaryngologica Italica, 2023, 43, 26-31.	0.7	1
2089	Angiogenesis Inhibitors in the Treatment of Cancer. , 2023, , 1-33.		0
2090	Construction and validation of an angiogenesis-related lncRNA prognostic model in lung adenocarcinoma. Frontiers in Genetics, $0,14,.$	1.1	0
2091	The evaluation of tumor microenvironment infiltration and the identification of angiogenesis-related subgroups in skin cutaneous melanoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	O
2092	Sequential-delivery nanocomplex for combined anti-angiogenesis and gene therapy against colorectal cancer. International Journal of Pharmaceutics, 2023, 637, 122850.	2.6	0
2093	Significance of circulating tumor cells in lung cancer: a narrative review. Translational Lung Cancer Research, 2023, 12, 877-894.	1.3	2

#	Article	IF	Citations
2094	Bench-to-bedside development of multifunctional flexible embolic agents. Theranostics, 2023, 13, 2114-2139.	4.6	0
2095	miR-1246 in tumor extracellular vesicles promotes metastasis via increased tumor cell adhesion and endothelial cell barrier destruction. Frontiers in Oncology, 0, 13, .	1.3	2
2096	Efficacy and Toxic Effects of Endostar Combined with Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Non-Small Cell Lung Cancer. Advances in Clinical Medicine, 2023, 13, 5627-5633.	0.0	0
2097	Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis. International Journal of Molecular Sciences, 2023, 24, 7400.	1.8	2
2107	Predictive genomic biomarkers of therapeutic effects in renal cell carcinoma. Cellular Oncology (Dordrecht), 0, , .	2.1	0
2114	Regional Onco-Sphere: Lymph Node Metastasis. , 2023, , 267-287.		0
2116	Nervous System Interactions with Nonimmune Elements in Cancer Microenvironment: A Missing Piece?. , 2023, , 117-129.		0
2151	IMAN: An Iterative Mutual-Aid Network for Breast Lesion Segmentation on Multi-modal Ultrasound Images. , 2023, , .		0